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Abstract 
Proteins and RNA are used as enzymes in nature, while DNA is used for the storage and 
transfer of genetic information. Proteins and RNA are biopolymers that can fold into complex 
secondary and tertiary structures to enable substrate binding and catalysis. Given the structural 
similarity to RNA, single-stranded DNA should also be able to function as enzymes. DNA 
enzymes, or deoxyribozymes, have not been found in nature, but in vitro selection has led to the 
identification of deoxyribozymes for a variety of reactions. De novo enzyme identification favors 
the use of nucleic acids over proteins for several reasons. First, nucleic acids can be amplified by 
natural enzymes, whereas proteins cannot be amplified in any way. Second, the number of 
possible sequences is smaller for nucleic acids (4n, where n is the length of the biopolymer) than 
for proteins (20n). Therefore, selection experiments for identifying nucleic acid enzymes will 
cover a larger fraction of total sequence space. Furthermore, within the sequence space evaluated, 
a large portion of nucleic acid sequences will fold into secondary and tertiary structures, whereas 
most random protein sequences are unlikely to fold into high-order structures. Considering 
nucleic acid enzymes, DNA has additional advantages over RNA because DNA can be directly 
amplified by polymerases whereas RNA requires an extra reverse transcription step. DNA is also 
cheaper and more stable compared to RNA. 
Post-translational modifications (PTMs) are essential for protein functions. The ability to 
site-specifically modify peptides and proteins will enable better understanding and applications 
of these biomolecules. The idea of using DNA enzymes for peptide and protein modification is 
very attractive, especially considering that DNA enzymes with site selectivity can be de novo 
identified without the requirement of a known enzyme as the starting point. 
PEGylation is an important artificial PTM for therapeutic peptides and proteins. 
PEGylation improves the pharmacokinetic properties of biopharmaceuticals by increasing 
circulation half-time, reducing immunogenicity, increasing solubility, and suppressing 
aggregation. Peptide and protein PEGylation is most commonly achieved by solely chemical 
means. However, these chemical strategies generally lack site selectivity among different target 
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sites in the substrates. Some chemical strategies also suffer from off-target reactivity, i.e., poor 
chemoselectivity. Enzymatic approaches for PEGylation have also been developed, yet their 
application is limited by the substrate specificities and the sequence selectivities of the natural 
enzymes used. In Chapter 2, DNA enzymes were identified for PEGylation of tyrosine in a 
DNA-tethered peptide substrate using a 5′-phosphorimidazolide-activated oligonucleotide-PEG 
conjugate (Imp-oligo-PEG5k) as the PEG donor. Two different approaches are described for the 
identification of DNA enzymes that are functional with untethered peptide substrates. The first 
approach is to increase the length of the tether between the peptide substrate and the DNA 
anchor for mimicking a peptide free in solution. The selection experiment using this approach 
did not lead to deoxyribozymes, and further analysis of other deoxyribozymes with untethered 
peptide reactivities suggests that the long tethers may interfere with catalysis. Thus, the first 
approach was discontinued. The second approach is to alternate the position of the tether 
between the peptide substrate and the DNA anchor. The rationale is that DNA enzymes are 
expected to perform catalysis without the requirement of any tether if the enzymes are identified 
from selection experiments with alternating tether positions. Ongoing efforts include selection 
experiments using the second approach and mixed-sequence peptide substrates to identify 
deoxyribozymes with untethered peptide reactivity. 
In Chapter 3, a two-step strategy is described for DNA-catalyzed peptide modification. In 
this strategy, a DNA enzyme first catalyzes the transfer of the 2¢-azido-2¢-deoxyadenosine 
5¢-monophosphoryl group (2¢-Az-dAMP) from the analogous 5¢-triphosphate (2¢-Az-dATP) onto 
the tyrosine hydroxyl group (azido-adenylylation). Second, a particular modification of interest 
is attached to the azido group by copper-catalyzed azide-alkyne cycloaddition (CuAAC) using an 
alkyne-functionalized reagent. Eleven deoxyribozymes with azido-adenylylation activity are 
described in Chapter 3. One of the DNA enzymes is selective for the YPR sequence motif and is 
able to discriminate between tyrosine residues within a single peptide on the basis of sequence 
context. Another deoxyribozyme is peptide sequence-general, functions with free peptides, and 
allows their subsequent CuAAC labeling with moieties such as PEG and fluorescein. The use of 
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azido-adenylylation deoxyribozymes is a versatile method for the synthesis of site-specifically 
modified peptides and proteins, since the azide group installed by the DNA enzyme can be used 
for any particular modification as long as the corresponding alkyne derivative is available. 
One of our long-term goals is DNA-catalyzed site-specific modification of protein 
substrates. In Chapter 4, two proteins, human annexin V and human TNF-related apoptosis-
inducing ligand (TRAIL) 114–281, and a 36-mer peptide pancreatic polypeptide (PP) with an 
additional C-terminal cysteine were used as the substrates to evaluate two different approaches 
for identifying deoxyribozymes. The first approach is to directly use protein substrates during in 
vitro selection experiments. This approach requires the surviving deoxyribozymes to 
simultaneously adopt functions of both binding to the protein substrates and catalyzing the 
modification. However, the selection experiments using this approach did not lead to 
deoxyribozymes. The second approach is to decouple the binding and catalytic functions 
required for DNA-catalyzed protein modification. In this modular approach, the binding function 
is assigned to the predefined aptamer domain, which is placed adjacent to the initially random 
enzyme domain. The sequence of the enzyme domain will be subsequently identified through in 
vitro selection in the presence of the aptamer domain. Ongoing efforts are focused on the 
identification of DNA aptamers that bind to annexin V, TRAIL, and PP, with benzyl, naphthyl, 
and indolyl modifications. Once the DNA aptamers are identified, they will be used as the 
binding modules in selection experiments to identify DNA enzymes for protein modification. 
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Chapter 1: Introduction to Natural and Engineered Enzymes 
1.1 Enzymatic Catalysis 
Enzymes are macromolecular biological catalysts that adopt three-dimensional structures 
and accelerate the chemical conversion of substrates to products by enthalpy effects and/or entropy 
effects.1 Organisms in our world use enzymes as the solutions to the challenges faced in daily life. 
Some enzymes have evolved to achieve high rate enhancement. An extreme example is triose 
phosphate isomerase, which catalyzes the reversible interconversion of dihydroxyacetone 
phosphate and D-glyceraldehyde 3-phosphate at a rate that is limited merely by substrate 
diffusion.2 Another essential property of enzymes is their high specificity, especially when they 
are compared with small-molecule catalysts. Unlike small-molecule catalysts that often react with 
any relevant functional group accessible, enzymes can discriminate between different reaction 
sites on their substrates to enable chemical reactions with high chemoselectivity and site 
selectivity. One example is TEV protease, which specifically cleaves the amide bond between 
glutamine and serine residues in the peptide sequence ENLYFQS.3 
1.2 Natural Enzymes 
1.2.1 Proteins 
Most enzymes found in nature are protein enzymes. Proteins are polymers of amino acids 
connected via amide linkages. The natural amino acids contain a variety of chemical functional 
groups to promote protein structure and enable catalysis (Figure 1.1). Throughout known life, 
proteins are composed of 22 genetically encoded (proteinogenic) amino acids, 20 in the standard 
genetic code and additional two incorporated by special translation mechanisms. The diversity of 
the 22 proteinogenic amino acids is expanded by unnatural amino acids and post-translational 
modifications. A protein’s function depends upon its secondary, tertiary, and quaternary structure. 
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Local primary amino acid sequences can stabilize secondary structures such as a-helices, b-sheets, 
and turns. Tertiary structures are formed by the combination of secondary structures, and 
quaternary structures containing multiple protein subunits can be formed. In the structure of a 
protein enzyme, a small region is designated as the active site, where the chemical reaction is 
catalyzed. The amino acid side chains in the active site are responsible for the interactions with 
the substrate(s) to enable the catalysis. 
 
Figure 1.1. Structures of protein backbone and amino acid side chains. Proteins are made of amino 
acids connected by amide bonds. 
Protein enzymes are responsible for many essential biochemical procedures. Four 
important reactions involved in the central dogma of molecular biology are catalyzed by protein 
enzymes, namely DNA replication, RNA replication, transcription, and reverse transcription. 
Problems in the expression, folding, localization, or catalytic efficiency of protein enzymes can 
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result in diseases. Protein enzymes have also been used in a variety of industries such as 
pharmaceuticals, biofuels, and consumer products.4 
1.2.2 Ribozymes 
RNA was originally thought to be involved only in the transfer of information between the 
DNA data storage to the proteins that catalyzed essential cellular functions. However, RNA was 
discovered to be catalytic in the early 1980s.5,6 RNA is a polymer of four different ribonucleotides 
connected via phosphodiester linkages (Figure 1.2A). These four ribonucleotides can be further 
modified after the transcription. More than 100 different post-transcriptional modifications are 
known so far,7 some of which are involved in the catalytic functions of RNA enzymes.8 Similar to 
proteins, RNA can also form complex secondary and tertiary structures. Hydrogen bonds between 
different ribonucleotides lead to secondary structures like hairpin loops, bulges, and internal loops. 
Tertiary structures are formed by the interactions of secondary structures. In RNA, secondary 
structures can be stable without being involved in any tertiary structure, whereas secondary 
structures in proteins generally cannot form without the presence of tertiary structures. The 
negatively charged RNA backbone enables interaction with metal ions, which can be important 
for structure or catalysis.9,10 
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Figure 1.2. Ribozymes. (A) Structures of RNA backbone and nucleobases. RNA is made of 
ribonucleotides connected by phosphodiester bonds. (B) Group I intron from Tetrahymena 
thermophila. The self-splicing pathway for the group I intron is shown. A guanosine residue binds 
and attacks the 5′-splice site. A conformation change follows and the 3′-hydroxyl group attacks 
the 5′-end of the exon, resulting in ligation. The active site is shown in the crystal structure of the 
group I intron. Panel B adapted with permission from ref. 24. 
The first-discovered RNA enzyme was the Tetrahymena thermophile group I intron, which 
catalyzes RNA cleavage as part of intron splicing (Figure 1.2B).5,11 The RNase P ribozyme was 
also discovered in the early 1980s to catalyze the cleavage of RNA phosphodiester backbone.6 
RNase P is a ribonucleoprotein complex (RNP), with RNA catalyzing the direct RNA hydrolysis 
using a water molecule. The RNA component alone is sufficient for catalysis in vitro, but in vivo 
activity requires the additional protein component.12 Many other natural ribozymes have since 
been discovered to catalyze a variety of RNA processing reactions such as self-splicing,13-15 RNA 
hydrolysis,16,17 and self-cleavage.18,19 Similar to RNase P, some ribozymes function as part of RNP 
complexes where the RNA performs the catalysis, though both the RNA and protein are required. 
The most well-known RNP is the ribosome, in which the RNA is responsible for catalyzing the 
peptidyl transfer reaction during protein translation.20-23 The abundance of natural catalytic RNAs 
and their involvement in gene expression and protein synthesis indicate the important roles of 
catalytic RNAs in biological systems.24 
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1.3 Engineered and Artificial Enzymes 
The catalytic efficiencies and substrate specificities of natural protein and RNA enzymes 
result from billions of years of evolutionary pressure. However, these properties of natural 
enzymes only occasionally overlap with features sought by humans. Therefore, methods such as 
directed evolution, rational design, and in vitro selection have been developed both to engineer 
existing enzymes and to design or identify new enzymes. Natural enzymes modified or artificially 
developed in the laboratory are referred to as engineered enzymes or artificial enzymes. 
1.3.1 Proteins 
Two general strategies for protein enzyme engineering are directed evolution and rational 
design. Directed evolution mimics the process of natural selection to evolve protein enzymes 
toward desired properties. Rational design of protein enzymes utilizes the understanding of 
structure-function relationships to predict protein sequences that fold into specific structures for 
novel functions. Moreover, these two methods are not mutually exclusive; researchers often apply 
both for protein engineering. 
1.3.1.1 Directed Evolution 
As an accelerated evolution methodology, directed evolution allows protein enzymes to 
evolve through laboratory selection pressures for desired catalytic properties on a practical time 
scale (Figure 1.3).25 A parent enzyme, which is a known enzyme with catalytic activity similar to 
that of the desired new enzyme, is required as the starting point. The gene diversification step 
generates a diverse library of gene mutants. This library is then translated into a corresponding 
library of protein variants, which are screened or selected for the desired property. The entire 
process is iterated until protein enzymes with the desired property are identified.  
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Figure 1.3. Schematic diagram for directed evolution of protein enzymes. A library of genetic 
variants is prepared by gene diversification. Translation is performed to express the protein 
mutants, which are screened or selected. The process is iterated, until protein enzymes with the 
desired property are identified. Figure adapted with permission from ref. 25. 
Gene diversification techniques allow the exploration of a protein’s sequence space. In the 
absence of known structure-function relationships, random mutagenesis is usually used for library 
preparation. Chemical mutagens including ethyl methanesulfonate,26 nitrous acid,27 and 2-
aminopurine28 can cause DNA damage and result in errors during replication. However, these 
approaches are biased in the mutations formed and therefore not commonly used for library 
generation. Error-prone PCR (epPCR) harnesses the low fidelity of DNA polymerases under 
certain conditions to enable in vitro random mutagenesis.29 The DNA polymerases used in epPCR 
also exhibit mutational biases, but unbalanced deoxyribonucleoside triphosphates (dNTPs) 
concentrations and proprietary mixtures of polymerases can help to reduce the imbalance in the 
mutational spectrum.30,31 Focused mutagenesis is used to maximize the possibility that improved 
variants are included in the generated library, provided that substantial structural information is 
available regarding substrate binding or catalysis of the parent enzyme. The most straightforward 
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approach for focused mutagenesis is to use synthetic DNA oligonucleotides that contain one or 
more degenerate codons at positions corresponding to targeted amino acid residues. In an ideal 
case, a degenerated DNA library of 1012 members can target about ten amino acid residues in a 
directed evolution experiment. The mutagenic oligonucleotide is generally incorporated into the 
gene library as a mutagenic cassette32 via either restriction enzyme cloning or gene assembly.33-35 
Recombination strategies have also been used to further increase the diversity of the genetic library. 
Both homologous and non-homologous recombination techniques have been developed. DNA 
shuffling36 and the staggered extension process37 are two examples from the former category, 
while incremental truncation for the creation of hybrid enzymes (ITCHY)38 and non-homologous 
random recombination (NRR)39 belong to the latter category. 
To identify protein enzymes with the desired property, the library of protein variants needs 
to be screened or selected in a manner that maintains the correspondence between genotype (the 
gene) and phenotype (the function of the protein enzyme). One approach is in vivo 
compartmentalization, which utilizes an organism as the individual compartment for both the gene 
and the translated protein. Yeast display40 and phage display41 are two examples for the in vivo 
compartmentalization approach. In vitro compartmentalization is an alternative format for 
maintaining the connection between genotype and phenotype. Aqueous droplets in water-oil 
emulsions are used to compartmentalize individual genes together with gene products generated 
via in vitro transcription and translation.42 The linkage between genotype and phenotype can also 
be achieved by attaching protein variants to their encoding mRNA via either covalent or non-
covalent interaction, as shown respectively in mRNA display43 and ribosome display.44 
The screening or selection step is used to enrich desired variants and to eliminate undesired 
ones. Screening is a one-at-a-time process, while selection allows the examine of many variants in 
parallel. The throughput of screening is determined by the readout techniques. Traditional methods 
such as chromatography, mass spectrometry, and colorimetric assays have a practical throughput 
limit of ~104 variants.25 Methods such as fluorescence-activated cell sorting (FACS) can screen 
larger libraries of ~108 members.40 Unlike screening methods that are typically limited by 
8 
measurement throughput, selection methods suffer from a transformation bottleneck which 
restricts the library size to ~109–1010 per experiment.45,46 The recently developed phage-assisted 
continuous evolution (PACE) system allows directed evolution experiments with libraries of 1012 
members. 47 In the PACE system, the phage’s ability to infect host cells depends on the desired 
protein function. Because the evolution cycle is based on phage replication, PACE enables several 
hundred rounds of selection, mutation, and replication to take place per week without manual 
intervention. 
The impact of directed evolution is significant in the field of protein enzyme engineering. 
Many engineered protein enzymes have been developed for enhanced thermostability,48 catalytic 
activity,49 and new reactions.50 However, directed evolution suffers from several disadvantages. A 
parent enzyme is required as the starting point, which may limit the reaction scope of the evolved 
enzymes. In addition, directed evolution experiments for reprogramming substrate selectivity are 
often challenging, leading to relaxed selectivity rather than changed selectivity.51 
1.3.1.2 De Novo Enzyme Design 
De novo enzyme design models the active site within the context of a full-length protein 
based on the understanding of fundamental reaction mechanisms. With the knowledge of 
individual reaction steps such as bond breaking, bond formation, and charge transfer, a 
minimalistic three-dimensional model of the active site, labelled theozyme, is assembled (Figure 
1.4).52 This theozyme is docked in silico into structurally characterized scaffolds from the Protein 
Data Bank (PDB) to choose scaffolds compatible with the presence of the theozyme. Common 
programs used for the docking step are RosettaMatch,53 ORBIT,54 and Scaffold Select.55 Redesign 
of the residues in and around this implanted active-site pocket are often needed for optimal packing 
of the transition state and the catalytic groups.56,57 The top ranking in silico designs are expressed 
and assayed for their enzymatic properties. In most cases, directed evolution is also performed to 
improve the properties of the designed enzymes.58 Following this general scheme, many protein 
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enzymes have been generated to catalyze reactions such as retroaldolization,59 Kemp elimination,60 
Diels-Alder cycloaddition,61 and ester hydrolysis.62 
 
Figure 1.4. Schematic illustration of de novo design of protein enzymes. (A) A mechanism is 
chosen for the desired reaction, in the example the Kemp elimination. (B) An active-site motif is 
chosen to realize the stabilizing interactions required by the mechanism. (C) An optimal geometry 
is defined for the theozyme via quantum chemistry methods. (D) An ensemble of side-chain 
conformations is generated to stabilize the optimal theozyme. (E) Protein scaffolds from the PDB 
database are scanned for potential grafting sites for the proposed theozyme using computer 
programs such as RosettaMatch. (F) The chosen scaffolds are minimized, and the surrounding 
residues are further designed to stabilize the binding-site geometry. Figure adapted with 
permission from ref. 52. 
Completely de novo protein enzymes have also been designed with both the active site and 
the scaffold artificially built.63 The catalytically active Cys-His-Glu triads were installed into 
heptameric a–helical barrels, which resulted in artificial hydrolases with activities comparable to 
the most efficient redesigned hydrolases based on natural protein scaffolds. This work 
demonstrates that completely de novo design of enzymes with control of all residues is possible, 
although the extent to which a wide variety of reactions are subject to this approach is unclear. 
While the power to design novel enzymes is exciting, there are still many challenges in 
predicting and designing enzymatic protein structures. Besides the difficulty due to technical and 
theoretical issues, the precise description of structure-function relationships is complicated by the 
dynamic nature of enzymes.58 In almost all cases, directed evolution is needed to improve the first 
generation of newly designed enzymes. However, with our understanding of protein enzyme 
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structure and function becoming more thorough and our computational algorithm becoming more 
powerful, computational design of protein enzymes will be more applicable for obtaining useful 
new enzymes. 
1.3.2 Nucleic Acid Enzymes 
The discovery of natural ribozymes instigated great interest in the capabilities of nucleic 
acid enzymes. In the laboratory, both RNA and DNA enzymes have been identified to catalyze 
various chemical reactions. The technique used for the identification of nucleic acid enzymes is in 
vitro selection. 
1.3.2.1 In Vitro Selection 
In vitro selection for nucleic acid enzymes is the experimental process by which random 
sequences of DNA or RNA are examined in parallel to identify those particular sequences that 
have a desired function.64 A general in vitro selection procedure for nucleic acid enzymes starts 
with a large population of random sequences (~1014 molecules; Figure 1.5). Catalytically active 
sequences are enriched through a selection step followed by a separation method to isolate the 
nucleic acid molecules with desired enzymatic activity. Some inactive sequences will also survive 
due to either artifacts of the separation technique or the background of the enzymatic reaction 
sought in the selection experiment. However, after the selection step, the fraction of catalytically 
active sequences in the pool increases, which is vital for the success of in vitro selection. The 
surviving sequences from selection step are amplified to generate more copies of each sequence 
for the subsequent selection round. This selection-amplification process is iterated until desired 
catalysis is observed. Finally, individual enzymes from the pool are sequenced and characterized. 
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Figure 1.5. Schematic illustration of in vitro selection. The initial pool contains ~1014 sequences. 
The active sequences, represented as red dots, are enriched through a selection step and then 
amplified by PCR. The selection and amplification steps are iterated until active sequences 
dominate the selection pool. 
Ribozymes and deoxyribozymes are ideal for in vitro selection experiments for several 
reasons. First and foremost, both RNA and DNA can be amplified, which enables the multiple-
round process of in vitro selection. The amplification of RNA molecules involves reverse 
transcription of RNA to cDNA, PCR of cDNA, and transcription of replicated cDNA. For DNA 
enzymes, the amplification step is more straightforward, as DNA molecules can be directly 
replicated via PCR. On the contrary, there is no known technique yet to amplify protein molecules. 
Second, a much larger fraction of sequence space can be explored in nucleic acid selection 
experiments than protein selection experiments. Nucleic acids have 4 monomers and a smaller 
sequence space compared to proteins that have 20 monomers. Within the sequence space evaluated, 
a large fraction of nucleic acid sequences will fold into complex secondary and tertiary structures, 
whereas most random protein sequences are unlikely to fold into high-order structures. Therefore, 
nucleic acid enzymes can be more easily identified via in vitro selection. Considering nucleic acid 
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enzymes, DNA has several practical advantages compared to RNA in its stability, ease of 
synthesis, and simplicity in amplification. 
1.3.2.2 Ribozymes 
Artificial ribozymes have been identified via in vitro selection for RNA modification 
reactions including RNA cleavage by transesterification,65 ligation,66,67 polymerization,68,69 and 
phosphorylation,70,71 providing important contributions for supporting the RNA World 
hypothesis.72,73 RNA enzymes have also been found to catalyze other reactions such as acyl 
transfer,74,75 biphenyl isomerization,76 Diels-Alder cycloaddition,77,78 and aldolization.79 Despite 
the success in the identification of novel ribozymes, detailed structural and mechanistic 
understanding of their functions is limited, even though such understanding is not necessary for 
the use of in vitro selection. Currently, only three artificial ribozymes, an RNA-cleaving lead-
dependent ribozyme,80,81 a ribozyme that catalyzes the Diels-Alder reaction,82 and class I ligase 
ribozymes,83,84 have crystal structures, providing us detailed knowledge about their structures and 
functions (Figure 1.6). 
 
Figure 1.6. Structures of artificial ribozymes. (A) Crystal structure of a lead-dependent RNA-
cleaving ribozyme. The ribozyme is shown with the magenta backbone, and the substrate strand 
is yellow. The red arrowhead indicates the cleavage site. (B) Crystal structure of a ribozyme that 
catalyzes the Diels-Alder reaction. The structure shows the ribozyme-product complex with the 
product in blue. The electron density shows the location of bound metal ions. (C) Crystal structure 
of a class I ligase ribozyme. The structure shows the active site in blue and the ligation junction in 
red. Panels A, B, and C are reprinted with permission from ref. 80, 82, and 83, respectively. 
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1.3.2.3 Deoxyribozymes 
The chemical structure of DNA is very similar to that of RNA. DNA lacks the 2′-hydroxyl 
group of RNA, and the nucleobase thymine is present in place of uracil (Figure 1.7A). Natural 
deoxyribozymes have not been identified. In nature, DNA is primarily double-stranded and used 
as the long-term repository of genetic information. However, in single-stranded form, DNA can 
fold into secondary and tertiary structures required for catalysis. 
 
Figure 1.7. Deoxyribozymes. (A) Structure of DNA backbone and nucleobases. DNA is made of 
2′-deoxyribonucleotides connected via phosphodiester linkages. (B) The first-discovered 
deoxyribozyme catalyzes the cleavage of a ribonucleotide embedded within a DNA substrate. The 
cleavage site is indicated with an arrowhead. Panel B adapted with permission from ref. 85. 
DNA enzymes have been identified in a laboratory via in vitro selection. The first 
deoxyribozyme was discovered in 1994 to catalyze the cleavage of a single ribonucleotide 
embedded in a DNA substrate (Figure 1.7B).85 Since then, many DNA enzymes have been 
identified to catalyze the modification of nucleic acid substrates, as base-pairing interactions can 
be easily engineered between the substrate and the deoxyribozyme. These modification reactions 
include RNA cleavage via transesterification86,87 or hydrolysis;88 RNA ligation;89-91 DNA cleavage 
via hydrolysis,92,93 deglycosylation,94 or radical formation;95 DNA ligation;96 and DNA 
phosphorylation.97,98 The reaction scope of catalysis by DNA is not limited to nucleic acid 
substrates. In particular, DNA enzymes have been found to catalyze the modification of peptide 
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substrates by phosphorylation,99,100 dephosphorylation,101 nucleopeptide formation,102-107 and the 
formation of dehydroalanine from phosphoserine.108 Some of these deoxyribozymes can catalyze 
their modification reaction with peptide sequence selectivity.100,106 
Similar to artificial ribozymes, structural and mechanistic understanding of deoxyribozyme 
function is limited. Currently, crystal structures are available for two deoxyribozymes, the 9DB1 
RNA-ligating deoxyribozyme109 and the 8-17 RNA-cleaving deoxyribozyme (Figure 1.8).110 
However, the knowledge gained from these two structures is hardly applicable to the identification 
of novel deoxyribozymes. 
 
Figure 1.8. Structures of deoxyribozymes. (A) Crystal structure of the 9DB1 deoxyribozyme. The 
deoxyribozyme is shown in green, and the substrate strands are blue and red. The ligation site is 
marked with a purple sphere. (B) Crystal structure of the 8-17 deoxyribozyme. AsfvPolX proteins, 
which were utilized to facilitate the crystallization, are colored in light blue or cyan. Panel A and 
B adapted with permission from ref. 109 and ref. 110, respectively. 
1.4 Protein Side Chain Modification 
Many natural proteins are modified by enzymes after translation for the real-time dynamics 
and regulation of their structures and functions. Common natural post-translational modifications 
(PTMs) include not only additions of small chemical groups such as acetylation, methylation, and 
phosphorylation, but also attachment of other biopolymers such as glycosylation and 
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ubiquitination.111 PTMs are essential for almost all cellular processes including trafficking, 
differentiation, migration, and signaling (Figure 1.9).112 
 
Figure 1.9. Biological roles played by post-translational modifications. This schematic figure 
shows the locations and functions of some post-translational modifications. Ac, acetyl group; GPI, 
glycosylphosphatidylinositol; Me, methyl group; P, phosphoryl group; Ub, ubiquitin. Figure 
reprinted with permission from ref. 112. 
Artificial PTMs can also be introduced into proteins. For example, the installment of 
fluorophores is widely used to study spatial behaviors of target proteins.113 Another example is the 
addition of polyethylene glycol molecules (PEGylation), which improves the pharmaceutical 
properties of protein drugs.114 Given the significance of PTMs, the production of modified proteins 
in a highly efficient and site-specific way is of great scientific interest. Many efforts have been 
focused on the development of novel chemistry for protein modification.115-117 However, powerful 
as they are, these chemical approaches lack site selectivity to discriminate two reaction sites in the 
same protein substrate. In some cases, poor chemoselectivity is also an issue faced by these 
chemical approaches. 
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1.5 Thesis Research Focus 
The ability to site-specifically modify peptides and proteins will enable better 
understanding and applications of these biomolecules. Therefore, the research described in this 
thesis is focused on the identification of deoxyribozymes for covalent modifications at tyrosine 
residues in peptides and proteins. The work has focused on two specific modification reactions: 
PEGylation and azido-adenylylation. Chapter 2 reports the identification of deoxyribozymes for 
tyrosine PEGylation in peptide substrates. These deoxyribozymes use a 5′-phosphorimidazolide-
activated oligonucleotide-PEG conjugate as the PEG donor. These PEGylation DNA enzymes 
catalyze the formation of a phosphodiester bond between the phosphorimidazolide and the tyrosine 
side chain within a peptide substrate that is covalently attached via a tether to a DNA anchor 
oligonucleotide. Chapter 3 describes the identification of deoxyribozymes for tyrosine azido-
adenylylation in peptide substrates. These deoxyribozymes transfer the 2¢-azido-2¢-
deoxyadenosine 5¢-monophosphoryl group (2¢-Az-dAMP) from the analogous 5¢-triphosphate (2¢-
Az-dATP) onto the tyrosine hydroxyl group of a peptide, which is either tethered to a DNA anchor 
or free. One deoxyribozyme is able to differentiate two tyrosine sites within the same peptide 
substrate based on their sequence contexts. Another deoxyribozyme is able to azido-adenylylate 
untethered peptides, and the modified peptides are further derivatized via copper-catalyzed azide-
alkyne cycloaddition (CuAAC). Chapter 4 discusses the efforts to identify deoxyribozymes for 
tyrosine azido-adenylylation in protein substrates. The direct approach and the modular approach 
are the two strategies studied in this chapter. In the direct approach, in vitro selection experiments 
were performed to identify deoxyribozymes that can simultaneously adopt both functions of 
binding to the protein substrates and catalyzing the modifications. The modular approach was 
designed to decouple the binding and catalytic functions, by incorporating a predefined aptamer 
module into the selection experiments. The modular approach is very different from the studies 
where independently identified aptamer and enzyme modules are concatenated to form new 
17 
catalysts. In the modular approach, the enzyme modules will be identified from initially random 
sequences with the presence of the aptamer modules. 
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Chapter 2: DNA Enzymes with Tyrosine PEGylation Activity on Peptide 
Substrates† 
2.1 Introduction 
2.1.1 Basic Features of PEGylation 
Since the approval of recombinant human insulin by the US Food and Drug Administration 
(FDA) in 1982, the field of peptide and protein therapeutics has grown significantly. Compared to 
small molecules, peptide and protein drugs offer many advantages, including high specificity, high 
biological activity, and few adverse effects. In addition, due to their vast diversity, peptides and 
proteins can be used to treat a number of different diseases including bacterial infection, various 
cancers, endocrine disorders, and autoimmune diseases. However, such therapy has its own 
pitfalls. Common issues associated with therapeutic peptides and proteins are rapid body 
clearance, poor physical stability, enzymatic degradation, and immunogenicity.1,2 One strategy to 
overcome the aforementioned limitations is PEGylation, defined as the attachment of 
poly(ethylene glycol) (PEG) chains. PEGylation can improve pharmacokinetic properties of 
proteins by increasing their clearance time, suppressing aggregation, and shielding them from 
proteases and the immune system.3 Currently ten PEGylated protein biopharmaceuticals are 
marketed in the US (Table 2.1).4 Most of these therapeutic proteins are modified by non-specific 
PEGylation methods. However, these methods inevitably lead to a heterogeneous mixture of 
PEGylated isomers that have different bio-activity and stability properties among each other. On 
the other side, site-specific PEGylation methods allow the synthesis of modified proteins with 
                                                             
†  Former Silverman laboratory graduate student Shannon M. Walsh performed selections for 
kinase deoxyribozymes with HEG10-tethered peptides and performed experiments to evaluate the 
tether dependence of the nucleopeptide-forming 8XJ105 deoxyribozyme.23 
Silverman laboratory undergraduate student James E. Brady performed in vitro selection 
experiments to identify PEGylation deoxyribozymes with untethered peptide activity using 
alternating tethers and mixed-sequence peptide substrates. 
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optimal therapeutic properties, and potentially streamline the production and purification of 
modified proteins. 
Table 2.1: Marketed PEGylated biopharmaceuticals in the United States. The column “site-
specific” demonstrates whether the drug is synthesized by site-specific PEGylation. Table adapted 
with permission from ref. 4. 
brand name protein indication year 
approved 
site-
specific 
Adagen® adenosine deaminase severe combined 
immunodeficiency 
1990 No 
Oncaspar® asparaginase acute lymphoblastic 
leukemia 
1994 No 
PegIntron® interferon a-2b chronic hepatitis C 2000 No 
PEGASYS® interferon a-2a chronic hepatitis C 2001 No 
Neulasta® granulocyte colony-
stimulating factor (G-CSF) 
neutropenia 2002 Yes 
SOMAVERT® human growth hormone 
(hGH) 
acromegaly 2003 No 
Mircera® erythropoietin (EPO) anemia 2007 No 
CIMZIA® anti-tumor necrosis 
factor a Fab¢ 
Crohn’s disease, 
rheumatoid arthritis, 
psoriatic arthritis, and 
ankylosing spondylitis 
2008 Yes 
KRYSTEXXA® urate oxidase chronic gout 2010 No 
PLEGRIDY® interferon b-1a relapsing forms of 
multiple sclerosis 
2014 Yes 
2.1.2 Non-Enzymatic PEGylation 
As an artificial post-translational modification, PEGylation is not endogenously catalyzed 
by any natural protein enzymes. Therefore, various chemical approaches have been developed to 
target functional groups in peptide and protein substrates for PEGylation. All of the marketed 
PEGylated biopharmaceuticals are synthesized via these chemical means. 
2.1.2.1 PEGylation Approaches Targeting Lysine Residues 
The initial PEGylation work used cyanuric chloride to prepare activated PEG for 
attachment to protein substrates at lysine residues. The PEG-dichlorotriazine derivative reacts with 
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a lysine side chain to form a secondary amine linkage (Figure 2.1A).5,6 However, the activated 
PEG can also react with other nucleophilic functional groups in a protein such as tyrosine, serine, 
threonine, cysteine, and histidine. In addition, the remaining chloride is reactive enough to allow 
crosslinking of protein molecules that contain additional nucleophilic residues. 
Another activated PEG species widely used for lysine modification is the 
N-hydroxysuccinimide ester of PEG carboxylic acid (PEG-NHS, Figure 2.1B).7 Several marketed 
biopharmaceuticals with PEGylation modification are synthesized with PEG-NHS, including 
Adagen®, Oncaspar®, PegIntron®, PEGASYS®, SOMAVERT®, and Mircera®.4 However, all of 
these protein drugs are PEGylated non-site specifically, leading to heterogeneous mixture of 
PEGylated material with each PEG conjugate having its own activity and stability properties. 
 
Figure 2.1. PEGylation approaches targeting lysine residues. (A) Reaction with PEG-
dichlorotriazine. (B) Reaction with PEG-NHS. 
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2.1.2.2 PEGylation Approaches Targeting N-Terminal Amines 
N-terminal PEGylation takes advantage of the fact that the a-amino group at the protein 
N-terminus has a lower pKa (about 7.6–8) than the pKa of the e-amino side chain of lysines (about 
9.3–9.5).8 The selective PEGylation at the N-terminus is achieved by performing the reaction in 
mildly acidic conditions (e.g., pH 6–6.5) and with less reactive PEGylating reagents, such as 
aldehyde-functionalized PEG (PEG-aldehyde, Figure 2.2).9 However, in most cases complete 
selectivity is not observed, even though the extensive heterogeneity frequently observed in lysine 
chemistry is greatly reduced after careful optimization of reaction conditions.10 Two site-specific 
PEGylated protein drugs, Neulasta® and PLEGRIDY®, are synthesized with PEG-aldehyde 
reagents.4 
 
Figure 2.2. PEGylation at the N-terminal amine with PEG-aldehyde. The imine product can be 
reduced (e.g., with cyanoborohydride) to form a more stable derivative. 
2.1.2.3 PEGylation Approaches Targeting Cysteine Residues 
Cysteine is another target for site-specific PEGylation, mainly due to its low abundance in 
natural proteins and the high nucleophilicity of the thiol group.11 In the absence of a free cysteine 
in a native protein, one or more free cysteines can be introduced by genetic engineering.12 
However, incorrect disulfide formation and protein dimerization are the issues associated with 
expressing a protein that contains an odd number of cysteine residues.13 
Several PEG derivatives, such as PEG-maleimide (Figure 2.3A)12, PEG-iodoacetamide 
(Figure 2.3B)14, and PEG-(2-pyridyl disulfide) (Figure 2.3C)15, have been developed for cysteine-
targeting modification. Among these three different strategies, the PEG-maleimide has been used 
to synthesize the marketed protein drug, CIMZIA®.4 
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Figure 2.3. PEGylation approaches targeting cysteine residues. (A) Reaction with PEG-
maleimide. (B) Reaction with PEG-iodoacetamide. (C) Disulfide exchange with PEG-(2-pyridyl 
disulfide). 
2.1.2.4 PEGylation Approaches Targeting Unnatural Amino Acids 
The site-specific incorporation of unnatural amino acids with bioorthogonal reactivity 
provides another versatile tool for PEGylation of peptides and proteins. Two examples of unnatural 
amino acids used for PEGylation include p-acetylphenylalanine16 and p-azidophenylalanine.17 The 
former phenylalanine derivative reacts selectively with PEG-hydrazide or PEG-aminooxy (Figure 
2.4A), while the latter derivative can be coupled to PEG-alkyne through copper-catalyzed azide-
alkyne cycloaddition (CuAAC) (Figure 2.4B). The main difficulty with unnatural amino acid-
targeting PEGylation is the relatively low yield for the expression of protein targets.18 
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Figure 2.4. PEGylation approaches targeting unnatural amino acids. Reaction of 
p-acetylphenylalanine with PEG-hydrazide (A) or PEG-aminooxy (B). (C) Reaction of 
p-azidophenylalanine with PEG-alkyne via CuAAC. 
2.1.3 Enzymatic PEGylation 
Natural protein enzymes with promiscuous substrate specificity have also been utilized for 
PEGylation in a few cases. For example, Sortase A (SrtA) derived from Staphylococcus aureus 
catalyzes a transpeptidase reaction between the N-terminal amino group of glycine and a specific 
internal peptide sequence, LPETG, on the target protein.19 When a polyglycine-derived compound 
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with a pendant PEG group (PEG-polyglycine) is provided, SrtA conjugates the PEG-polyglycine 
with the LPETG-tagged target protein (Figure 2.5A). 
 
Figure 2.5. Enzymatic PEGylation approaches. (A) PEGylation catalyzed by SrtA. (B) 
GlycoPEGylation. (C) PEGylation mediated by TGase. 
In an approach named GlycoPEGylation, a natural sialylation system is harnessed to 
introduce PEG molecules into target proteins (Figure 2.5B).20 A protein is first incubated with a 
galactosyltransferase and uridine 5¢-diphospho-N-acetylgalactosamine (UDP-GalNAc). Once the 
GalNAc is installed, the protein is incubated with a sialyltransferase and a cytidine monophosphate 
(CMP) activated sialic acid derivative containing a PEG moiety. The sialyltransferase adds the 
sialyl-PEG group to the GalNac residue and thus PEGylates the protein. 
Another class of enzymes for peptide and protein PEGylation are the transglutaminases 
(TGases, Figure 2.5C).21 These enzymes create a covalent bond between the primary amine from 
the PEG molecule and the carboxamide group of glutamine via an acyl transfer reaction. However, 
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this enzymatic strategy is limited by the requirement that the glutamine residue must be in a 
flexible loop portion of the target protein for catalysis by the transglutaminase. 
These enzymatic PEGylation methods rely solely on the substrate scope of the natural 
enzymes for site selectivity. However, in some cases, the site selectivity (if any) provided by the 
natural enzymes is not satisfactory for particular purposes. Therefore, DNA enzymes with 
PEGylation activity will be valuable alternative tools, especially considering that DNA enzymes 
with site selectivity can be de novo identified without the requirement of a known enzyme as the 
starting point. 
2.2 Results and Discussion 
2.2.1 In Vitro Selection Strategy 
To achieve DNA-catalyzed peptide and protein PEGylation, the PEG donors should be 
recognized by DNA enzymes. Considering the amorphous structure of PEG molecules after their 
hydration in water, additional recognition moieties in the PEG donors would be desired. The most 
expedient candidate is an oligonucleotide linker. A 5¢-phosphorylated 3¢-amino pentamer, 
pCGTGC-NH2, was chosen. The pentamer was conjugated to PEG carboxylic acid with average 
molecular weight of 5,000 (PEG5k-COOH) by the amide coupling reaction (Figure 2.6). Following 
the 5′-phosphorimidazolide (Imp) activation, this Imp-oligo-PEG5k conjugate served as the PEG 
donor in the PEGylation selection experiments.  
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Figure 2.6. Preparation of the PEG donor for in vitro selection experiments. PEG5k-COOH was 
first activated by N-(3-dimethylaminopropyl)-N¢-ethylcarbodiimide (EDC) and N-hydroxy-
succinimide (NHS), and then coupled with 5¢-phosphorylated 3¢-amino oligonucleotide at room 
temperature overnight. The yield of oligo-PEG5k synthesis was 40%. The 5¢-phosphoryl group was 
then transformed into 5′-phosphorimidazolide in quantitative yield by 2 h treatment with EDC and 
imidazole. 
Previous efforts by former Silverman lab graduate student Chih-Chi Chu for DNA-
catalyzed nucleopeptide formation showed that the Imp moiety is a reactive electrophile for the 
phenolic hydroxyl group on tyrosine side chain.22 Thus, the initial GA1 selection experiment was 
performed with the tripeptide CYA prepared by solid-phase peptide synthesis as the substrate 
(Figure 2.7). All in vitro selection experiments are given alphanumeric codes in the following 
pattern: A-Z, AA-ZZ, AA1-ZZ1, etc. This tripeptide was covalently attached via a disulfide 
linkage and a hexa(ethylene glycol) [HEG] tether to a DNA anchor oligonucleotide, which was 
bound by Watson-Crick base pairs to one of the fixed-sequence binding arms of the random N40 
DNA pool. The DNA-anchored peptide substrate was ligated to the initially random DNA pool 
using T4 DNA ligase. The initially random region of the DNA sequences was flanked by fixed-
sequence regions to enable PCR amplification of the DNA sequences and substrate binding. 
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Figure 2.7. Arrangement of initially random DNA pool (N40) and peptide substrate for the GA1 
selection experiment of deoxyribozymes for PEGylation. The dashed loop enables selection but is 
dispensable for catalysis. 
The GA1 selection experiment began with ligation of the initially random DNA pool to the 
DNA-anchored peptide substrate. The ligation product was isolated by polyacrylamide gel 
electrophoresis (PAGE). Next, the selection step was performed in which the DNA sequences were 
incubated with Imp-oligo-PEG5k and divalent metal ions in a buffered solution to enable DNA 
catalysis. After exposure of the substrate-conjugated N40 pool to the PEG donor, the catalytically 
active DNA sequences, which were now attached to an PEG group, were separated from the 
inactive pool by PAGE. As the standard for PAGE shift of the PEGylated DNA sequences, a 
5¢-phosphorylated 3¢-amino octamer, pTGGGTGCG-NH2, was conjugated to PEG5k-COOH by 
the amide coupling reaction and then ligated to the DNA pool (Figure 2.8). PCR was performed 
to amplify the catalytically active DNA sequences that survived the previous selection step. The 
entire selection process was iterated, each time enriching the population with catalytically active 
sequences, until the DNA enzymes dominated the population. 
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Figure 2.8. Preparation of PAGE shift standard for in vitro selection experiments. A 
5¢-phosphorylated 3¢-amino octamer was conjugated to PEG5k-COOH as described in the synthesis 
of the oligo-PEG5k conjugate and then ligated to the initially random pool. 
2.2.2 Identification and Characterization of Deoxyribozymes from the GA1 Selection 
Experiment 
The GA1 selection experiment was performed. In each selection round, the incubation 
conditions included 10 µM Imp-oligo-PEG5k in 70 mM HEPES, pH 7.5, 1 mM ZnCl2, 20 mM 
MnCl2, 40 mM MgCl2, and 150 mM NaCl at 37 °C for 14 h. After 7 rounds, the PEGylation 
activity of the pool reached 32% (Figure 2.9), and individual deoxyribozymes were cloned, which 
led to the identification of four different enzymes (Figure 2.10). All four sequences have 
PEGylation activity with 13-36% yield in 24 h (Figure 2.11A), when these enzymes are assayed 
in cis, i.e., ligating the DNA-anchored peptide substrate to the DNA pool. However, when these 
active sequences are assayed in trans, i.e., without ligating the DNA-anchored peptide substrate to 
the pool, only one enzyme, 7GA102, showed 34% PEGylation yield (Figure 2.11B). 
 
Figure 2.9. Progression of the GA1 selection experiment. Arrow marks the cloned round. 
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Figure 2.10. Sequences of the initially random region of the PEGylation deoxyribozymes 
identified from the GA1 selection experiment. A dot denotes conservation with the uppermost 
sequence, and a dash denotes a gap. 
 
Figure 2.11. Assays of the deoxyribozymes identified from the GA1 selection experiment (yield 
at 24 h). (A) In cis conditions. (B) In trans conditions. Incubation conditions: 70 mM HEPES, pH 
7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl at 37 °C with 10 µM Imp-
oligo-PEG5k. The PAGE image shows the PEGylation catalyzed by 7GA102 at 24 h. 
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Figure 2.12. Characterization of 7GA102 deoxyribozyme. (A) MALDI mass spectrometry 
analysis of 7GA102 product and PEG5k-COOH. (B) DTT assay for 7GA102 product. (C) Kinetic 
comparison of 7GA102 activity with CYA substrate and CYPA substrate. 
Tyrosine PEGylation catalyzed by 7GA102 was verified. MADLI mass spectrometry of 
the PEGylation product confirms the addition of the PEG moiety to the DNA-anchored peptide 
substrate (Figure 2.12A). 7GA102 product has a mass distribution with a full width at half 
maximum (FWHM) of 1000 that is similar to the FWHM for the mass distribution of 
PEG5k-COOH. Additionally, the average mass of 7GA102 product (~13500) matched with the 
calculated mass (13500) based on the average mass of PEG5k-COOH. The PEGylation product 
was reduced with dithiothreitol (DTT) to cleave the disulfide bond between the DNA anchor 
oligonucleotide and the tripeptide substrate (Figure 2.12B). The large PAGE shift upon DTT 
reduction suggested that the PEG group is installed on the tripeptide, in comparison with a much 
smaller PAGE shift induced by the removal of merely the tripeptide if PEGylation occurred at 
another position (for example, a nucleobase functional group). Moreover, the PEGylation 
catalyzed by 7GA102 is specific for tyrosine. With the DNA-anchored CYA substrate, 7GA102 
41 
deoxyribozyme has 34% PEGylation yield with kobs of 0.16 h–1 in 24 h (Figure 2.12C). On the 
contrary, the DNA-anchored phosphorylated tyrosine substrate (CYPA) is not a substrate. 
The interaction between 7GA102 deoxyribozyme and the Imp substrate was further 
evaluated. Several 5¢-phosphorylated 20-mer oligonucleotides were synthesized. After the Imp 
activation, these 20-mer oligonucleotides were used in place of Imp-oligo-PEG5k for the in trans 
assay (Figure 2.13). Catalytic activity with 51% yield in 24 h was observed when all five 
nucleotides (CGTGC) from the Imp-oligo-PEG5k were conserved at the 5¢-end of the 20-mer 
oligonucleotide (p-CGTGCAACAACAACAACAAC, referred to as Oligo1), establishing that the 
pentamer segment in the Imp substrate is the recognition motif by 7GA102 enzyme. A lower yield 
(14% yield in 24 h) was observed for 7GA102 deoxyribozyme when it was incubated with the 
Imp-activated 20-mer oligonucleotide substrate (p-CGCAACGCAATTAATGTGAG, referred to 
as Oligo2) in which only the first two nucleotides (CG) were conserved. Catalytic activity of 
7GA012 enzyme was abolished (<1% yield in 24 h) when the Imp-activated 20-mer 
oligonucleotide substrate used (p-CTACCTTTATGCGTATCGAA, referred to as Oligo3) has 
only a single nucleotide (5¢-C) conserved. The abolish of activity with Oligo3 suggested that a 
single nucleotide is not sufficient for the recognition by 7GA102 deoxyribozyme. The activity of 
7GA102 deoxyribozyme was also abolished when the Imp-activated 20-mer oligonucleotide 
substrate used (p-AACGGCCGCATCAGACAGCG, referred to as Oligo4) shares no conservation 
with the Imp-oligo-PEG5k substrate. The data above also suggests that 7GA102 enzyme can be 
used for the introduction of almost any modification X, by using Imp-CGTGC-X in place of Imp-
oligo-PEG5k during the catalysis. However, some synthetic effort might be required to prepare the 
p-CGTGC-X conjugate. For the sake of discussion, deoxyribozymes identified with 
Imp-oligo-PEG5k substrate will still be referred to as PEGylation deoxyribozymes in this 
dissertation. 
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Figure 2.13. 7GA102 reactivity with different Imp substrates. The table shows the sequences of 
oligonucleotides used. p represents a phosphoryl group. Underlined are conserved nucleotides 
from the Imp-oligo-PEG5k substrate used in the selection experiment. 
2.2.3 Reselection of 7GA102 Deoxyribozyme 
Reselection of 7GA102 deoxyribozyme was performed in the KJ1 selection experiment by 
generating a partially randomized pool (25% randomization). The fixed-sequence binding arms 
flanking the initially random region were changed to prevent contamination of the reselection 
experiment by the parent deoxyribozyme. A hexapeptide substrate CAAYAA was used instead of 
the tripeptide CYA. Activity was observed in reselection round 8 with 22% PEGylation yield 
(Figure 2.14A). However, when the active pool was assayed in trans, PEGylation was almost 
abolished with only 1.2% yield in 24 h (data not shown). This observation that selection pool is 
only active in cis was unexpected for this reselection experiment, because the parent 
deoxyribozyme for the reselection experiment, 7GA102, is active both in cis and in trans. One 
reasonable explanation is that before deoxyribozymes with desired activity were able to emerge, 
the population of selection pool had already been taken over by sequences that catalyze side 
reactions. A possible side reaction is the PEGylation of 5¢-hydroxyl group, which was supported 
by the elimination of in cis activity when 5¢-hydroxyl group was replaced with 5¢-phosphoryl 
group (Figure 2.14B). 
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Figure 2.14. Evaluation of the KJ1 reselection experiment. (A) Progression of the selection 
experiment. (B) In cis assay of KJ1 pool from round 8 with 5¢-hydroxyl group and 5¢-phosphoryl 
group (yield at 24 h). 
To avoid the emergence of sequences that PEGylate 5¢-hydroxyl group, another reselection 
experiment of 7GA102 deoxyribozyme, NH1, was initiated from DNA pool with an additional 
5¢-methoxy-T at the 5¢-end (Figure 2.15A). Primer oligonucleotide with 5¢-methoxy-T at the 5¢-end 
was also used during PCR step. After 7 rounds, the PEGylation activity of the pool reached 38% 
(Figure 2.15B). The active pool from round 7 showed robust PEGylation activity under both in cis 
and in trans conditions (Figure 2.15C). Time pressure was applied at round 7 by incubating the 
selection sample at 37 °C for 2 h. Upon the imposition of time pressure, the activity did not 
decrease much, indicating that fast deoxyribozymes had already dominated the pool. The active 
pool from round 7 was cloned, and eight deoxyribozymes were identified (Figure 2.16). The 
sequence alignment of 7GA102 and its reselected variants revealed that the 3¢-half of the initially 
random region was highly conserved. 
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Figure 2.15. Evaluation of the NH1 reselection experiment. (A) Design of the NH1 selection 
experiment. The 5¢-end of the initially random pool was protected by 5¢-methoxy-T, the structure 
of which is shown on the right. (B) Progression of the selection experiment. Arrow marks the 
cloned round. (C) Assay of the round 7 active pool under in cis and in trans conditions (yield at 24 
h). 
 
Figure 2.16. Sequences of the initially random region of the PEGylation deoxyribozymes 
identified from the NH1 selection experiment. The sequence of 7GA102 deoxyribozyme is also 
included. A dot denotes conservation with the uppermost sequence. A strongly conserved region 
is observed at the 3¢-end of the sequences, indicated by the grey box. 
Two representative deoxyribozymes, 7NH101 and 7NH108, were synthesized and 
characterized. Both enzymes show robust PEGylation activity (56% and 40%, respectively) on the 
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tethered CAAYAA substrate after 24 h incubation (Figure 2.17A). 7NH101 and 7NH108 
deoxyribozymes can also utilize the 20-mer DNA substrate Oligo1 after the Imp activation (Figure 
2.17B). 
 
Figure 2.17. Evaluation of the deoxyribozymes identified from the NH1 selection experiment. (A) 
Single-turnover PEGylation activity of 7NH101 and 7NH108. (B) Single-turnover catalytic 
activity of 7NH101 and 7NH108 with the activated 20-mer DNA substrate Oligo1. 
2.2.4 Selection Efforts towards Untethered Peptide Activity with Long Tether 
For the eventual goal of peptide and protein modification, deoxyribozymes such as 
7GA102 will be most useful if they can function with free peptide substrates that are not tethered 
to a DNA anchor oligonucleotide. Unfortunately, neither 7GA102 nor its reselected variants 
catalyze PEGylation of untethered peptide substrate. 
To identify PEGylation deoxyribozymes with untethered peptide activity, the NJ1 selection 
experiment was performed with a hexapeptide CAAYAA covalently attached via a disulfide 
linkage and a HEG10 tether to the DNA anchor (Figure 2.18A). Activity was observed in round 9 
with 6.5% PEGylation yield (Figure 2.18B). However, when the active pool was assayed in trans, 
catalyzed PEGylation was almost abolished with <0.5% yield in 24 h (data not shown). When in 
cis selection sample from round 8 was treated with DTT, only a small PAGE shift was observed 
for the PEGylated pool (Figure 2.18C), suggesting that the PEG moiety was not installed on the 
peptide but at another position (for example, a nucleobase functional group). This emergence of 
DNA sequences that catalyze side reactions is similar to the result of the KJ1 selection experiment. 
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Figure 2.18. NJ1 selection experiment with HEG10 tether. (A) Arrangement of initially random 
DNA pool (N40) and peptide substrate for the NJ1 selection experiment. (B) Progression of the 
selection experiment. (C) DTT assay for the round 8 active pool. 
Extensive study was performed by former Silverman lab graduate student Shannon Walsh 
using HEG10-tethered peptides during in vitro selection experiments to identify kinase 
deoxyribozymes with untethered peptide activity.23 Yet, no activity was observed for any of these 
selection experiments. Therefore, the tether dependence was evaluated for the nucleopeptide-
forming 8XJ105 deoxyribozyme that was identified from a selection experiment using untethered 
peptide substrates (Figure 2.19). Use of a tethered peptide substrate was expected to result in an 
increased yield compared to an untethered peptide substrate, and the peptide substrate connected 
via a longer tether such as the HEG10 tether was expected to react similarly to the untethered 
peptide substrate. As expected with the untethered peptide substrate, 8XJ105 catalyzes 
nucleopeptide formation in 30% yield. The nucleopeptide formation yield increases to 50% with 
the DNA-anchored HEG-tethered peptide substrate. Surprisingly, the HEG6 and HEG10-tethered 
peptide substrates are modified with only <5% yield. These results suggested that the initial 
hypothesis was incorrect; and a long tether between the DNA anchor and peptide substrate did not 
mimic an untethered peptide substrate. The long tether was not inert as expected and instead 
prevented the 8XJ105 deoxyribozyme from catalyzing the reaction of the peptide substrate. These 
results are similar to those observed for the 15MZ36 deoxyribozyme.24 15MZ36 catalyzes 
nucleopeptide formation in 75%, 60%, and 10% yield with C3-tethered, HEG-tethered, and 
untethered CYA, respectively. However, HEG10-tethered CYA is not modified (<0.5% in 24 h) by 
15MZ36. Combined, these results suggest that the use of tethers longer than HEG interfere with 
47 
DNA-catalyzed peptide modification. On this basis, the use of tethers longer than HEG during 
selection experiments was discontinued. 
 
Figure 2.19. The tether dependence of the nucleopeptide-forming 8XJ105 deoxyribozyme.23 
Untethered and tethered peptide substrates were evaluated. 8XJ105 successfully catalyzes the 
reaction of a free peptide and HEG-tethered peptide substrate. However, peptide substrates 
connected via a HEG6 or HEG10 tether were not accepted as substrates. Figure adapted with 
permission from ref. 23. 
2.2.5 Selection Efforts towards Untethered Peptide Activity Using Alternating Tethers 
Since the long tether between the peptide substrate and DNA anchor oligonucleotide does 
not mimic untethered peptide substrates, a new method to identify deoxyribozymes with 
untethered peptide reactivity is needed. In vitro selection experiments with alternating positions of 
the tethers between the peptide substrate and the DNA anchor are intended to identify 
deoxyribozymes that perform catalysis without the requirement of any tether (Figure 2.20). 
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Figure 2.20. The in vitro selection strategy using alternating tethers. 
In all previous efforts with PEGylation deoxyribozymes, in vitro selection experiments 
were performed with L substrates, i.e., peptide substrates tethered to the DNA anchors that were 
bound to the left-hand binding arms of DNA pools by Watson-Crick base pairs. The PN1 selection 
experiment was performed to validate that PEGylation deoxyribozymes can also be identified from 
selection experiments using R substrates, peptide substrates tethered to the DNA anchors base-
paired with the right-hand binding arms of DNA pools (Figure 2.21A). Considering the side 
reactions observed in the KJ1 and NJ1 selection experiments, an additional DTT reduction step 
was included. After the selection step, the PEGylated pool purified by PAGE was reduced by DTT, 
and another PAGE separation was performed. If the PEG group is attached not at the peptide 
substrate but instead at some undesired position within the DNA itself (for example, the 5¢-
hydroxyl group or a nucleobase functional group), then disulfide cleavage will lead to only a small 
PAGE shift, in comparison with the much larger PAGE shift upon removal of the entire PEG-
modified hexapeptide. Therefore, the difference in PAGE shift enables the separation of DNA 
enzymes with tyrosine PEGylation activity from sequences that catalyze side reactions. After 7 
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rounds, the PEGylation activity of the pool reached 16% (Figure 2.21B), and individual 
deoxyribozymes were cloned, which led to the identification of two different enzymes, 7PN106 
and 7PN113 (Figure 2.22). Both enzymes show PEGylation activity (5.6% and 14%, respectively) 
on the tethered AAYAAC substrate after 24 h incubation (Figure 2.23). 
 
Figure 2.21. The PN1 selection experiment using the R substrate. (A) Arrangement of initially 
random DNA pool (N40) and peptide substrate. (B) Progression of the selection experiment. Arrow 
marks the cloned round. 
 
Figure 2.22. Sequences of the initially random region of the PEGylation deoxyribozymes 
identified from the PN1 selection experiment. A dot denotes conservation with the uppermost 
sequence. 
 
Figure 2.23. Single-turnover PEGylation activity of 7PN106 and 7PN113 (yield at 24 h). 
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After the success in identifying deoxyribozyme from the PN1 selection experiment, a new 
in vitro selection experiment, TX1, was performed with alternating tether positions during odd and 
even rounds of the selection experiment (Figure 2.20). PEGylation was observed in round 7 with 
19% activity and in round 8 with 12% activity (Figure 2.24). The active pool from round 7 was 
cloned, and three deoxyribozymes, 7TX101, 7TX107, and 7TX113, were identified (Figure 2.25). 
All of these three deoxyribozymes have PEGylation yield of 42-69% in 24 h with the L substrate 
that was used during odd rounds (Figure 2.26A), while only 7TX101 and 7TX113 show robust 
PEGylation activity with the R substrate (37% and 16%, respectively). Similar to 7GA102 and its 
reselected variants, all three enzymes require only the pentamer segment in the Imp-oligo-PEG5k 
for catalysis (Figure 2.26B). Untethered peptide activity was evaluated by PAGE using 5¢-32P-
radiolabeled 20-mer DNA oligonucleotide substrate, Oligo1, for the two enzymes, 7TX101 and 
7TX113, that are active with both L and R substrates. However, no addition of the untethered 
peptide to Imp-activated Oligo1 was observed after 24 h incubation with either deoxyribozyme 
(Figure 2.26C). This result suggests that these two deoxyribozymes require a tethered peptide 
substrate for catalysis, though they do not require a specific tether position. This result also 
indicates a lack of interaction between the peptide substrate and the DNA pool during the TX1 
selection experiment.  
In three previous efforts with tyrosine-modifying deoxyribozymes, deoxyribozymes with 
better interaction with their peptide substrates have been found from selection experiments in 
which mixed-sequence peptides are used.22,25,26 Therefore, two new selection experiments, YR1 
and YS1, were designed, using the respective DNA-anchored peptides, TDNYTRL and 
VKKYLNS (Figure 2.27). Both peptide sequences are derived from human vasoactive intestinal 
peptide (VIP), which is involved in the regulation of circadian rhythm.27 The YR1 and YS1 
selection experiments are currently being performed by Silverman lab undergraduate student 
James Brady. 
51 
 
Figure 2.24. Progression of the TX1 selection experiment. Arrow marks the cloned round. 
 
Figure 2.25. Sequences of the initially random region of the PEGylation deoxyribozymes 
identified from the TX1 selection experiment. A dot denotes conservation with the uppermost 
sequence. 
 
Figure 2.26. Evaluation of deoxyribozymes identified from the TX1 selection experiment (yield 
at 24 h). (A) Single-turnover PEGylation activity assayed with both L and R substrates. (B) Single-
turnover activity with the activated 20-mer DNA substrate Oligo1. (C) Untethered peptide assay 
with 7TX101 and 7TX113 (S = substrate).  
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Figure 2.27. Design of in vitro selection experiments YR1 and YS1. 
2.3 Summary and Future Directions 
PEGylation is an important artificial post-translational modification for therapeutic 
peptides and proteins. PEGylation improves the pharmacokinetic properties of biopharmaceuticals 
by increasing circulation half-time, reducing immunogenicity, increasing solubility, and 
suppressing aggregation. Peptide and protein PEGylation is most commonly achieved by solely 
chemical means. However, these chemical strategies generally lack site selectivity among different 
target sites in the substrates. Some chemical strategies also suffer from off-target reactivity, i.e., 
poor chemo-selectivity. Enzymatic approaches for PEGylation have also been developed, yet their 
application is limited by substrate specificity and sequence selectivity of the natural enzymes used. 
These issues of current PEGylation methods can be addressed by de novo identification of 
deoxyribozymes. 
DNA enzymes were identified for PEGylation of tyrosine in a peptide substrate using a 5′-
phosphorimidazolide-activated oligonucleotide-PEG conjugate (Imp-oligo-PEG5k) as the PEG 
donor. The first deoxyribozyme, 7GA102, validated the in vitro selection strategy. Reselection of 
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7GA102 resulted in the emergence of DNA sequences that PEGylate the 5¢-hydroxyl group of the 
DNA pool. Another reselection experiment performed with an additional 5¢-methoxy-T at the 5¢-
end of the pool provided eight sequence variants of 7GA012. However, none of these 
deoxyribozymes functions with untethered peptide substrate. 
The NJ1 selection experiment was performed using the hexapeptide substrate CAAYAA 
connected to the DNA anchor with long tether. However, only DNA sequences that catalyze side 
reactions were enriched in the selection experiment. The study on tether dependence of 
nucleopeptide-forming deoxyribozymes with untethered peptide activity undermined the original 
hypothesis that a sufficiently long tether between the peptide and DNA anchor would mimic an 
untethered peptide substrate. Thus, the use of long tether during selection experiments was 
discontinued. 
A new method to identify deoxyribozymes with untethered peptide activity was developed. 
In vitro selection experiments with alternating positions of the tether between the peptide substrate 
and the DNA anchor are expected to identify deoxyribozymes that perform catalysis without the 
requirement of any tether. Moreover, after the selection step, the PEGylated pool purified by 
PAGE was reduced by DTT and another PAGE separation was performed. This additional 
DTT/PAGE operation was designed to avoid emergence of DNA sequences that catalyze 
undesired reactions. 7PN106 and 7PN113 deoxyribozymes were successfully identified from the 
PN1 selection experiment using peptide substrate tethered to DNA anchor base-paired with the 
right binding arm of the DNA pool. With the success of the PN1 selection experiment, the TX1 
selection experiment with alternating tether positions was performed, leading to the identification 
of 7TX101 and 7TX113 deoxyribozymes. However, no untethered peptide activity was observed 
for either DNA enzyme, even though robust PEGylation was catalyzed by both enzymes with 
tethered peptide substrates used during their identification. This result suggests that more 
interaction between the peptide substrate and the DNA pool is needed. Ongoing selection 
experiments YR1 and YS1 are using mixed-sequence peptide substrates with alternating tether 
positions for identification of deoxyribozymes with untethered peptide reactivity. 
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2.4 Materials and Methods 
2.4.1 Substrate Preparation Procedures 
Oligonucleotides and reagents. DNA oligonucleotides were obtained from Integrated DNA 
Technologies (Coralville, IA) or prepared by solid-phase synthesis on an ABI 394 instrument using 
reagents from Glen Research. All oligonucleotides were purified by 7 M urea denaturing PAGE 
with running buffer 1× TBE (89 mM each Tris and boric acid and 2 mM EDTA, pH 8.3) as 
described.28,29 PEG5k-COOH was obtained from JenKem Technology USA (Plano, TX). 
Solid-phase peptide synthesis. All amino acid monomers were obtained from Chem-Impex 
(Wood Dale, IL). Peptides were prepared by solid-phase synthesis using 
N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (HATU) as 
coupling agent, and using Fmoc Rink amide MBHA resin from Chem-Impex. Each synthesis was 
performed at 0.2 mmol scale, initiated using 0.260 g of Rink amide resin with a loading capacity 
of 0.77 mmol/g. All peptide synthesis operations were performed as previously described.30 
Synthesis of DNA-anchored peptide conjugates. DNA-anchored peptide conjugates were 
synthesized by disulfide formation between a DNA HEG-tethered 5¢- or 3¢-thiol and the N-terminal 
or C-terminal cysteine side chain of the peptide, as previously reported [HEG = hexa(ethylene 
glycol)].31The 5¢-thiol DNA anchor oligonucleotide was 5¢-HO-C6-SS-C6-p-HEG-X-3¢, and the 3¢-
thiol DNA anchor oligonucleotide was 5¢-X-HEG-p-C3-SS-C3-OH-3¢, where X represents the 
specific oligonucleotide sequence (Table 2.2). The 5¢- or 3¢-disulfide linker was introduced via 
standard solid-phase DNA synthesis and unmasked to a thiol by DTT treatment. The free thiol was 
activated as the pyridyl disulfide by treatment with 2,2¢-dipyridyl disulfide in DMF. The activated 
DNA substrate was coupled with the free thiol of the peptide N-terminal or C-terminal Cys, 
forming the DNA-anchored peptide conjugate. All steps were performed as previously described.31 
Synthesis of oligo-PEG5k conjugate. The oligo-PEG5k conjugate was synthesized by amide 
formation between a DNA 3¢-amino group and the carboxyl group of the PEG5k-COOH. The 3¢-
amino DNA oligonucleotide was 5¢-p-X-p-C7-NH2-3¢, where X represents the specific 
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oligonucleotide sequence (Table 2.2). A sample containing 5 nmol of 3¢-amino oligonucleotide 
was brought to 100 µL total volume containing 100 mM MES, pH 6.0, 5 mM PEG5k-COOH, 5 mM 
N-hydroxysuccinimide (NHS), 50 mM N-(3-dimethylaminopropyl)-N¢-ethylcarbodiimide (EDC), 
and 10% (v/v) DMF. The sample was incubated at room temperature for 12 h and purified by 15% 
PAGE. 
Procedures for the preparation of 5¢-Imp substrate. A sample containing 4 nmol of 
5¢-phosphorylated oligonucleotide was brought to 40 µL total volume containing 100 mM EDC 
and 100 mM imidazole (pH 6.0 with HCl). The sample was incubated at room temperature for 2 h. 
A Micro Bio-Spin P-6 desalting column (Bio-Rad) was prepared by centrifuging at 1000 g for 1 
min and rinsing 4´ by adding 500 µL of water followed by centrifuging at 1000 g for 1 min. The 
40 µL sample was applied to the column and eluted by centrifuging at 1000 g for 4 min. The eluent 
was quantified by UV absorbance (A260). The volume of the sample was brought down by 
SpeedVac so that the concentration of 5¢-Imp substrate was 100 µM. 
Procedure for 3¢-32P-radiolabeling of AAYAAC-HEG-DNA substrate. The AAYAAC-
HEG-DNA substrate was 3¢-32P-radiolabeled by incubating 20 pmol of the conjugate, 20 µCi of 
a-32P-dCTP (800 Ci/mmol), and 10 units of terminal deoxytransferase (Fermentas) in 20 µL of 1´ 
TdT reaction buffer (200 mM potassium cacodylate, 25 mM Tris, pH 7.2, 0.01% Triton X-100, 
and 1 mM CoCl2) at 37 °C for 30 min. The sample was purified by 20% PAGE. 
Table 2.2: Oligonucleotide sequences used in the selection experiments. All sequences are written 
5¢ to 3¢. T represents 5¢-methoxy-T. p represents a phosphoryl group. For all selections, the reverse 
PCR primer was (AAC)4XCCATCAGGATCAGCT, where X denotes the hexa(ethylene glycol) 
[HEG] spacer to stop Taq polymerase. 
oligonucleotide purpose oligonucleotide sequence 
  
pentamer DNA for oligo-PEG conjugate p-CGTGC-C7-NH2 
  
Preparation of selection standard 
octamer DNA for oligo-PEG conjugate p-TGGGTGCG-C7-NH2 
random pool for standard preparation CGAAGTCGCCATCTCTTC-N40-
ATAGTGAGTCGTATTAAGCTGATCCTGATGGGGATAATACGACTCACTAT 
splint for ligation step in standard preparation CGCACCCAATAGTGAGTCGTATTATCCCCATCAGGATCAGCT 
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Table 2.2 (cont.) 
oligonucleotide purpose oligonucleotide sequence 
  
Selection with DNA-HEG-CYA (leading to 7GA102) 
DNA-HEG-CYA substrate GGATAATACGACTCACTAT-HEG-CYA 
forward primer for selection CGAAGTCGCCATCTCTTC 
random pool for selection CGAAGTCGCCATCTCTTC-N40-ATAGTGAGTCGTATTAAGCTGATCCTGATGG 
splint for ligation step during selection ATATGTCTTTCAATAGTCCCCATCAGGATCAGCTCTATTGAAAGACATAT 
  
DNA substrate for evaluation of Imp substrate requirement 
DNA substrate Oligo1 p-CGTGCAACAACAACAACAAC 
DNA substrate Oligo2 p-CGCAACGCAATTAATGTGAG 
DNA substrate Oligo3 p-CTACCTTTATGCGTATCGAA 
DNA substrate Oligo4 p-AACGGCCGCATCAGACAGCG 
  
Reselection of 7G102 deoxyribozyme (KJ1 selection) 
DNA-HEG-CAAYAA substrate GGAATATCTCGTTTCTTAT-HEG-CAAYAA 
forward primer for selection CGAATTAAGACTGAATTC 
partially randomized pool for selection CGAAGTATAAACCTGTTC-N40-ATAAGAAACGAGATATAGCTGATCCTGATGG 
splint for ligation step during selection ATAAGAAACGAGATATTCCCCATCAGGATCAGCTATATCTCGTTTCTTAT 
  
Reselection of 7GA102 deoxyribozyme (leading to 7NH101 and 7NH108) 
DNA-HEG-CAAYAA substrate GGATCCTGGATACAAATAT-HEG-CAAYAA 
forward primer for selection TCGAAGTATAAACCTGTTC 
random pool for selection TCGAAGTATAAACCTGTTC-N40-ATATTTGTATCCAGGAAGCTGATCCTGATGG 
splint for ligation step during selection ATATTTGTATCCAGGATCCCCATCAGGATCAGCTTCCTGGATACAAATAT 
  
Selection with DNA-HEG10-CAAYAA (NJ1 selection) 
DNA-HEG10-CAAYAA substrate GGATAATACGACTCACTAT-HEG10-CAAYAA 
forward primer for selection TCGAAGTCGCCATCTCTTC 
random pool for selection TCGAAGTCGCCATCTCTTC-N40-ATAGTGAGTCGTATTAAGCTGATCCTGATGG 
splint for ligation step during selection ATATGTCTTTCAATAGTCCCCATCAGGATCAGCTCTATTGAAAGACATAT 
  
Selection with AAYAAC-HEG-DNA (leading to 7PN106 and 7PN113) 
AAYAAC-HEG-DNA substrate AAYAAC-HEG-GAACAGGTTTATACGGA 
forward primer for selection CGAAGTATAAACCTGTTC 
random pool for selection CGAAGTATAAACCTGTTC-N40-ATATTTGTATCCAGGAAGCTGATCCTGATGG 
splint for ligation step during selection GAACAGGTTTATACTTCGTCCGTATAAACCTGTTC 
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Table 2.2 (cont.) 
oligonucleotide purpose oligonucleotide sequence 
  
Selection with alternating AAYAAC-HEG-DNA and DNA-HEG-CAAYAA 
(leading to 7TX101, 7TX107, and 7TX113) 
AAYAAC-HEG-DNA substrate (odd rounds) AAYAAC-HEG-GAAATAGCCATCATGGA 
DNA-HEG-CAAYAA substrate (even rounds) GGACTATTGAAAGACATAT-HEG-CAAYAA 
forward primer for selection p-CGAAATGATGGCTATTTC 
random pool for selection p-CGAAATGATGGCTATTTC-N40-ATATGTCTTTCAATAGAGCTGATCCTGATGG 
splint for ligation step in odd round GAAATAGCCATCATTTCGTCCATGATGGCTATTTC 
splint for ligation step in even round ATATGTCTTTCAATAGTCCCCATCAGGATCAGCTCTATTGAAAGACATAT 
helper DNA for selection step in odd round GGACTATTGAAAGACATAT 
helper DNA for selection step in even round GAAATAGCCATCATGGA 
  
Selection with alternating TDNYTRLC-HEG-DNA and DNA-HEG-CTDNYTRL 
TDNYTRLC-HEG-DNA substrate (odd rounds) TDNYTRLC-HEG-GAAGGAGGCTTTCGGGA 
DNA-HEG-CTDNYTRL substrate (even rounds) GGACTACCTTTATGCGTAT-HEG-CTDNYTRL 
forward primer for selection p-CGAACGAAAGCCTCCTTC 
random pool for selection p-CGAACGAAAGCCTCCTTC-N40-ATACGCATAAAGGTAGAGCTGATCCTGATGG 
splint for ligation step in odd round GAGGCTTTCGTTCGTCCCGAAAGCCTCCTTC 
splint for ligation step in even round ATACGCATAAAGGTAGTCCCCATCAGGATCAGCTCTACCTTTATGCGTAT 
helper DNA for selection step in odd round GGACTACCTTTATGCGTAT 
helper DNA for selection step in even round GAAGGAGGCTTTCGGGA 
  
Selection with alternating VKKYLNSC-HEG-DNA and DNA-HEG-VKKYLNS 
VKKYLNSC-HEG-DNA substrate (odd rounds) VKKYLNSC-HEG-GAACTGTTGCAATGGGA 
DNA-HEG-CVKKYLNS substrate (even rounds) GGAGAGCCACTGATGATAT-HEG-CAAYAA 
forward primer for selection p-CGAACATTGCAACAGTTC 
random pool for selection p-CGAACATTGCAACAGTTC-N40-ATATCATCAGTGGCTCAGCTGATCCTGATGG 
splint for ligation step in odd round GAACTGTTGCAATGTTCGTCCCATTGCAACAGTTC 
splint for ligation step in even round ATATCATCAGTGGCTCTCCCCATCAGGATCAGCTGAGCCACTGATGATAT 
helper DNA for selection step in odd round GGAGAGCCACTGATGATAT 
helper DNA for selection step in even round GAACTGTTGCAATGGGA 
  
 
2.4.2 In Vitro Selection Procedures for GA1, KJ1, NH1, NJ1, and PN1 Selection 
Experiments 
Procedure for ligation step in round 1. A 25 µL sample containing 500 pmol of DNA pool, 
630 pmol of DNA splint, and 750 pmol of 5¢-phosphorylated DNA-anchored peptide substrate was 
annealed in 5 mM Tris, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 °C for 3 min 
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and cooling on ice for 5 min. To this solution was added 3 µL of 10´ T4 DNA ligase buffer that 
lacks DTT (400 mM Tris, pH 7.8, 100 mM MgCl2, and 5 mM ATP) and 2 µL of 5 U/µL T4 DNA 
ligase (Thermo Fisher). The sample was incubated at 37 °C for 12 h and purified by 8% PAGE. 
Procedure for ligation step in subsequent rounds. A 17 µL sample containing the PCR-
amplified DNA pool (~5–10 pmol), 40 pmol of DNA splint, and 60 pmol of 5¢-phosphorylated 
DNA-anchored peptide substrate was annealed in 5 mM Tris, pH 7.5, 15 mM NaCl, and 0.1 mM 
EDTA by heating at 95 °C for 3 min and cooling on ice for 5 min. To this solution was added 2 
µL of 10´ T4 DNA ligase buffer that lacks DTT (400 mM Tris, pH 7.8, 100 mM MgCl2, and 5 
mM ATP) and 1 µL of 1 U/µL T4 DNA ligase (Thermo Fisher). The sample was incubated at 37 
°C for 12 h and purified by 8% PAGE. 
Procedure for selection step in round 1. Each selection experiment was initiated with 200 
pmol of the ligated pool. A 16 µL sample containing 200 pmol of ligated pool was annealed in 5 
mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 °C for 3 min and cooling 
on ice for 5 min. The selection reaction was initiated by bringing the sample to 40 µL total volume 
containing 70 mM HEPES, pH 7.5, 40 mM MgCl2, 20 mM MnCl2, 1 mM ZnCl2, 150 mM NaCl, 
and 10 µM Imp-oligo-PEG5k. The Mn2+ was added from a 10´ stock solution containing 200 mM 
MnCl2. The Zn2+ was added from a 10´ stock solution containing 10 mM ZnCl2, 20 mM HNO3, 
and 200 mM HEPES at pH 7.5; this stock solution was freshly prepared from a 100´ stock of 100 
mM ZnCl2 in 200 mM HNO3. The metal ion stocks were added last to the final sample. The sample 
was incubated at 37 °C for 14 h and separated by 8% PAGE. 
Procedure for selection step in subsequent round. An 8 µL sample containing the ligated 
pool was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 
°C for 3 min and cooling on ice for 5 min. The selection reaction was initiated by bringing the 
sample to 20 µL total volume containing 70 mM HEPES, pH 7.5, 40 mM MgCl2, 20 mM MnCl2, 
1 mM ZnCl2, 150 mM NaCl, and 10 µM Imp-oligo-PEG5k. The sample was incubated at 37 °C for 
14 h and separated by 8% PAGE. 
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Procedure for DTT reduction in each round for PN1 selection. The sample from the 
selection step was brought to 20 µL total volume containing 100 mM HEPES, pH 7.5, and 50 mM 
DTT. The sample was incubated at 37 °C for 2 h and separated by 8% PAGE. 
Procedure for PCR. In each selection round, two PCR reactions were performed, 10-cycle 
PCR followed by 30-cycle PCR. First, a 100 µL sample was prepared containing the DTT 
reduction product, 200 pmol of forward primer, 50 pmol of reverse primer, 20 nmol of each dNTP, 
10 µL of 10´ polymerase buffer [1´ = 20 mM Tris-HCl, pH 8.8, 10 mM (NH4)2SO4, 10 mM KCl, 
2 mM MgSO4, and 0.1% Triton X-100], and Pfu polymerase. This sample was cycled according 
to the following PCR program: 94 °C for 2 min, 10´ (94 °C for 30 s, 47 °C for 30 s, 72 °C for 30 
s), 72 °C for 5 min. Pfu polymerase was removed by phenol/chloroform extraction. Second, a 50 
µL sample was prepared containing 1 µL of the 10-cycle PCR product, 100 pmol of forward 
primer, 25 pmol of reverse primer, 10 nmol of each dNTP, 20 µCi of a-32P-dCTP (800 Ci/mmol), 
5 µL of 10´ polymerase buffer, and Pfu polymerase. This sample was cycled according to the 
following PCR program: 94 °C for 2 min, 30´ (94 °C for 30 s, 47 °C for 30 s, 72 °C for 30 s), 72 
°C for 5 min. Samples were separated by 8% PAGE. 
2.4.3 In Vitro Selection Procedures for TX1, YR1, and YS1 Selection Experiments 
Procedures for ligation in even rounds, DTT reduction, and PCR were performed 
identically as those in GA1, KJ1, NH1, NJ1, and PN1 selection experiments. 
Procedure for ligation step in round 1. A 25 µL sample containing 500 pmol of 5¢-
phosphorylated DNA pool, 630 pmol of DNA splint, and 750 pmol of DNA-anchored peptide 
substrate was annealed in 5 mM Tris, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 
°C for 3 min and cooling on ice for 5 min. To this solution was added 3 µL of 10´ T4 DNA ligase 
buffer that lacks DTT (400 mM Tris, pH 7.8, 100 mM MgCl2, and 5 mM ATP) and 2 µL of 5 
U/µL T4 DNA ligase (Thermo Fisher). The sample was incubated at 37 °C for 12 h and purified 
by 8% PAGE. 
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Procedure for ligation step in subsequent odd rounds. A 17 µL sample containing the PCR-
amplified 5¢-phosphorylated DNA pool (~5–10 pmol), 40 pmol of DNA splint, and 60 pmol of 
DNA-anchored peptide substrate was annealed in 5 mM Tris, pH 7.5, 15 mM NaCl, and 0.1 mM 
EDTA by heating at 95 °C for 3 min and cooling on ice for 5 min. To this solution was added 2 
µL of 10´ T4 DNA ligase buffer that lacks DTT (400 mM Tris, pH 7.8, 100 mM MgCl2, and 5 
mM ATP) and 1 µL of 1 U/µL T4 DNA ligase (Thermo Fisher). The sample was incubated at 37 
°C for 12 h and purified by 8% PAGE. 
Procedure for selection step in round 1. Each selection experiment was initiated with 200 
pmol of the ligated pool. A 16 µL sample containing 200 pmol of ligated pool and 250 pmol of 
helper DNA (included to base pair with one of the fixed-sequence binding arms of the DNA pool) 
was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 °C for 
3 min and cooling on ice for 5 min. The selection reaction was initiated by bringing the sample to 
40 µL total volume containing 70 mM HEPES, pH 7.5, 40 mM MgCl2, 20 mM MnCl2, 1 mM 
ZnCl2, 150 mM NaCl, and 10 µM Imp-oligo-PEG5k. The Mn2+ was added from a 10´ stock 
solution containing 200 mM MnCl2. The Zn2+ was added from a 10´ stock solution containing 10 
mM ZnCl2, 20 mM HNO3, and 200 mM HEPES at pH 7.5; this stock solution was freshly prepared 
from a 100´ stock of 100 mM ZnCl2 in 200 mM HNO3. The metal ion stocks were added last to 
the final sample. The sample was incubated at 37 °C for 14 h and separated by 8% PAGE. 
Procedure for selection step in subsequent round. An 8 µL sample containing the ligated 
pool and 50 pmol of helper DNA was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 
mM EDTA by heating at 95 °C for 3 min and cooling on ice for 5 min. The selection reaction was 
initiated by bringing the sample to 20 µL total volume containing 70 mM HEPES, pH 7.5, 40 mM 
MgCl2, 20 mM MnCl2, 1 mM ZnCl2, 150 mM NaCl, and 10 µM Imp-oligo-PEG5k. The sample 
was incubated at 37 °C for 14 h and separated by 8% PAGE. 
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2.4.4 Cloning and Screening 
Using 1 µL of a 1:1000 dilution of the 10-cycle PCR product from the end of the selection 
round being cloned, 30-cycle PCR was performed using the above procedure, omitting a-32P-
dCTP and using 25 pmol of forward primer and 25 pmol of reverse cloning primer, where the 
extensions with TAA stop codons in each frame were included to suppress false negatives in blue-
white screening.32 The PCR product was purified on 2% agarose and cloned using a TOPO TA 
cloning kit (Invitrogen). Miniprep DNA samples derived from individual E. coli colonies were 
assayed by digestion with EcoRI to ascertain the presence of the expected inserts. Using the 
miniprep DNA samples, PCR (same conditions as 30-cycle PCR during selection, omitting a-32P-
dCTP) was performed to obtain the deoxyribozymes. Half of the PCR product was used to perform 
screening assays. Each screening assay used ~0.1 pmol of 5¢-32P-radiolabeled DNA-anchored 
peptide substrate or 3¢-32P-radiolabeled DNA-anchored peptide substrate, 50 pmol of helper DNA 
(if needed), and ~20 pmol of deoxyribozyme and followed the single-turnover assay procedure 
described in the subsequent section. 
2.4.5 Single-Turnover Deoxyribozyme in cis Assay Procedure 
The DNA-anchored peptide substrate was 5¢-32P-radiolabeled using g-32P-ATP and T4 
polynucleotide kinase. A 17 µL sample containing 0.4 pmol of 5¢-32P-radiolabeled DNA-anchored 
peptide substrate, 2 pmol of DNA splint, and 4 pmol of deoxyribozyme was annealed in 5 mM 
Tris, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 °C for 3 min and cooling on ice 
for 5 min. To this solution was added 2 µL of 10´ T4 DNA ligase buffer that lacks DTT (400 mM 
Tris, pH 7.8, 100 mM MgCl2, and 5 mM ATP) and 1 µL of 1 U/µL T4 DNA ligase (Thermo 
Fisher). The sample was incubated at 37 °C for 12 h and purified by 8% PAGE. 
A 4 µL sample containing the DNA-anchored peptide substrate ligated to an individual 
deoxyribozyme was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by 
heating at 95 °C for 3 min and cooling on ice for 5 min. The DNA-catalyzed reaction was initiated 
by bringing the sample to 10 µL total volume containing 70 mM HEPES, pH 7.5, 40 mM MgCl2, 
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20 mM MnCl2, 1 mM ZnCl2, 150 mM NaCl, and 10 µM freshly activated Imp substrate. The 
sample was incubated at 37 °C. At appropriate time points, a 2 µL aliquot was quenched with 6 
µL of stop solution (80% formamide, 1´ TBE [89 mM each Tris and boric acid and 2 mM EDTA, 
pH 8.3], 50 mM EDTA, 0.025% bromophenol blue, 0.025% xylene cyanol). Samples were 
separated by 8% PAGE and quantified with a PhosphorImager. 
2.4.6 Single-Turnover Deoxyribozyme in trans Assay Procedure 
The DNA-anchored peptide substrate was 5¢-32P-radiolabeled using g-32P-ATP and T4 
polynucleotide kinase. An 8 µL sample containing 0.1 pmol of 5¢-32P-radiolabeled DNA-anchored 
peptide substrate or 3¢-32P-radiolabeled DNA-anchored peptide substrate was annealed with 2 
pmol of deoxyribozyme in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 
95 °C for 3 min and cooling on ice for 5 min. The DNA-catalyzed reaction was initiated by 
bringing the sample to 20 µL total volume containing 70 mM HEPES, pH 7.5, 1 mM ZnCl2, 20 
mM MnCl2, 40 mM MgCl2, 150 mM NaCl, and 10 µM freshly activated Imp substrate. The sample 
was incubated at 37 °C. At appropriate time points, a 2 µL aliquot was quenched with 6 µL of stop 
solution (80% formamide, 1´ TBE [89 mM each Tris and boric acid and 2 mM EDTA, pH 8.3], 
50 mM EDTA, 0.025% bromophenol blue, 0.025% xylene cyanol). Samples were separated by 
20% PAGE and quantified with a PhosphorImager. Values of kobs were obtained by fitting the 
yield versus time data directly to first-order kinetics; i.e., yield = Y•(1 – e–kt), where k = kobs and Y 
is the final yield.  
2.4.7 Free Peptide Assay Procedure 
The 20-mer DNA substrate (Oligo1) was 5¢-32P-radiolabeled using g-32P-ATP and T4 
polynucleotide kinase. A sample containing 4 nmol of 5¢-phosphorylated Oligo1 and 2 pmol of 5¢-
32P-radiolabeled Oligo1 was brought to 40 µL total volume containing 100 mM EDC and 100 mM 
imidazole (pH 6.0 with HCl). The sample was incubated at room temperature for 2 h. A Micro 
Bio-Spin P-6 desalting column (Bio-Rad) was prepared by centrifuging at 1000 g for 1 min and 
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rinsing 4´ by adding 500 µL of water followed by centrifuging at 1000 g for 1 min. The 40 µL 
sample was applied to the column and eluted by centrifuging at 1000 g for 4 min. The eluant was 
dried by SpeedVac and redissolved in 8 µL of water. 
A 4 µL sample containing 200 pmol of deoxyribozyme and 220 pmol of both helper DNA 
oligonucleotides used during the identification of the deoxyribozyme was annealed with 175 pmol 
of AAYAA pentapeptide in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating 
at 95 °C for 3 min and cooling on ice for 5 min. The DNA-catalyzed reaction was initiated by 
bringing the sample to 10 µL total volume containing 70 mM HEPES, pH 7.5, 1.5 mM ZnCl2 
(optimized), 20 mM MnCl2, 40 mM MgCl2, 150 mM NaCl, and 25 µM Imp substrate. The sample 
was incubated at 37 °C for 24 h. Samples were separated by 20% PAGE and quantified with a 
PhosphorImager. 
2.4.8 Mass Spectrometry 
The PEGylation product was prepared from a 10 µL sample containing 1.0 nmol of DNA-
anchored HEG-tethered tripeptide substrate and 1.2 nmol of deoxyribozyme, which were annealed 
in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 °C for 3 min and 
cooling on ice for 5 min. The DNA-catalyzed PEGylation reaction was initiated by bringing the 
sample to 50 µL total volume containing 70 mM HEPES, pH 7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 
mM MgCl2, 150 mM NaCl, and 150 µM Imp-oligo-PEG5k. The sample was incubated at 37 °C for 
24 h and separated by 15% PAGE. The product was quantified after gel extraction by UV 
absorbance (A260), providing 55% overall yield for the PEGylation of the DNA-anchored peptide 
substrate. The gel-purified sample was analyzed by mass spectrometry on an Applied Biosystems 
Voyager DE-STR instrument with matrix 3-hydroxypicolinic acid in linear negative ion mode. 
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Chapter 3: DNA Enzymes with Tyrosine Azido-Adenylylation Activity on 
Peptide Substrates† 
3.1 Introduction 
3.1.1 Chemical Methods Targeting Tyrosine for Peptide and Protein Modification 
Synthesis of modified peptides and proteins is essential for understanding the functions of 
natural post-translational modifications, monitoring protein distributions in vivo, modulating 
therapeutic properties of peptides, proteins, antibodies, and antibody-drug conjugates, and other 
applications.1,2 In nature, tyrosine is modified via a wide array of chemical changes.3 Tyrosine 
has often been targeted for synthetic modification on the basis of its electron-rich nature and 
typically low abundance on protein surfaces. These chemical approaches are powerful tools for 
the synthesis of modified proteins, even though they each rely solely on differential physical 
accessibilities to discriminate among several tyrosines in the substrate. Some of these chemical 
methods also suffer from off-target reactivity of other electron-rich residues such as tryptophan. 
3.1.1.1 Transition Metal-Free Approaches 
Several transition-metal-free strategies have emerged for modifying tyrosine residues in 
protein substrates. Electron-deficient diazonium salts have been shown to react with tyrosine 
ortho to the phenol group (Figure 3.1A).4,5 The introduction of ketones, aldehydes, and more 
recently alkynes6 at the para position in the diazonium salts provides an additional biorthogonal 
handle for a second-step modification, for example, with fluorophore reagents. 
                                                             
† This research has been published:  
Wang, P.; Silverman, S. K. DNA-Catalyzed Introduction of Azide at Tyrosine for Peptide 
Modification. Angew. Chem. Int. Ed. 2016, 55, 10052-10056. 
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Figure 3.1. Chemical methods targeting tyrosine for peptide and protein modification. (A) 
Reaction with diazonium salts.4,5 (B) Three-component Mannich reaction.7 (C) Reaction with 
preformed imines.8 (D) Ene-type reaction with diazodicarboxylate reagents.9 (E) Ce(IV)-
mediated oxidative coupling reaction.10 (F) Pd-catalyzed allylic O-alkylation.11  
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Another approach developed for tyrosine modification is a three-component Mannich-
type reaction with aldehydes and anilines (Figure 3.1B).7 Solvent-exposed tyrosine residues 
found in lysozyme, RNase A, and chymotrypsinogen A can be successfully modified via this 
transformation. However, this approach has off-target activity with accessible tryptophan 
residues and reduced disulfides. 
Other methods for tyrosine modification include reaction with preformed imines (Figure 
3.1C)8 and aqueous ene-type reaction with azomaleimides (Figure 3.1D).9 The latter approach 
has been utilized for the preparation of well-defined glycoconjugate vaccines12 and DNA-protein 
conjugates in model streptavidin and myoglobin proteins.13 
3.1.1.2 Transition Metal-Mediated Approaches 
Oxidative couplings of tyrosine residues mediated by Ce(IV) have been explored (Figure 
3.1E).10 N,N-Dialkylated aniline bearing an additional electron-donating group in the para 
position was reported as the most reactive. With optimizations of incubation period and reagent 
concentrations, this strategy can be compatible with a variety of substrates. 
Tyrosine can also be modified by palladium-catalyzed Tsuji-Trost reaction (Figure 
3.1F).11 Tyrosine O-alkylation with a rhodamine dye or lipophilic moieties is achieved by using 
p-allylpalladium complexes that are generated from allyl acetates/carbamates and 
Pd(OAc)2/triphenylphosphine tris(sulfonate) (TPPTS) as a catalytic system. 
3.1.2 Enzymatic Methods Targeting Tyrosine for Peptide and Protein Modification 
Natural protein enzymes have been harnessed for tyrosine modification in a few cases. 
For example, an enzymatic cascade utilizes the tandem reaction comprising a fungal tyrosinase-
catalyzed hydroxylation of tyrosine to L-DOPA residue, followed by O-alkylation catalyzed by 
catechol-O-methyltransferase (COMT) (Figure 3.2A).14 However, this strategy cannot be used to 
modify tyrosine residues present within a-helices. 
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Figure 3.2. Enzymatic methods targeting tyrosine for peptide and protein modification. (A) 
Tandem enzymatic reaction with a fungal tyrosinase and the mammalian catechol 
O-methyltransferase (COMT).14 (B) Tyrosine oxidation followed by strain-promoted (4 + 2) 
cycloaddition.15  
In another example, a mushroom tyrosinase is used for in situ generation of 1,2-quinone 
from tyrosine, which is followed by strain-promoted quinone-alkyne cycloaddition (SPOCQ) 
with bicyclo[6.1.0]nonyne (BCN) (Figure 3.2B).15 This method was applied for the synthesis of 
an antibody-drug conjugate where BCN-monomethyl auristatin F conjugate was coupled with 
AT1002, a potent anti-influenza antibody, at the genetically engineered C-terminal tyrosine 
residue via SPOCQ. 
As discussed above, these enzymatic methods targeting tyrosine for peptide and protein 
modification rely on the substrate scope of the natural enzymes for site selectivity among 
different tyrosines. However, in some cases, the site selectivity (if any) provided by the natural 
enzymes is not satisfactory for particular purposes. Therefore, DNA enzymes with tyrosine 
modification activity will be valuable alternative tools, especially considering that DNA enzymes 
with site selectivity can be de novo identified without the requirement of a known enzyme as the 
starting point. 
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3.2 Results and Discussion 
3.2.1 In Vitro Selection Strategy 
To achieve DNA-catalyzed peptide and protein modification, a two-step approach was 
pursued (Figure 3.3A). In this approach, a deoxyribozyme first catalyzes the transfer of the 2¢-
azido-2¢-deoxyadenosine 5¢-monophosphoryl group (2¢-Az-dAMP) from the analogous 5¢-
triphosphate (2¢-Az-dATP) onto the tyrosine hydroxyl group (azido-adenylylation). Second, a 
particular modification of interest is attached to the azido group by copper-catalyzed azide-
alkyne cycloaddition (CuAAC)16,17 using an alkyne-functionalized reagent. 
 
Figure 3.3. Overview of DNA-catalyzed introduction of azide at tyrosine residues. (A) Two-step 
peptide modification by DNA-catalyzed azido-adenylylation and CuAAC, with PEGylation as 
the specific example. (B) Arrangement of initially random DNA pool (N40) and peptide substrate 
for in vitro selection of deoxyribozymes for azido-adenylylation. The dashed loop enables 
selection but is dispensable for catalysis. Figure adapted with permission from ref. 19. 
In vitro selection experiment was initially performed to establish viability of this 
approach. The hexapeptide CAAYAA prepared by solid-phase peptide synthesis was used as the 
substrate (Figure 3.3B). This hexapeptide was covalently attached via a disulfide linkage and a 
hexa(ethylene glycol) [HEG] tether to a DNA anchor oligonucleotide, which was bound by 
Watson-Crick base pairs to one of the fixed-sequence binding arms of the random N40 DNA 
pool. The DNA-anchored peptide substrate was ligated to the initially random DNA pool using 
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T4 DNA ligase. The initially random region of the DNA sequences was flanked by fixed-
sequence regions to enable PCR amplification of the DNA sequences and substrate binding. 
The in vitro selection process began with ligation of the initially random DNA pool to the 
DNA-anchored peptide substrate (Figure 3.4). The ligation product was isolated by 
polyacrylamide gel electrophoresis (PAGE). Next, the selection step was performed in which the 
DNA sequences were incubated with 2¢-Az-dATP and divalent metal ions in a buffered solution 
to enable DNA catalysis. After exposure of the substrate-conjugated N40 pool to 2¢-Az-dATP, the 
catalytically active DNA sequences, which were now attached to an azido group, were increased 
in mass by CuAAC with alkyne-modified poly(ethylene glycol) that has an average molecular 
weight of 5000 (PEG5k-alkyne). For catalytically active DNA sequences, this “capture step”18 
attachment of PEG induces a sufficiently large PAGE shift that enables the selection process. At 
the outset of these selection experiments, we did not have any way to prepare an exact standard 
with an azido-adenylylated peptide moiety. Therefore, as the capture control for both the 
CuAAC reaction and the PAGE migration, we used an azido-modified substrate that was 
prepared by conjugating a 3¢-C3-NH2 oligonucleotide with 6-azidohexanoic acid (Figure 3.5). 
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Figure 3.4. Diagram of in vitro selection procedure for deoxyribozymes with tyrosine azido-
adenylylation activity. 
 
Figure 3.5. PAGE image of capture control reaction using PEG5k-alkyne (S = substrate, 
P = product). Figure adapted with permission from ref. 19. 
After PAGE separation, treatment with dithiothreitol (DTT) cleaved the disulfide bond, 
and another PAGE separation was performed. As discussed in Chapter 2, this additional 
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DTT/PAGE operation proved necessary to avoid emergence of DNA sequences that catalyze 
undesired reactions. If the PEG-modified 2¢-Az-dAMP group is attached not at the tyrosine 
residue but instead at some undesired position within the DNA itself (for example, the 5¢-
hydroxyl group or a nucleobase functional group), then disulfide cleavage will lead to only a 
small PAGE shift, in comparison with the much larger PAGE shift upon removal of the entire 
PEG-modified hexapeptide. Therefore, the difference in PAGE shift enables the separation of 
DNA enzymes with azido-adenylylation activity from sequences that catalyze side reactions. 
PCR was performed to amplify the catalytically active DNA sequences that survived the 
previous selection, capture, and disulfide cleavage steps. The entire selection process was 
iterated, each time enriching the population with catalytically active sequences, until the DNA 
enzymes dominated the population. 
3.2.2 Identification and Characterization of DzAz1 Deoxyribozyme Family 
The initial selection experiment designated PP1 according to our systematic 
alphanumeric nomenclature was performed. In each selection round, the incubation conditions 
included 100 µM 2¢-Az-dATP in 70 mM HEPES, pH 7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM 
MgCl2, and 150 mM NaCl at 37 °C for 14 h. After 8 rounds, the azido-adenylylation activity of 
the pool reached 16% (Figure 3.6A), and individual deoxyribozymes were cloned.19 A single 
sequence, named DzAz1 (deoxyribozyme for azido-adenylylation 1, Figure 3.7), was identified. 
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Figure 3.6. Progression of the selection experiments PP1 (A) and RV1 (B). In each round, 
“control” refers to the yield for the control capture reaction using an azido-modified substrate, 
and “selection” refers to the yield for the CuAAC capture reaction for the indicated selection 
experiment. Arrows mark the cloned rounds. Figure adapted with permission from ref. 19. 
 
Figure 3.7. Sequences of the initially random region of the DzAz1 deoxyribozyme and 
reselected variants DzAz1b and DzAz1c. Dots denote the same nucleotide as in the uppermost 
sequence of the listing. Figure adapted with permission from ref. 19. 
Reselection of the DzAz1 deoxyribozyme was performed in the RV1 selection 
experiment by generating a partially randomized pool (25% randomization). The fixed-sequence 
binding arms flanking the initially random region were changed to prevent contamination of the 
reselection experiment by the parent deoxyribozyme (Table 3.2). The reselection was cloned 
from round 6 with 27% activity (Figure 3.6B). Two reselected variants DzAz1b and DzAz1c 
were identified (Figure 3.7). The sequence alignment of DzAz1, DzAz1b, and DzAz1c revealed 
that the 5¢-half of the N40 sequence was highly conserved. 
With the DNA-anchored CAAYAA substrate, the reselected variant DzAz1b has 58% 
single-turnover azido-adenylylation yield with kobs of 0.38 ± 0.03 h–1, and variant DzAz1c has 
56% yield with kobs of 0.19 ± 0.03 h–1; parent DzAz1 has 40% yield with kobs of 0.79 ± 0.07 h–1 
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(each n = 3, mean ± sd; Figure 3.8). Product identity was validated by MALDI mass 
spectrometry (Table 3.3). Both Zn2+ and one of Mn2+ or Mg2+ are required for catalysis; Mn2+ is 
much more effective (Figure 3.9). All three deoxyribozymes in the DzAz1 family retain 
substantial activity when natural ATP is used in place of 2¢-Az-dATP (Figure 3.8), suggesting 
utility of this general approach for studying natural tyrosine adenylylation (AMPylation).3,20,21 
 
Figure 3.8. Single-turnover kinetic assays of the DzAz1 deoxyribozyme and its variants DzAz1b 
and DzAz1c. Incubation conditions: 70 mM HEPES, pH 7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 
mM MgCl2, and 150 mM NaCl at 37 °C with 100 µM 2¢-Az-dATP or natural ATP. In the PAGE 
image, representative time points are shown for DzAz1b at t = 0, 2, and 24 h. S = substrate, P = 
product. Figure adapted with permission from ref. 19. 
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Figure 3.9. Assays of metal ion dependence of the DzAz1 deoxyribozyme and its DzAz1b and 
DzAz1c sequence variants. Each assay used the DNA-anchored CAAYAA peptide substrate. 
Incubation conditions: 70 mM HEPES, pH 7.5, combinations of 1 mM ZnCl2, 20 mM MnCl2, 
and 40 mM MgCl2 as appropriate, and 150 mM NaCl at 37 °C with 100 µM 2¢-Az-dATP. The 
yield at 24 h for each metal ion combination is shown. Figure adapted with permission from ref. 
19. 
The peptide sequence requirement of DzAz1 family deoxyribozymes was studied with 
four DNA-anchored octapeptides CLQTYPRT, CQQPYITN, CERSYLMK, and CFQPYMQE 
(Figure 3.10). The first peptide sequence comprises amino acids 19–25 from the 32-mer salmon 
calcitonin (sCT),22 and the remaining three sequences correspond respectively to amino acids 
15–21, 54–60 (with C56S), and 78–84 of human interleukin-22 (146-mer, hIL-22, amino acids 
34–179 of the genomic sequence);23 an artificial N-terminal cysteine was appended onto each 
peptide to allow disulfide linkage to the DNA anchor oligonucleotide. sCT is a hormone 
prescribed for bone-related disorders such as osteoporosis, Paget’s disease, and hypercalcemia; 
hIL-22 is a cytokine involved in proliferation, host defense, and the inflammatory response. All 
three deoxyribozyme show partial discrimination among the four peptide sequences. 
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Figure 3.10. Activities of DzAz1 family deoxyribozymes with the four DNA-anchored peptide 
substrates (yield at 24 h; n = 3, mean ± sd). Figure adapted with permission from ref. 19. 
3.2.3 Identification and Characterization of Peptide Sequence-Selective Deoxyribozymes  
In two previous efforts with tyrosine-modifying deoxyribozymes, peptide sequence-
selective catalysis by DNA was found from selection experiments in which mixed-sequence 
peptides were the substrates.24,25 Therefore, four new in vitro selection experiments, RW1–RZ1, 
were performed, each using one of the four respective DNA-anchored peptides CLQTYPRT, 
CQQPYITN, CERSYLMK, and CFQPYMQE. Each selection experiment was performed using 
the same incubation conditions as for the PP1 selection experiment. The fixed-sequence binding 
arms flanking the initially random region were varied between the selection experiments (Table 
3.2). After 8–12 rounds, each selection experiment showed 16–44% pool azido-adenylylation 
activity (Figure 3.11), and individual deoxyribozymes were cloned. 
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Figure 3.11. Progression of the selection experiments RW1 (A), RX1 (B), RY1 (C), and RZ1 
(D). In each round, “control” refers to the yield for the control capture reaction using an azido-
modified substrate, and “selection” refers to the yield for the CuAAC capture reaction for the 
indicated selection experiment. Arrows mark the cloned rounds. Figure adapted with permission 
from ref. 19. 
Five unique deoxyribozymes sequences designated DzAz2 through DzAz6 were 
identified from the RW1 selection experiment with the sCT-derived octapeptide CLQTYPRT, 
while the other three selections, RX1, RY1, and RZ1, with the hIL-22 peptides each led to a 
single DNA sequence, respectively named DzAz7, DzAz8, and DzAz9 (Figure 3.12). These 
eight new DNA enzymes share no obvious sequence conservation among themselves or with 
DzAz1 family enzymes. 
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Figure 3.12. Sequences of the initially random region of DzAz2–DzAz9 deoxyribozymes. Dots 
denote the same nucleotide as in the uppermost sequence of the listing. Figure adapted with 
permission from ref. 19. 
Among these eight deoxyribozymes, DzAz2, DzAz7, and DzAz8 catalyze azido-
adenylylation of their corresponding peptide substrates in 61–87% yield in 24 h with kobs of 0.1–
0.5 h–1 (Figure 3.13A); the other deoxyribozymes have lower 9–27% yields. Natural ATP is 
generally tolerated well in place of 2¢-Az-dATP (Figure 3.13B). Product identity was validated 
by MALDI mass spectrometry for DzAz2, DzAz7, and DzAz8 (Table 3.3) 
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Figure 3.13. Single-turnover kinetic assays of DzAz2–DzAz9 deoxyribozymes. Incubation 
conditions: 70 mM HEPES, pH 7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM 
NaCl at 37 °C with 100 µM 2¢-Az-dATP (A) or natural ATP (B). Figure adapted with permission 
from ref. 19. 
All eight deoxyribozymes were evaluated for azido-adenylylation activity with each of 
the four mixed-sequenced DNA-anchored peptides (Figure 3.14). DzAz8 does not discriminate 
among any of the peptide sequences. In sharp contrast, DzAz2 functions well only with the 
CLQTYPRT substrate that was used during its identification. The other six deoxyribozymes each 
exhibit partial discrimination among the four peptide sequences, which is similar to the behavior 
observed with DzAz1 family enzymes. 
82 
 
Figure 3.14. Activities of DzAz2–DzAz9 with the four DNA-anchored peptide substrates (yield 
at 24 h; n = 3, mean ± sd). Black bars denote the particular peptide substrate used during 
identification of that deoxyribozyme; grey bars are for the other peptide. Figure adapted with 
permission from ref. 19. 
The peptide sequence dependence of DzAz2 was analyzed further by testing its 
azido-adenylylation activity with systematic mutants of the DNA-anchored CLQTYPRT 
substrate. As expected, mutation of the tyrosine residue to phenylalanine or serine abolished 
activity (Figure 3.15A). The six amino acids surrounding the tyrosine residue were then 
individually replaced with alanine, revealing that the required motif is YPR (Figure 3.15B). 
Introduction of this YPR motif into the other three peptide substrates enabled their azido-
adenylylation by DzAz2 (Figure 3.15C), establishing YPR as both necessary and sufficient for 
DzAz2 reactivity. In contrast, although the activity of the non-selective DzAz8 deoxyribozyme 
was also abolished upon mutating the tyrosine residue to phenylalanine or serine, all alanine 
mutations of CLQTYPRT were tolerated well (Figure 3.16). 
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Figure 3.15. Peptide sequence requirement of DzAz2 (yield at 24 h; n = 3, mean ± sd). (A) 
Activity of DzAz2 upon mutation of Tyr to Phe or Ser in the DNA-anchored peptide substrate. 
Either mutation abolished activity. (B) Azido-adenylylation activity of DzAz2 with a series of 
DNA-anchored peptide substrates in which a single amino acid was mutated to Ala. (C) DzAz2 
activity requires only the YPR motif in the peptide substrate. Each of the three alternative DNA-
anchored peptide sequences was mutated to introduce the YPR motif while retaining all other 
existing amino acids. In all three cases, full activity was observed. Figure adapted with 
permission from ref. 19. 
 
Figure 3.16. Peptide sequence tolerance of DzAz8 (yield at 24 h; n = 3, mean ± sd). (A) Activity 
of DzAz8 upon mutation of Tyr to Phe or Ser in the DNA-anchored peptide substrate. Either 
mutation abolished activity. (B) Azido-adenylylation activity of DzAz8 with a series of DNA-
anchored peptide substrates in which a single amino acid was mutated to Ala. Figure adapted 
with permission from ref. 19. 
The ability of DzAz2 to differentiate between two tyrosine residues within one peptide 
substrate was also evaluated. The LQTYPRT (site 1) and QQPYITN (site 2) sequence motifs 
were concatenated in either order within a longer peptide substrate via an arbitrary tripepide 
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linker (ASK). The longer DNA-anchored peptide substrate was azido-adenylylated by DzAz2, 
and the product (as a mixture of site 1 and site 2 modifications) was PAGE-separated. The 
discrimination between the two sites was revealed by MALDI mass spectrometry (Figure 3.17), 
after Lys-C cleavage to separate the two peptide segments and DTT treatment to remove the 
DNA anchor oligonucleotide. Peak intensity ratios from MALDI mass spectrometry were used to 
calculate the discrimination factors, assuming that the response factor for each peptide fragment 
does not change upon azido-adenylylation. With the peptide substrate 
CLQTYPRTASKQQPYITN (peptide A), the two discrimination factors were 3.6 and 130; with 
the peptide substrate CQQPYITNASKLQTYPRT (peptide B), the two discrimination factors 
were 438 and 109. In each case, DzAz2 preferentially modified LQTYPRT (site 1), which 
suggested that DzAz2 is able to discriminate between two tyrosine residues within one longer 
peptide substrate on the basis of their sequence contexts. 
 
Figure 3.17. DzAz2 differentiates between two Tyr in one peptide substrate. Each peptide 
product fragment is labelled Prod1 or Prod2 corresponding to site 1 or site 2 modification, and 
with a subscripted L or R corresponding to the fragment location on the left or right side of the 
longer peptide before Lys-C cleavage. From each mass spectrum, peak intensity ratios were used 
to calculate two discrimination factors, one as Prod1L/Prod2L and the other as Prod1R/Prod2R, 
assuming that the response factor for each peptide fragment does not change upon azido-
adenylylation. For peptide A, Prod1L/Prod2L was 3.6, and Prod1R/Prod2R was 130; the smaller 
value is reported. For peptide B, Prod1L/Prod2L was 438, and Prod1R/Prod2R was 109. Figure 
adapted with permission from ref. 19. 
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3.2.4 Azido-Adenylylation of Untethered Peptide Substrates 
For the eventual goal of peptide and protein modification, deoxyribozymes such as 
DzAz8 will be most useful if they can function with free peptide substrates that are not tethered 
to a DNA anchor oligonucleotide. Azido-adenylylation of untethered sCT was achieved by 
DzAz8 in 14% yield in 24 h, as revealed by HPLC (Figure 3.18A). In contrast, the sCT-specific 
DzAz2 did not function with untethered sCT. DzAz8 was also assayed with the 28-mer N-
terminal fragment of atrial natriuretic peptide (atriopeptin, ANP), which can induce natriuresis 
(sodium excretion in urine) and vasodilation and is commercialized in Japan for treatment of 
heart failure.26 Azido-adenylylation of ANP by DzAz8 in 59% yield in 24 h was observed 
(Figure 3.18A). Both sCT and ANP were also adenylylated with natural ATP lacking the 
2¢-azido group, in respective yields of 6.7% and 16% (Figure 3.18B). 
 
Figure 3.18. Azido-adenylylation (A) and adenylylation (B) by DzAz8 of sCT and ANP, 
assayed by HPLC (t = 24 h). Figure adapted with permission from ref. 19. 
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The HPLC-purified azido-adenylylated sCT and ANP were further derivatized 
quantitatively via CuAAC using either PEG5k-alkyne or fluorescein-alkyne (Figure 3.19). The 
fluorescein-modified sCT and ANP were also validated by MALDI mass spectrometry (Table 
3.3). 
 
Figure 3.19. Modification via CuAAC of azido-adenylylated sCT and ANP with PEG5k-alkyne 
(A) and fluorescein-alkyne (B), assayed by SDS-PAGE and imaging by Coomassie stain or 
fluorescence. un = unmodified substrate; Az = azido-adenylylated substrate. S = substrate; P = 
product. std = 2, 5, 10 kDa. Ascorbate is the reducing agent required for CuAAC. Figure adapted 
with permission from ref. 19. 
3.2.5 Comparison between PEGylation Deoxyribozymes and Azido-Adenylylation 
Deoxyribozymes 
The properties of PEGylation deoxyribozymes discussed in Chapter 2 and azido-
adenylylation deoxyribozymes are compared in Table 3.1. In terms of the substrate scope, the 
PEGylation deoxyribozymes are only active with tethered peptide substrates. None of the 
PEGylation DNA enzymes work with untethered peptide substrates, and none were further tested 
with protein substrates. The azido-adenylylation deoxyribozymes are functional with both 
tethered and free peptide substrates. With tethered peptide substrates, some of the azido-
adenylylation DNA enzymes show peptide sequence selectivity. One such deoxyribozyme, 
DzAz8, is able to catalyze modification of free peptide substrates. However, no azido-
adenylylation product was observed when DzAz8 was tested with free protein substrates (data 
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not shown). Therefore, one of the future directions is to identify deoxyribozymes that can 
catalyze azido-adenylylation of protein substrates. 
Table 3.1: Comparison between PEGylation deoxyribozymes and azido-adenylylation 
deoxyribozymes. In the columns of substrate scope, “yes” or “no” represents whether the activity 
on the corresponding substrate is observed; “n/a” represents that the substrate was not assayed. 
deoxyribozyme type substrate scope reaction workflow 
tethered 
peptide 
untethered 
peptide 
protein step(s) to 
final product 
reagent 
availability 
PEGylation yes no n/a 1 synthesis needed 
azido-adenylylation yes yes no 2 commercially 
available 
In terms of the workflow for the preparation of modified peptides and proteins, 
PEGylation deoxyribozymes provides a one-step synthetic route to final products, whereas 
azido-adenylylation deoxyribozymes need a subsequent CuAAC step to incorporate the 
modification of interest. As discussed in Chapter 2, the PEGylation deoxyribozymes can be used 
to introduce any particular modification of interest by using the corresponding 
phosphorimidazolide-activated substrate where the PEG moiety used for PEGylation is replaced 
with the modification of interest, although some synthetic effort might be required to prepare the 
activated substrate. For the application of azido-adenylylation deoxyribozymes, 2¢-Az-dATP can 
be directly purchased, and various kinds of alkyne-functionalized reagents are commercially 
available. 
3.3 Summary and Future Directions 
Tyrosine has been explored as the target for the synthesis of modified peptides and 
proteins. Both chemical and enzymatic strategies for tyrosine modification have been developed. 
However, these approaches lack site selectivity among different tyrosines in the substrate. Some 
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tyrosine derivatization reactions suffer from off-target reactivity of other electron-rich residues 
such as tryptophan. The issues of poor site selectivity and chemoselectivity can be addressed by 
de novo identification of deoxyribozymes. 
DNA enzymes were identified for azido-adenylylation of tyrosine residues in peptide 
substrates, which provides the azido group for subsequent derivatization via CuAAC. The first 
deoxyribozyme, DzAz1, and its reselected mutants validated the in vitro selection strategy. Eight 
different deoxyribozymes were identified from in vitro selection experiments that used 
mixed-sequence peptide substrates. One of the DNA enzymes, DzAz2, is selective for the YPR 
sequence motif and is able to discriminate between tyrosine residues within a single peptide on 
the basis of sequence context. Another deoxyribozyme, DzAz8, is peptide sequence-general, 
functions with free peptides, and allows their subsequent CuAAC labeling with moieties such as 
PEG and fluorescein. 
These results reveal DNA enzymes as potential catalysts for the synthesis of 
site-selectively modified peptides and proteins. Finding peptide sequence selectivity by 
deoxyribozymes such as DzAz2, together with such observations made for two previously 
reported DNA-catalyzed reactions,24,25 establishes that DNA enzymes have the broader ability to 
interact with side chains of peptide substrates. The identification of DzAz8 also expands the list 
of DNA enzymes that can catalyze reactions of free peptide substrates. Future efforts are focused 
on combining the key features of peptide sequence selectivity and reactivity with free peptide 
substrates, and extending DNA-catalyzed reactivity from peptides to larger protein substrates. 
3.4 Materials and Methods 
3.4.1 Substrate Preparation Procedures 
Oligonucleotides, peptides, and DNA-anchored peptide conjugates were prepared as 
described in Chapter 2. PEG5k-alkyne was obtained from Laysan Bio (Arab, AL). Fluorescein-
alkyne was obtained from Tenova Pharmaceuticals (San Diego, CA). 2′-Az-dATP was obtained 
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from TriLink BioTechnologies (San Diego, CA). The peptides sCT and ANP were obtained from 
Anaspec (Fremont, CA). 
Preparation of azido-modified oligonucleotide for capture control. A sample containing 5 
nmol of 3¢-C3-NH2 oligonucleotide was brought to 100 µL total volume containing 100 mM 
MES, pH 6.0, 6 mM 6-azidohexanoic acid (Chem-Impex), 6 mM N-hydroxysuccinimide (NHS), 
50 mM N-(3-dimethylaminopropyl)-N¢-ethylcarbodiimide (EDC), and 10% (v/v) DMF. The 
sample was incubated at room temperature for 12 h and purified by HPLC [Shimadzu 
Prominence instrument; Phenomenex Gemini-NX C18 column, 5 µm, 10 ´ 250 mm; gradient of 
10% solvent A (20 mM triethylammonium acetate in 50% acetonitrile/50% water, pH 7.0) and 
90% solvent B (20 mM triethylammonium acetate in water, pH 7.0) at 0 min to 70% solvent A 
and 30% solvent B at 40 min with flow rate of 3.5 mL/min]. 
Table 3.2: Oligonucleotide sequences used in the selection experiments. All sequences are 
written 5¢ to 3¢. For all selections, the reverse PCR primer was (AAC)4XCCATCAGGATCAGCT, 
where X denotes the hexa(ethylene glycol) [HEG] spacer to stop Taq polymerase. Table adapted 
with permission from ref. 19. 
oligonucleotide purpose oligonucleotide sequence 
  
Selection with DNA-HEG-CAAYAA (leading to DzAz1) 
DNA-HEG-CAAYAA substrate GGACTATTGAAAGACATAT-HEG-CAAYAA 
forward primer for selection CGAAATGATGGCTATTTC 
random pool for selection CGAAATGATGGCTATTTC-N40-ATATGTCTTTCAATAGAGCTGATCCTGATGG 
splint for ligation step during selection ATATGTCTTTCAATAGTCCCCATCAGGATCAGCTCTATTGAAAGACATAT 
  
Reselection of DzAz1 deoxyribozyme (leading to DzAz1b and DzAz1c) 
DNA-HEG-CAAYAA substrate GGATCCTGGATACAAATAT-HEG-CAAYAA 
forward primer for selection CGAAGTATAAACCTGTTC  
partially randomized pool for selection CGAAGTATAAACCTGTTC-N40-ATATTTGTATCCAGGAAGCTGATCCTGATGG 
splint for ligation step during selection ATATTTGTATCCAGGATCCCCATCAGGATCAGCTTCCTGGATACAAATAT 
  
Selection with DNA HEG-CLQTYPRT (leading to DzAz2–DzAz6) 
DNA-HEG-CLQTYPRT substrate GGACTACCTTTATGCGTAT-HEG-CLQTYPRT 
forward primer for selection CGAACGAAAGCCTCCTTC 
random pool for selection CGAACGAAAGCCTCCTTC-N40-ATACGCATAAAGGTAGAGCTGATCCTGATGG 
splint for ligation step during selection ATACGCATAAAGGTAGTCCCCATCAGGATCAGCTCTACCTTTATGCGTAT 
  
90 
Table 3.2 (cont.) 
oligonucleotide purpose oligonucleotide sequence 
  
Selection with DNA HEG-CQQPYITN (leading to DzAz7) 
DNA-HEG-CQQPYITN substrate GGAATATCTCGTTTCTTAT-HEG-CQQPYITN 
forward primer for selection CGAATTAAGACTGAATTC 
random pool for selection CGAATTAAGACTGAATTC-N40-ATAAGAAACGAGATATAGCTGATCCTGATGG 
splint for ligation step during selection ATAAGAAACGAGATATTCCCCATCAGGATCAGCTATATCTCGTTTCTTAT 
  
Selection with DNA HEG-CERSYLMK (leading to DzAz8) 
DNA-HEG-CERSYLMK substrate GGAATGGCTTGATTGGTAT-HEG-CERSYLMK 
forward primer for selection CGAATTGAGTAAATATTC 
random pool for selection CGAATTGAGTAAATATTC-N40-ATACCAATCAAGCCATAGCTGATCCTGATGG 
splint for ligation step during selection ATACCAATCAAGCCATTCCCCATCAGGATCAGCTATGGCTTGATTGGTAT 
  
Selection with DNA HEG-CFQPYMQE (leading to DzAz9) 
DNA-HEG-CFQPYMQE substrate GGATCAGGTTACTAATTAT-HEG-CFQPYMQE 
forward primer for selection CGAAATAGATTATCATTC 
random pool for selection CGAAATAGATTATCATTC-N40-ATAATTAGTAACCTGAAGCTGATCCTGATGG 
splint for ligation step during selection ATAATTAGTAACCTGATCCCCATCAGGATCAGCTTCAGGTTACTAATTAT 
  
 
3.4.2 In Vitro Selection Procedures 
Procedures for ligation, DTT reduction, and PCR were performed as described in Chapter 
2. 
Procedure for selection step in round 1. Each selection experiment was initiated with 200 
pmol of the ligated pool. A 16 µL sample containing 200 pmol of ligated pool was annealed in 5 
mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 °C for 3 min and 
cooling on ice for 5 min. The selection reaction was initiated by bringing the sample to 40 µL 
total volume containing 70 mM HEPES, pH 7.5, 40 mM MgCl2, 20 mM MnCl2, 1 mM ZnCl2, 
150 mM NaCl, and 100 µM 2′-Az-dATP. The Mn2+ was added from a 10´ stock solution 
containing 200 mM MnCl2. The Zn2+ was added from a 10´ stock solution containing 10 mM 
ZnCl2, 20 mM HNO3, and 200 mM HEPES at pH 7.5; this stock solution was freshly prepared 
from a 100´ stock of 100 mM ZnCl2 in 200 mM HNO3. The metal ion stocks were added last to 
the final sample. The sample was incubated at 37 °C for 14 h and precipitated with ethanol. 
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Procedure for selection step in subsequent round. An 8 µL sample containing the ligated 
pool was annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 
°C for 3 min and cooling on ice for 5 min. The selection reaction was initiated by bringing the 
sample to 20 µL total volume containing 70 mM HEPES, pH 7.5, 40 mM MgCl2, 20 mM MnCl2, 
1 mM ZnCl2, 150 mM NaCl, and 100 µM 2′-Az-dATP. The sample was incubated at 37 °C for 
14 h and precipitated with ethanol. 
Procedure for capture step in each round. The sample from the selection step was brought 
to 20 µL total volume containing 100 mM HEPES, pH 7.5, 10 mM PEG5k-alkyne, 40 mM tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA), 10 mM sodium ascorbate, and 5 mM CuSO4. 
The concentrations of all reagents were optimized (not shown). The four reagents were added 
from 100 mM (10´), 1 M (25´), freshly prepared 100 mM (10´), and 100 mM (20´) stock 
solutions, respectively; the four reagents were mixed together and then added at once to the other 
components. The sample was incubated at 4 °C for 1 h and separated by 8% PAGE. 
3.4.3 Cloning and Screening 
Cloning and screening were performed as described in Chapter 2. 
3.4.4 Single-Turnover Deoxyribozyme Assay Procedure 
The DNA-anchored peptide substrate was 5¢-32P-radiolabeled using g-32P-ATP and T4 
polynucleotide kinase. An 8 µL sample containing 0.1 pmol of 5¢-32P-radiolabeled DNA-
anchored peptide substrate and 2 pmol of deoxyribozyme was annealed in 5 mM HEPES, pH 
7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 °C for 3 min and cooling on ice for 5 
min. The DNA-catalyzed azido-adenylylation reaction was initiated by bringing the sample to 20 
µL total volume containing 70 mM HEPES, pH 7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM 
MgCl2, 150 mM NaCl, and 100 µM 2′-Az-dATP or ATP. The sample was incubated at 37 °C. At 
appropriate time points, a 2 µL aliquot was quenched with 6 µL of stop solution (80% 
formamide, 1´ TBE [89 mM each Tris and boric acid and 2 mM EDTA, pH 8.3], 50 mM EDTA, 
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0.025% bromophenol blue, 0.025% xylene cyanol). Samples were separated by 20% PAGE and 
quantified with a PhosphorImager. Values of kobs were obtained by fitting the yield versus time 
data directly to first-order kinetics; i.e., yield = Y•(1 – e–kt), where k = kobs and Y is the final yield. 
Each kobs value is reported with error calculated as the standard deviation from the indicated 
number of independent determinations. 
3.4.5 Tyrosine Site Discrimination Assay for DzAz2 
The azido-adenylylation product of peptide A or peptide B was prepared from an 8 µL 
sample containing 600 pmol of DNA-anchored HEG-tethered peptide substrate and 660 pmol of 
deoxyribozyme, which were annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM 
EDTA by heating at 95 °C for 3 min and cooling on ice for 5 min. The DNA-catalyzed azido-
adenylylation reaction was initiated by bringing the sample to 20 µL total volume containing 70 
mM HEPES, pH 7.5, 1 mM ZnCl2, 20 mM MnCl2, 40 mM MgCl2, 150 mM NaCl, and 100 µM 
2′-Az-dATP. The sample was incubated at 37 °C for 24 h and separated by 20% PAGE. The 
product was quantified by absorbance (A260); in each case, ~400 pmol was obtained. From each 
sample, 50 pmol was dissolved in 5 µL of water and brought to a total volume of 10 µL 
containing 100 mM Tris, pH 8.0, 40 mM DTT, and 0.6 ng/µL Lys-C (Roche cat. no. 
11420429001). The sample was incubated at 37 °C for 12 h, desalted by Millipore C18 ZipTip, 
and analyzed by MALDI mass spectrometry (Bruker UltrafleXtreme, matrix 2,5-
dihydroxybenzoic acid). 
3.4.6 Free Peptide Assay Procedure 
The azido-adenylylation or adenylylation product from each untethered peptide was 
prepared from a 10 µL sample containing 3.3 nmol of free unmodified DNA anchor 
oligonucleotide (lacking 3′-phosphate, HEG, and thiol) and 3 nmol of deoxyribozyme, which 
were annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 °C 
for 3 min and cooling on ice for 5 min. The DNA-catalyzed azido-adenylylation reaction was 
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initiated by bringing the sample to 30 µL total volume containing 70 mM HEPES, pH 7.5, 5 mM 
ZnCl2 (optimized), 20 mM MnCl2, 40 mM MgCl2, 150 mM NaCl, 100 µM untethered peptide 
and 1 mM 2′-Az-dATP or ATP. The sample was incubated at 37 °C for 24 h and separated by 
HPLC (Shimadzu Prominence instrument; Phenomenex Jupiter Proteo C12 column, 4 µm, 
10 ´ 250 mm). The reaction for azido-adenylylation or adenylylation of sCT was analyzed with a 
gradient of 28% solvent A (acetonitrile) and 72% solvent B (0.1% TFA in water) at 0 min to 
40% solvent A and 60% solvent B at 60 min with flow rate of 2 mL/min. The reaction for azido-
adenylylation or adenylylation of ANP was analyzed with a gradient of 17% solvent A and 83% 
solvent B at 0 min to 29% solvent A and 71% solvent B at 60 min with flow rate of 2 mL/min. 
The HPLC-purified sample was analyzed by MALDI mass spectrometry (Bruker 
UltrafleXtreme, matrix 2,5-dihydroxybenzoic acid). The HPLC response factor of azido-
adenylylated or adenylylated peptide over unmodified peptide was assigned as 1.2 on the basis of 
UV absorbance data (A205) for sCT, ANP, and AMP. The yield of each DzAz8-catalyzed 
reaction was calculated from the peak integrals, accounting for the response factor. 
3.4.7 CuAAC Derivatization of Azido-Adenylylated Peptide Substrates 
For CuAAC modification of each azido-adenylylated peptide product, 0.4 nmol of 
HPLC-purified sample was brought to 5 µL total volume containing 100 mM HEPES, pH 7.5, 10 
mM PEG5k-alkyne or fluorescein-alkyne, 40 mM tris(3-hydroxypropyltriazolylmethyl)amine 
(THPTA), 10 mM sodium ascorbate, and 5 mM CuSO4. The final four reagents were added from 
100 mM (10´; PEG5k-alkyne in water and fluorescein-alkyne in DMSO), 1 M (25´), freshly 
prepared 100 mM (10´), and 100 mM (20´) stock solutions, respectively; the four reagents were 
mixed together and then added at once to the other components. The sample was incubated at 4 
°C for 1 h. For SDS-PAGE analysis, the sample was separated by 16.5% Tris-Tricine SDS-
PAGE. For mass spectrometry, the sample was analyzed by MALDI mass spectrometry (Bruker 
UltrafleXtreme, matrix 2,5-dihydroxybenzoic acid). 
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3.4.8 Mass Spectrometry 
The azido-adenylylation product was prepared from an 8 µL sample containing 600 pmol 
of DNA-anchored HEG-tethered peptide substrate and 660 pmol of deoxyribozyme, which were 
annealed in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA by heating at 95 °C for 3 
min and cooling on ice for 5 min. The DNA-catalyzed azido-adenylylation reaction was initiated 
by bringing the sample to 20 µL total volume containing 70 mM HEPES, pH 7.5, 1 mM ZnCl2, 
20 mM MnCl2, 40 mM MgCl2, 150 mM NaCl, and 100 µM 2′-Az-dATP. The sample was 
incubated at 37 °C for 24 h and separated by 20% PAGE. The PAGE-purified sample was 
desalted by Millipore C18 ZipTip and analyzed by MALDI mass spectrometry (Bruker 
UltrafleXtreme; matrix 3-hydroxypicolinic acid). 
Table 3.3: MALDI mass spectrometry data. “DNA” here refers to the DNA anchor 
oligonucleotide. The azido group in azido-adenylylation product of peptide A or peptide B was 
reduced to an amino group by the DTT used to cleave the peptide from the DNA anchor 
oligonucleotide.27 The calculated mass takes this reaction into account. Table adapted with 
permission from ref. 19. 
deoxyribozyme product [M+H]+ 
calcd. 
[M+H]+ 
found 
error, % 
(found – calcd.) 
DzAz1 DNA-HEG-CAAY(Az-dAMP)AA 7317.4 7319.6 +0.03 
DzAz2 DNA-HEG-CLQTY(Az-dAMP)PRT 7664.6 7667.6 +0.04 
DzAz7 DNA-HEG-CQQPY(Az-dAMP)ITN 7639.6 7642.5 +0.04 
DzAz8 DNA-HEG-CERSY(Az-dAMP)LMK 7832.7 7835.8 +0.04 
DzAz2 peptide A, Prod 1R 862.4 862.5 +0.01 
DzAz2 peptide A, Prod 2R 1190.0 1190.6 +0.05 
DzAz2 peptide A, Prod 2L 1309.6 1309.7 +0.008 
DzAz2 peptide A, Prod 1L 1637.7 1637.8 +0.006 
DzAz2 peptide B, Prod 2R 877.5 877.5 0 
DzAz2 peptide B, Prod 1R 1205.0 1205.6 +0.05 
DzAz2 peptide B, Prod 1L 1294.6 1294.7 +0.008 
DzAz2 peptide B, Prod 2L 1622.7 1622.8 +0.006 
DzAz8 sCT-(Az-dAMP) 3784.8 3787.6 +0.07 
DzAz8 ANP-(Az-dAMP) 3433.5 3434.7 +0.03 
DzAz8 sCT-AMP 3759.8 3762.9 +0.08 
DzAz8 ANP-AMP 3408.5 3410.3 +0.05 
– sCT-Fluorescein 4197.9 4199.4 +0.04 
– ANP-Fluorescein 3846.6 3844.6 –0.05 
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Chapter 4: Efforts towards DNA-Catalyzed Tyrosine Azido-Adenylylation of 
Protein Substrates† 
4.1 Introduction 
4.1.1 DNA-Catalyzed Modification of Protein Substrates 
Deoxyribozymes with the ability to site-specifically modify protein substrates can be 
powerful tools for biochemical studies. However, the phosphatase 14WM9 deoxyribozyme  is the 
only DNA enzyme known to function with a protein substrate.1 The 14WM9 deoxyribozyme can 
catalyze the dephosphorylation reaction in a 91-mer protein that has the phosphotyrosine-
containing peptide segment, CAAYPAA, at the C-terminus (Figure 4.1). Although this study 
showed that the 14WM9 DNA enzyme was capable of recognizing the YP residue in the context 
of a protein substrate, the reaction site was located at the unstructured end of the protein. Therefore, 
this result is still very different from modifying an amino acid side chain in a protein region with 
a well-defined structure. 
                                                             
†  Former Silverman laboratory graduate student Jagadeeswaran Chandrasekar identified the 
phosphatase deoxyribozymes and evaluated the 14WM9 activity with the protein substrate.1 
Former Silverman laboratory graduate student Chih-Chi Chu evaluated the recruiting effects of 
His6 tag and thrombin-binding aptamers on deoxyribozymes.2, 3 
Former Silverman laboratory staff Kevin M. Duffin performed in vitro selection experiments with 
unmodified DNA pools to identify aptamers that bind human annexin V and human TNF-related 
apoptosis-inducing ligand (TRAIL) 114–281. 
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Figure 4.1. Dephosphorylation of a larger protein substrate by the 14WM9 deoxyribozyme. The 
91-mer protein derived from prochlorosin ProcA2.8 and ending with ...CAAYPAA at its C-
terminus was dephosphorylated by the 14WM9 deoxyribozyme, digested in-gel by Lys-C, and 
analyzed by MALDI mass spectrometry. Figure adapted with permission from ref. 1. 
One of the challenges associated with DNA-catalyzed modification of protein substrates is 
the accessibility by a deoxyribozyme to the target residue on a structured protein, where both the 
DNA enzyme and the protein substrate are large biomolecules. Another challenge is the sufficient 
interaction between the deoxyribozyme and the target peptide segment to enable catalysis within 
the context of the protein structure. Both challenges might be overcome by identifying DNA 
enzymes from selection experiments that directly use protein substrates. If a deoxyribozyme has 
the ability to access and interact with the target residue for catalysis, then another major practical 
challenge is to achieve catalysis at low protein concentrations. In the previous chapter, azido-
adenylylation of untethered peptides was performed with 100 µM of the substrates. Such 
concentration might be impractically high for protein substrates. The concentration issue can be 
addressed if deoxyribozymes are recruited to their target proteins. 
4.1.2 Recruiting DNA Enzymes to Their Substrates by Hexahistidine (His6) Tags 
The ability of hexahistidine (His6) tags on peptide and protein substrates to recruit 
deoxyribozymes for modifying those substrates has been evaluated by former Silverman lab 
graduate student Chih-Chi Chu.2 In this study, the metal-mediated interaction between a His6 tag 
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and a nitrilotriacetic acid (NTA) group was used (Figure 4.2A). The tris(NTA)-modified DNA 
anchor oligonucleotide forms Watson-Crick base pairs with the fixed-sequence binding arm of the 
deoxyribozyme, which allows recruiting of the DNA enzyme to the His6-tagged peptide or protein 
substrate. 
 
Figure 4.2. Recruiting DNA enzymes to their substrates by hexahistidine (His6) tags. (A) The 
strategy of recruiting a DNA enzyme to its peptide or protein substrate for DNA-catalyzed 
modification of peptide or protein side chains. X = the amino acid side chain; Y–Z = the reaction 
partner for the peptide or protein. (B) Histidine tag recruiting improves both reaction rate and Km 
for the nucleopeptide-forming 8XJ105 deoxyribozyme using Cu2+ as the recruiting metal ion. (C) 
MALDI mass spectrometry analysis of the histidine recruiting effect for 6CF134. A negative 
control omitting the 3¢-tris(NTA) is shown with 0.9% conversion of the product. Figure modified 
with permission from ref. 2. 
For the nucleopeptide-forming 8XJ105 deoxyribozyme, this His6 tag recruiting strategy 
provided substantial improvements in yield, kobs, and Km for peptide substrates (Figure 4.2B). The 
His6/Cu2+ recruiting effect also allowed, for the first time, successful DNA-catalyzed tyrosine 
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phosphorylation of a discrete, untethered peptide substrate by the tyrosine kinase 6CF134 
deoxyribozyme (Figure 4.2C). However, where tested, DNA-catalyzed protein modification using 
this recruiting strategy was not observed. This unsuccessful outcome with protein substrates may 
be due to the inaccessibility of the targeting amino acid side chain or the difficulty for the 
deoxyribozymes to have enough interactions with the peptide segment for catalysis within the 
context of the protein structure. 
4.1.3 Recruiting DNA Enzymes to Their Substrates by Aptamer Modules 
The use of aptamers that bind to target proteins is another promising strategy for recruiting 
DNA enzymes to their protein substrates. Former Silverman lab graduate student Chih-Chi Chu 
also investigated the recruiting effect of thrombin-binding aptamer on the nucleopeptide-forming 
8XJ105 deoxyribozyme.3 In this study, the previously identified thrombin-binding 29-mer DNA 
aptamer HD22-29 (Apt29) was connected to the 8XJ105 deoxyribozyme at either the 3¢- or the 5¢-
end of the DNA enzyme by an oligonucleotide linker (A15). 8XJ105 is a peptide-sequence-general 
deoxyribozyme which shows robust catalytic yields with four thrombin-related tyrosine-
containing peptides (Figure 4.3A). 
 
Figure 4.3. Recruiting DNA enzymes to their substrates by aptamer modules, exemplified by the 
8XJ105 deoxyribozyme. (A) Peptide sequence tolerance of the 8XJ105 deoxyribozyme. The four 
peptides used are thrombin-related peptide segments located on the protein surface. (B) 
Determination of Kd value of Apt29 by filter-binding assay. (C) Thrombin binding of Apt29 and 
Apt29-8XJ105 conjugates in conditions where the Apt29-8XJ105 conjugates are catalytically 
active. Nonspecific binding was also observed for 8XJ105 and the arbitrary 18-mer DNA 
oligonucleotide (AAC)6. Figure adapted with permission from ref. 3. 
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Substantial binding of thrombin was observed for Apt29 at protein concentration of 100 
nM, when the aptamer was not connected to the 8XJ105 deoxyribozyme and tested under aptamer 
binding conditions (Figure 4.3B). However, under DNA-catalyzed reaction conditions, severe 
nonspecific binding was observed in negative controls with only 8XJ105 or the arbitrary 18-mer 
DNA oligonucleotide (AAC)6, even after extensive optimization of the conditions (Figure 4.3C). 
The binding of the Apt29-8XJ105 conjugates to thrombin was not verified due to nonspecific 
binding. Furthermore, no DNA-catalyzed reaction product was observed in SDS-PAGE for assays 
of Apt29-8XJ105 conjugates with thrombin (data not shown). 
In conclusion, for the case evaluated (one deoxyribozyme with one protein substrate), 
joining a DNA aptamer unit to a deoxyribozyme did not enable DNA-catalyzed modification of a 
protein substrate. However, the major issue observed in this study was the incompatibility between 
the aptamer binding conditions and the DNA-catalyzed reaction conditions. We anticipate that this 
issue can be resolved by de novo identification of suitable DNA aptamers for the DNA enzyme 
selection conditions. 
4.1.4 Modified Nucleotides Incorporated into Aptamers 
DNA aptamers have been identified to bind to many protein substrates via SELEX 
(Systematic Evolution of Ligands by EXponential enrichment). To increase the binding affinity 
between the aptamers and protein substrates, DNA aptamers with hydrophobic modifications have 
been identified (Figure 4.4A).4-6 In many cases, unmodified aptamers have weak binding affinities 
(Kd > 100 nM). Upon incorporation of hydrophobic modifications, selection experiments result in 
the identification of modified aptamers that have better binding affinities with dissociation 
constants in the low nanomolar range. The use of hydrophobic modifications during selection 
experiments is different from efforts in which modifications are incorporated into aptamers to 
improve their binding affinities after their identification from unmodified DNA pools. 
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Figure 4.4. Modified nucleotides incorporated into aptamers. (A) Binding affinities of SELEX 
libraries selected for binding to the 14 different proteins indicated with either unmodified, Bn-
modified, iBu-modified, or Trp-modified DNA. Binding affinities are shown (Kd, nM). Figure 
adapted with permission from ref. 5. (B) Schematic representation of the click-SELEX process. 
Figure adapted with permission from ref. 7. 
The introduction of hydrophobic modifications can be achieved by either  using modified 
nucleotide triphosphates in PCR reactions or using modified phosphoramidites during solid-phase 
DNA synthesis. Considerable synthetic efforts are usually required for the preparation of modified 
nucleotide triphosphates or phosphoramidites. A different approach, known as click-SELEX, 
employs copper-catalyzed azide-alkyne cycloaddition (CuAAC) to generate modified DNA 
libraries for aptamer selection experiments (Figure 4.4B).7 First, an alkyne-modified DNA library 
is prepared by replacing thymidine with C5-ethynyl-2¢-deoxyuridine (EdU). Second, this library is 
further modified through click reaction with an azide-containing compound, e.g., 
3-(2-azidoethyl)indole as shown in Figure 4.4B. This library can be then applied for in vitro 
selection experiments. As a proof of concept, the indole-modified DNA library was used in a 
selection experiment for binding to an improved GFP derivative, cycle 3 GFP (C3-GFP). An 
aptamer C12 was identified from the enriched pool of round 15 and showed strong binding to C3-
GFP with both high affinity (Kd = 18.4 nM) and high specificity. Therefore, this click-SELEX 
strategy is likely to be a versatile approach towards identification of nucleobase-modified 
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aptamers. In this chapter, we used the click-SELEX strategy to perform selection experiments for 
the identification of modified aptamers that bind protein substrates. 
4.2 Results and Discussion 
4.2.1 Development of Capture Method with Alkyne-Modified Resin 
To identify deoxyribozymes with azido-adenylylation activity on proteins, selection 
experiments were designed to directly use target proteins as the substrates. As discussed in Chapter 
3, the capture step is essential to the identification of deoxyribozymes from in vitro selection 
experiments. The previously used CuAAC capture reaction with alkyne-modified poly(ethylene 
glycol) that has an average molecular weight of 5000 (PEG5k-alkyne) enables the isolation of 
active DNA sequences based on their migration in polyacrylamide gel electrophoresis (PAGE). 
Even though there is no literature report about the recovery efficiency of DNA-protein conjugates 
from PAGE gels, the recovery of proteins by gel extraction is generally low in yield.8 Therefore, 
this gel-based capture approach was not used initially in the selection experiments with protein 
substrates. 
A resin-based capture method was developed as the alternative (Figure 4.5A). After the 
selection step, the sample was precipitated and incubated with alkyne-modified controlled pore 
glass (CPG-alkyne) together with CuAAC reagents. After the connection of active DNA sequences 
to the CPG, the resin was washed, removing the unbound and inactive DNA sequences. The bound 
deoxyribozymes were eluted from the resin by treatment with dithiothreitol (DTT) that cleaved the 
disulfide bond between the modified protein substrate and the active DNA sequences. Scintillation 
counting of the wash and elution fractions was used to quantify activity. 
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Figure 4.5. Capture method using CPG-alkyne. (A) Schematic illustration of the CuAAC capture 
reaction between azide-modified product and CPG-alkyne. (B) Capture assay with unmodified 
DNA and azide-modified DNA standard. 
The CPG-alkyne capture method was optimized for use during in vitro selection of azido-
adenylylation deoxyribozymes. To prevent the DNA pool from adhering to the reaction tube, low-
retention tubes were coated with a 5% PEG solution, incubated at room temperature overnight, 
and rinsed prior to use. To the sample was also added 0.5 µg of herring sperm DNA as a sacrificial 
oligonucleotide. The CPG-alkyne capture method was efficient for an azide-modified DNA 
oligonucleotide (prepared by conjugating a 3¢-C3-NH2 oligonucleotide with 6-azidohexanoic acid, 
as described in Chapter 3) with 56% capture yield, whereas <3% of the unmodified DNA was 
captured (Figure 4.5B). 
One major concern with the resin-based capture method is the unintended enrichment of 
aptamer sequences that bind to the resin via non-covalent interactions. A common strategy used to 
avoid the emergence of DNA aptamers for the resin is the inclusion of a pre-selection step between 
the ligation and selection steps. In this pre-selection step, the DNA sequences ligated to the 
substrate are subjected to CuAAC capture reaction with CPG-alkyne. The DNA sequences that do 
not bind to the CPG-alkyne are recovered in the wash and taken on to the selection step. However, 
this pre-selection step is not applicable in the selection experiments with protein substrates, 
because the reaction conditions used for CPG-alkyne capture may denature the protein substrates. 
Therefore, a pre-selection step could not be included in the selection experiments, even though the 
outcome of the selection experiments can be the emergence of aptamer sequences that bind to the 
CPG. 
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4.2.2 Selection Experiments with Protein Substrates Using Resin-Based Capture Method 
In vitro selection experiments were performed to identify azido-adenylylation 
deoxyribozymes with protein substrates. Two proteins, human annexin V and human TNF-related 
apoptosis-inducing ligand (TRAIL) 114–281, and a 36-mer peptide pancreatic polypeptide (PP) 
with an additional C-terminal cysteine were used as the substrates for the selection experiments 
(Figure 4.6). Annexin V is commonly used to detect apoptotic cells by its ability to bind 
phosphatidylserine that is a marker of apoptosis.9-11 TRAIL binds to the death receptors DR4 and 
DR5 to induce caspase-8-dependent apoptosis.12 Full-length TRAIL is composed of an N-terminal 
cytoplasmic domain, a transmembrane domain, and a C-terminal extracellular domain. The protein 
substrate TRAIL 114–281 is a soluble portion of the extracellular domain with similar function to 
the full-length protein and is henceforth abbreviated simply as TRAIL. PP is a polypeptide secreted 
in the pancreas to self-regulate pancreatic secretion activities.13 Both annexin V and TRAIL have 
only one cysteine residue in their amino acid sequences, which allows site-specific connections to 
the DNA anchor oligonucleotides. An artificial N-terminal cysteine was appended to PP to enable 
disulfide linkage to the DNA anchor oligonucleotide. The two protein substrates have very 
distinctive structures, with annexin V rich in a-helices and TRAIL rich in b-sheets. Therefore, the 
result from the selection experiments using these proteins may provide information about the 
preference for protein structure by deoxyribozymes. Each protein or peptide substrate was 
covalently attached at the cysteine residue via a disulfide linkage and a hexa(ethylene glycol) 
[HEG] tether to a DNA anchor oligonucleotide, which was bound by Watson-Crick base pairs to 
one of the fixed-sequence binding arms of the random DNA pool. The DNA anchor 
oligonucleotide contained three ribonucleotides (gga) at the 3¢-end that enables the ligation to the 
initially random DNA pool via T4 RNA ligase. The initially random region of the DNA sequences 
was flanked by fixed-sequence regions to enable PCR amplification of the DNA sequences and 
substrate binding. 
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Figure 4.6. Structures of the protein and peptide substrates used in the selection experiments. (A) 
Annexin V (PDB: 1HVG). (B) TRAIL (PDB: 1DG6). (C) PP (PDB: 1BBA). The amino acid 
sequences of these substrates can be found via the PDB entry. The amino acid sequence of PP is 
also listed in Table 4.5. 
The in vitro selection process began with ligation of the initially random DNA pool to the 
DNA-anchored substrate (Figure 4.7). The ligation product was desalted by a Micro Bio-Spin P-6 
column (Bio-Rad). Next, the selection step was performed in which the DNA sequences were 
incubated with 2¢-Az-dATP and divalent metal ions in a buffered solution to enable DNA catalysis. 
After exposure of the substrate-conjugated pool to 2¢-Az-dATP, the catalytically active DNA 
sequences, which were now attached to an azido group, were precipitated and captured with the 
CPG-alkyne via the CuAAC reaction. After the CPG was washed extensively, the active DNA 
sequences were eluted from the resin by treatment with dithiothreitol (DTT), which cleaved the 
disulfide bond between the protein or peptide substrate and the DNA anchor. PCR was performed 
to amplify the catalytically active DNA sequences that survived the previous selection, capture, 
and disulfide cleavage steps. The entire selection process was iterated, each time enriching the 
population with catalytically active sequences, until the DNA enzymes dominated the population. 
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Figure 4.7. Diagram of in vitro selection procedure for deoxyribozymes with tyrosine azido-
adenylylation activity on protein substrates using resin-based capture method. 
The selection experiments designated as AK2–AP2 according to our systematic 
alphanumeric nomenclature were performed to identify azido-adenylylation deoxyribozymes that 
are functional with protein and long peptide substrates (Figure 4.8). The selection experiments 
with protein substrates were performed with an N40 or N80 initially random region. The length of 
the initially random region is an important variable in deoxyribozyme selection experiments.14 
Larger random regions may enable more complex catalytic DNA structures, which may lead to 
more interactions between the DNA enzyme and the protein substrate. However, all selection 
experiments evaluate 1014 DNA sequences, which is a much smaller fraction of the 1048 possible 
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N80 sequences compared to the fraction of the 1024 possible N40 sequences. Therefore, for any 
specific random region length used for a selection experiment, a compromise is made between the 
structural complexity and the sequence-space coverage. 
 
Figure 4.8. Design of the AK2–AP2 selection experiments to identify azido-adenylylation 
deoxyribozymes with protein and long peptide substrates. Initially random region lengths are 
indicated. 
All selections were performed with 100 µM 2¢-Az-dATP in 70 mM HEPES, pH 7.5, 1 mM 
ZnCl2, 20 mM MnCl2, 40 mM MgCl2, and 150 mM NaCl at 37 °C for 14 h. After 4 rounds of 
selection, the capture yield of the AP2 pool reached 34% (Figure 4.9A). However, when the 4AP2 
pool was not incubated with 2¢-Az-dATP, a capture yield of 32% was observed (Figure 4.9B). This 
result indicated that the 4AP2 pool was dominated by aptamer sequences that bind to the CPG-
alkyne, and the observed capture yield was due to non-catalytic binding rather than azido-
adenylylation. This negative outcome of the AP2 selection experiment reemphasized that the lack 
of a pre-selection step during selection experiments using resin-based capture methods makes 
these selection experiments prone to the emergence of aptamer sequences. Therefore, all five of 
the AK2–AP2 selection experiments were discontinued. The capture approach based on CPG-
alkyne was also discontinued. 
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Figure 4.9. The AP2 selection experiment. (A) Progression of the selection experiment. In each 
round, “control” refers to the yield for the control capture reaction using an azido-modified 
substrate, and “selection” refers to the yield for the CuAAC capture. (B) Capture of the 4AP2 pool 
after the selection step where the pool was incubated with or without 2¢-Az-dATP. 
4.2.3 Selection Experiments with Protein Substrates Using Gel-Based Capture Method 
An alternative capture method was required to enable selection experiments with protein 
substrates. The gel-based CuAAC capture reaction with PEG-alkyne was originally considered 
unsuitable, because the recovery of proteins from PAGE gels is generally low in yield. However, 
if the protein moiety is removed by reducing the disulfide bond via DTT treatment, the DNA 
moiety in the capture product should be extracted from the PAGE gel with high efficiency. To 
validate this process, the ligation products of both proteins to the N80 DNA pool were treated with 
N-hydroxysuccinimide carboxyl PEG that has an average molecular weight of 10000 (PEG10k-
NHS). Lysine residues on the proteins were randomly modified by PEG10k-NHS, which provided 
model products of the CuAAC capture reactions. These model products were separated by 8% 
SDS-urea PAGE, in which the PAGE gel included each of 0.1% (w/v) SDS and 7 M urea. PEG 
molecules with larger molecular weight were used to induce a sufficiently large PAGE shift that 
enables the separation. When the excised gel pieces were incubated in the standard TEN buffer 
(10 mM Tris, pH 8.0, 300 mM NaCl, 1 mM EDTA) supplemented with 50 mM DTT, efficient 
recovery yields of the DNA moieties (>85%) were observed (Figure 4.10). When DTT was omitted 
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during the extraction, only ~30% of PEGylated DNA-protein conjugates were recovered from the 
gel pieces. This result showed that a gel-based CuAAC capture reaction with PEG10k-alkyne will 
be viable for selection experiments with protein substrates when the capture product is extracted 
using the TEN buffer supplemented with DTT. 
 
Figure 4.10. SDS-PAGE gel extraction efficiency. Gel pieces were incubated with 10 mM Tris, 
pH 8.0, 300 mM NaCl, 1 mM EDTA, with or without 50 mM DTT at 37 °C for 2 h. Scintillation 
counting of the extractant and the gel pieces was used to quantify extraction yield. 
The CP2–CT2 selection experiments were performed similarly to the previous set of 
selection experiments AK2–AP2, except using a different capture step (Figure 4.11). After 14 
rounds, no activity was observed in any of these selection experiments, which were discontinued. 
The negative outcome of these selection experiments suggested the difficulty for DNA pools to 
simultaneously adopt functions of both binding to the protein substrates and catalyzing their 
modification. 
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Figure 4.11. Diagram of in vitro selection procedure for deoxyribozymes with tyrosine azido-
adenylylation activity on protein substrates using gel-based capture method. 
We considered that a modular approach might facilitate the identification of 
deoxyribozymes with activity on protein substrates, by decoupling the binding and catalytic 
functions (Figure 4.12). In this modular approach, a predetermined aptamer domain engages in 
noncovalent interaction with the protein substrate, allowing a distinct enzyme domain, 
subsequently identified through in vitro selection in the presence of the aptamer domain, to be 
devoted to catalysis. 
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Figure 4.12. Schematic illustration of the modular approach to identify deoxyribozymes with 
tyrosine azido-adenylylation activity on protein substrates. 
4.2.4 Selection Experiments with Unmodified DNA Pools for Aptamers that Bind to 
Annexin V and TRAIL 
To perform selection experiments with predetermined aptamer domains, DNA aptamers 
that bind to the protein substrates must be first identified. Both annexin V and TRAIL were 
immobilized with Ni-NTA agarose via their His6 tag to enable the aptamer selection experiments. 
The selection process began with a pre-selection step in which the DNA pools were incubated with 
unmodified Ni-NTA agarose which did not have any protein immobilized (Figure 4.13). The flow-
through from the pre-selection step was incubated with the protein-bound Ni-NTA agarose. After 
incubation, the protein-bound resin was washed with the aptamer binding buffer to remove the 
unbound and inactive DNA sequences. Scintillation counting of the wash fractions and the protein-
bound Ni-NTA agarose was used to quantify binding activity. The active DNA sequences that 
were bound to the protein was recovered by phenol/chloroform extraction followed by ethanol 
precipitation. PCR was performed to amplify the active DNA sequences that survived the previous 
selection step. The entire selection process was iterated until the aptamer sequences dominated the 
population. 
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Figure 4.13. Schematic illustration of the in vitro selection strategy to identify DNA aptamers that 
bind to protein substrates. 
The AQ2–AY2 selection experiments were performed by former Silverman lab staff Kevin 
Duffin to identify DNA aptamers that bind to annexin V and TRAIL. Different conditions were 
used for these selection experiments, exploring key variables like temperature, Mg2+ 
concentration, and pool/protein ratio (Table 4.1). However, after 16 rounds of selection, no binding 
activity above background level (~5%) was observed in any of the selection experiments, which 
were discontinued. 
Table 4.1: Design of the AQ2–AY2 selection experiments. 
selection 
experiment 
target protein temperature / °C [Mg2+] / mM pool/protein ratio 
round 1–5 round 6–16 
AQ2 annexin V 37 40 10:1 1:1 
AR2 annexin V 25 40 10:1 1:1 
AS2 annexin V 37 5 10:1 1:1 
AT2 annexin V 37 40 1:1 1:4 
AV2 TRAIL 37 40 10:1 1:1 
AW2 TRAIL 25 40 10:1 1:1 
AX2 TRAIL 37 5 10:1 1:1 
AY2 TRAIL 37 40 1:1 1:4 
115 
4.2.5 Selection Experiments with Known Aptamers that Bind to Egg White Lysozyme 
Given the negative outcome from the AQ2–AY2 selection experiments, the design of 
aptamer selection experiments must be validated with positive controls. Two lysozyme aptamers, 
Apta1 and Apta8, were used for these control selection experiments.15 Egg white lysozyme was 
conjugated with the C-terminal carboxylic acid of the octapeptide HHHHHHAA (referred to as 
His6Ala2 peptide) via the amide coupling reaction to prepare the His6-lysozyme. Apta1 and Apta8 
each bound to His6-lysozyme that was immobilized on Ni-NTA agarose with 23% and 29% yields, 
respectively (Figure 4.14). As the negative control, random DNA pool bound to His6-lysozyme 
with ~5% background. Even though the binding yields of Apta1 and Apta8 to His6-lysozyme were 
not 100%, they were still 3- to 5-fold higher than the background binding of random DNA pool, 
which was sufficient for the control selection experiments. 
 
Figure 4.14. Binding of Apta1 and Apta8 aptamers to His6-lysozyme immobilized on Ni-NTA 
agarose. N40 denotes random DNA pool that serves as the negative control. Incubation conditions: 
25 mM Tris, pH 8.3, 5 mM K2HPO4, and 192 mM glycine at room temperature for 30 min. 
Nine selection experiments, DE2–DM2, were performed with DNA pools that included 
Apta1 or Apta8 at different percentages (Table 4.2). The process for the DE2–DM2 selection 
experiments was similar to that for the AQ2–AY2 selection experiments, except that the reported 
aptamer binding conditions were used as the selection conditions and the pool/protein ratio was 
kept as 1:1. Binding activity with ~20% yield was observed in round 2 for the selection 
experiments initiated with DNA pools that contained 10% (DE2 and DJ2) and 1% (DF2 and DK2) 
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known aptamers (Figure 4.15). The binding activity of the DNA pools from these four selections 
in round 2 was comparable to that observed for Apta1 and Apta8, suggesting that the sequence of 
Apta1 or Apta8 dominated each selection pool. Thus, the enrichment factors for these four 
selection experiments were estimated as 10–100, based on the calculation that 1–10% active 
sequences were enriched to 100% after one round of enrichment. For the other selection 
experiments, 25–30% binding yields were observed in round 3. The enrichment factors were 
estimated as 32–100 (i.e., the square root of 1000–10000), assuming that the enrichment factor for 
each selection does not change among different rounds. The outcome of the DE2–DM2 selection 
experiments validated that the design of aptamer selection experiments can enrich DNA sequences 
binding to target proteins. 
Table 4.2: Design of the DE2–DM2 selection experiments. 
selection 
experiment 
aptamer used percentage of known aptamer 
in the initial pool 
DE2 Apta1 10 
DF2 Apta1 1 
DG2 Apta1 0.1 
DH2 Apta1 0.01 
DJ2 Apta8 10 
DK2 Apta8 1 
DL2 Apta8 0.1 
DM2 Apta8 0.01 
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Figure 4.15. Progression of the in vitro selection experiments DE2–DM2 (panels A–H). In each 
round, “pre-selection” refers to the background binding observed in the pre-selection step using 
unmodified Ni-NTA agarose, and “selection” refers to the yield observed in the selection step 
using the Ni-NTA agarose-bound lysozyme for the indicated selection experiment. The indicated 
selection experiment and percentage of known aptamer in the initial pool was labeled in each panel. 
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4.2.6 Selection Experiments with Modified DNA Pools for Aptamers that Bind to Annexin 
V, TRAIL, and PP 
Inspired by the success in identifying aptamers from DNA pools modified with 
hydrophobic moieties,4-6 the EA2–EJ2 selection experiments were designed to incorporate benzyl, 
naphthyl, and indolyl groups via the click-SELEX strategy (Table 4.3).7 Benzyl azide was 
purchased from the commercial vendor. The other two azido-containing compounds were 
synthesized by reacting the corresponding bromide compounds with sodium azide (Figure 4.16).16 
These selection experiments were performed similarly as the AQ2–AY2 selection experiments, 
except that additional primer extension and click steps were incorporated (Figure 4.17). The 
alkyne-modified DNA pool was generated by primer extension of the reverse template with dATP, 
dGTP, dCTP, and EdUTP. After purified by PAGE, the primer extension product was further 
modified with one of the three azide compounds by the CuAAC reaction. After the CuAAC 
reaction, the product was precipitated with ethanol, and a second click reaction was performed to 
ensure that all the alkyne groups in the DNA pool were modified. 
Table 4.3: Design of the EA2–EJ2 selection experiments. 
selection 
experiment 
target protein hydrophobic 
modification 
EA2 annexin V benzyl 
EB2 annexin V naphthyl 
EC2 annexin V indolyl 
ED2 TRAIL benzyl 
EE2 TRAIL naphthyl 
EF2 TRAIL indolyl 
EG2 PP benzyl 
EH2 PP naphthyl 
EJ2 PP indolyl 
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Figure 4.16. Scheme for the synthesis of 2-(azidomethyl)naphthalene and 3-(2-azidoethyl)indole. 
 
Figure 4.17. Schematic illustration of the in vitro selection strategy to identify hydrophobically 
modified DNA aptamers that bind to protein substrates. 
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The incubation conditions for the EA2–EJ2 selection experiments were 70 mM HEPES, 
pH 7.5, 5 mM MgCl2, 150 mM NaCl, and 1 mM 2-mercaptoethanol. The pool/protein ratio was 
kept as 1:1 for all nine selection experiments. After 3 selection rounds, 31–71% background 
binding to unmodified Ni-NTA agarose was observed in the pre-selection step for the selection 
experiments with naphthyl and indolyl modifications (Figure 4.18). For the selection experiments 
with benzyl modification, 14–18% background binding was observed. The increase in background 
binding suggested the emergence of aptamer sequences that bind to unmodified Ni-NTA agarose, 
even though a pre-selection step was included during the selection experiments to remove those 
sequences. 
 
Figure 4.18. Progression of the in vitro selection experiments EA2–EJ2 (panels A–I). In each 
round, “pre-selection” refers to the background binding observed in the pre-selection step using 
unmodified Ni-NTA agarose, and “selection” refers to the yield observed in the selection step 
using Ni-NTA agarose-bound protein for the indicated selection experiment.  
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DNA aptamers modified with these hydrophobic groups have been identified from 
selection experiments where His6-tagged target proteins were immobilized on magnetic beads.4,6 
Therefore, the FA2–FJ2 selection experiments were designed to use magnetic beads in place of 
Ni-NTA agarose (Table 4.4). The FA2–FJ2 selection experiments are currently ongoing. 
Table 4.4: Design of the FA2–FJ2 selection experiments. 
selection 
experiment 
target protein hydrophobic 
modification 
FA2 annexin V benzyl 
FB2 annexin V naphthyl 
FC2 annexin V indolyl 
FD2 TRAIL benzyl 
FE2 TRAIL naphthyl 
FF2 TRAIL indolyl 
FG2 PP benzyl 
FH2 PP naphthyl 
FJ2 PP indolyl 
4.3 Summary and Future Directions 
One of our long-term goals is DNA-catalyzed site-specific modification of protein 
substrates. To achieve such goal with known deoxyribozymes, two different recruiting strategies 
via hexahistidine (His6) tags and DNA aptamers have been pursued, yet neither recruiting approach 
provided DNA-catalyzed protein modification.2,3 Therefore, methods to identify de novo 
deoxyribozymes with azido-adenylylation activity on protein substrates are investigated in this 
chapter. 
Two proteins, human annexin V and human TNF-related apoptosis-inducing ligand 
(TRAIL) 114–281, and a 36-mer peptide pancreatic polypeptide (PP) with an additional C-terminal 
cysteine were used as the substrates to evaluate various strategies for identifying deoxyribozymes. 
Both resin-based and gel-based capture methods were developed for selection experiments using 
protein substrates. For the selection experiments using resin-based capture methods, a 
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pre-selection step was intentionally omitted to avoid potential denaturation of the protein 
substrates, and aptamer sequences that bind to the resin used in the capture step quickly dominated 
the DNA pools. Thus, the selections using resin-based capture methods were discontinued. On the 
other hand, the gel-based capture method avoided the emergence of aptamer sequences. Therefore, 
selection experiments with protein substrates were performed using the gel-based capture method. 
Unfortunately, no activity was observed from these selection experiments after 14 rounds. 
To achieve the identification of deoxyribozymes that are functional with proteins, a 
modular approach was designed to decouple the binding and catalytic functions required for DNA-
catalyzed protein modification. The binding function is assigned to the predetermined aptamer 
domain, which is placed adjacent to the initially random enzyme domain. The sequence of the 
enzyme domain will be subsequently identified through in vitro selection in the presence of the 
aptamer domain. The aptamer domain is required to bind the protein substrate under conditions 
compatible with DNA catalysis. Therefore, aptamer selection experiments were performed to 
identify DNA sequences that bind to target proteins. No binding activity was observed in any of 
the selection experiments with unmodified DNA pools. Inspired by previous reports in which DNA 
aptamers with hydrophobic modifications bind to their target proteins with strong affinity and 
specificity,4-6 ongoing selection experiments are seeking DNA aptamers that bind to annexin V, 
TRAIL, and PP, with benzyl, naphthyl, and indolyl modifications introduced via the click-SELEX 
strategy.7 
4.4 Materials and Methods 
4.4.1 Substrate Preparation Procedures 
Oligonucleotides, peptides, and DNA-anchored peptide conjugates were prepared as 
described in Chapter 2. EdUTP was obtained from baseclick GmbH (Munich, Germany). Benzyl 
azide was obtained from Alfa Aesar (Tewksbury, MA). 2-(Bromomethyl)naphthalene, 3-(2-
bromoethyl)indole, and lysozyme from chicken egg white were obtained from Sigma-Aldrich (St. 
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Louis, MO). Ni-NTA agarose and Dynabeads® His-Tag Isolation & Pulldown (referred to as 
magnetic beads) was obtained from Thermo Fisher (Waltham, MA). 
Annexin V expression and purification. Human annexin V was expressed and purified by 
the previously reported procedures with minor modifications.17 The bacterial expression plasmid 
pProEx.Htb.annexin V that encodes annexin V was provided by Prof. S.J. Martin (Trinity College, 
Dublin, Ireland). Using 5 µL of the plasmid, 50 µL of competent DH5a E. coli bacteria was 
transformed by the heat shock method. The seed culture for protein expression was prepared by 
inoculation of an individual E. coli colony in 3 mL of LB containing 100 µg/mL of ampicillin and 
incubation at 37 °C with shaking at 220 rpm overnight. The seed culture was diluted into 300 mL 
of LB containing 100 µg/mL of ampicillin. After the cells were grown at 37 °C with shaking at 
220 rpm to an OD600 of 0.4–0.6, protein expression was induced by the addition of isopropyl-b-D-
1-thiogalactoside (IPTG) to a final concentration of 500 µM. After another 3 h incubation at 37 °C 
with shaking at 220 rpm, cells were harvested by centrifugation at 7500×g and 4 °C. The bacterial 
pellet was resuspended in 5 mL of lysis buffer [50 mM Tris, pH 8.5, 10 mM 2-mercaptoethanol, 1 
mM phenylmethanesulfonyl fluoride (PMSF), 2 µg/mL aprotinin, and 10 µg/mL leupeptin] and 
disrupted on ice for 10 min (alternating between 1 s pulses and 3 s pauses) using a Branson 
sonicator at 15% amplitude with a ⅛-inch tip. The supernatant from the bacterial lysate was 
recovered by centrifugation for 15 min at 15000×g and 4 °C and incubated with 250 µL of Ni-
NTA agarose by nutating at 4 °C overnight. Unbound protein was removed from the Ni-NTA 
agarose by centrifuging at 1000×g and 4 °C for 1 min. The Ni-NTA agarose was washed with 3´ 
500 µL of ice-cold wash buffer [20 mM Tris, pH 8.5, 100 mM KCl, 10% (v/v) glycerol, 10 mM 
2-mercaptoethanol, and 15 mM imidazole]. Annexin V was eluted from the Ni-NTA agarose with 
3´ 500 µL of ice-cold elution buffer [20 mM Tris, pH 7.5, 100 mM KCl, 10% (v/v) glycerol, 10 
mM 2-mercaptoethanol, 1 mM PMSF, 2 µg/mL aprotinin, 10 µg/mL leupeptin, and 150 mM 
imidazole]. Protein concentration was quantified by Bradford protein assay.18 From 300 mL of cell 
culture, 9.0 mg of annexin V was obtained. Therefore, the overall protein production yield was 30 
mg/L. 
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TRAIL expression and purification. Human TNF-related apoptosis-inducing ligand 
(TRAIL) 114–281 was expressed and purified by the previously reported procedures with minor 
modifications.19 The bacterial expression plasmid pETdwHisTRAIL that encodes soluble TRAIL 
(amino acids 114–281 of the genomic sequence) was provided by Dr. D.W. Seol (Chung-Aung 
University, Seoul, South Korea). Using 5 µL of the plasmid, 50 µL of competent Rosetta (DE3) 
E. coli bacteria was transformed by the heat shock method. The seed culture for protein expression 
was prepared by inoculation of an individual E. coli colony in 3 mL of LB containing 100 µg/mL 
of ampicillin and incubation at 37 °C with shaking at 220 rpm overnight. The seed culture was 
diluted into 300 mL of LB containing 100 µg/mL of ampicillin. After the cells were grown at 37 °C 
with shaking at 220 rpm to an OD600 of 0.4–0.6, protein expression was induced by the addition 
of IPTG to a final concentration of 500 µM. After an additional overnight incubation at 30 °C with 
shaking at 220 rpm, cells were harvested by centrifugation at 7500×g and 4 °C. The bacterial pellet 
was resuspended in 5 mL of lysis buffer (50 mM sodium phosphate, pH 8.5, 10 mM 2-
mercaptoethanol, 1 mM PMSF, 2 µg/mL aprotinin, and 10 µg/mL leupeptin) and disrupted on ice 
for 10 min (alternating between 1 s pulses and 3 s pauses) using a Branson sonicator at 15% 
amplitude with a ⅛-inch tip. The supernatant from the bacterial lysate was recovered by 
centrifugation for 15 min at 15000×g and 4 °C and incubated with 250 µL of Ni-NTA agarose by 
nutating at 4 °C overnight. Unbound protein was removed from the Ni-NTA agarose by 
centrifuging at 1000×g and 4 °C for 1 min. The Ni-NTA agarose was washed with 3´ 500 µL of 
ice-cold wash buffer [20 mM sodium phosphate, pH 8.5, 100 mM KCl, 10% (v/v) glycerol, 10 
mM 2-mercaptoethanol, and 30 mM imidazole]. TRAIL protein was eluted from the Ni-NTA 
agarose with 3´ 500 µL of ice-cold elution buffer [20 mM sodium phosphate, pH 7.5, 100 mM 
KCl, 10% (v/v) glycerol, 10 mM 2-mercaptoethanol, 1 mM PMSF, 2 µg/mL aprotinin, 10 µg/mL 
leupeptin, and 500 mM imidazole]. Protein concentration was quantified by Bradford protein 
assay. From 300 mL of cell culture, 3.6 mg of TRAIL was obtained. Therefore, the overall protein 
production yield was 12 mg/L. 
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The differences between the preparation procedures for annexin V and TRAIL were as 
follows. Annexin V was expressed in competent DH5a E. coli bacteria. TRAIL was expressed in 
competent Rosetta (DE3) E. coli bacteria. After the induction of protein expression by IPTG, the 
cell culture for annexin V expression was shaken at 220 rpm and 37 °C overnight. After the 
induction of protein expression by IPTG, the cell culture for TRAIL expression was shaken at 220 
rpm and 30 °C overnight. Tris was used in all the buffers for annexin V purification. Sodium 
phosphate was used in all the buffers for TRAIL purification. For annexin V purification, the wash 
and elution buffers contained, respectively, 15 mM and 150 mM of imidazole. For TRAIL 
purification, the wash and elution buffers contained, respectively, 30 mM and 500 mM of 
imidazole. 
Synthesis of DNA-anchored protein conjugates. DNA-anchored protein conjugates were 
synthesized by disulfide formation between a DNA HEG-tethered 3¢-thiol [HEG = hexa(ethylene 
glycol)] and the cysteine side chain of the protein (Cys316 for annexin V or Cys230 for TRAIL), 
similar to the synthetic procedure for DNA-anchored peptide conjugates. The 5¢-thiol DNA anchor 
oligonucleotide was 5¢-HO-C6-SS-C6-p-HEG-X-3¢, where X represents the specific 
oligonucleotide sequence (Table 4.5). The 5¢-disulfide linker was introduced via standard solid-
phase DNA synthesis and unmasked to a thiol by DTT treatment. A 50 µL sample containing 5 
nmol of DNA anchor oligonucleotide in 100 mM HEPES, pH 7.5, and 50 mM DTT was incubated 
at 37 °C for 2 h. The reduced product was precipitated to remove DTT by addition of 50 µL of 
water, 10 µL of 3 M NaCl, and 300 µL of ethanol. The precipitated product (HS-C6-p-HEG-DNA) 
was dissolved in 35 µL of water and 10 µL of 100 mM triethylammonium acetate, pH 7.0. 
Activation as the pyridyl disulfide was achieved by adding 5 µL of 100 mM 2,2′-dipyridyl disulfide 
in DMF and incubating at 37 °C for 2 h. The product (PySS-C6-p-HEG-DNA) was precipitated by 
addition of 50 µL of water, 10 µL of 3 M NaCl and 300 µL of ethanol and dissolved in 35 µL of 
water. Meanwhile, 6 nmol of protein that was expressed and purified with Ni-NTA agarose was 
buffer-exchanged into 10 mM NaCl using a Micro Bio-Spin P-6 column (Bio-Rad). Conjugation 
to the protein was performed by combining the activated DNA substrate and the protein into 40 
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µL total volume containing 20 mM triethylammonium acetate, pH 7.0. The sample was incubated 
at 37 °C for 12 h, and the DNA-anchored protein was purified by immobilized metal ion affinity 
chromatography (IMAC) using Ni-NTA agarose as described above in the protein purification 
section. The elution was buffer-exchanged into 1´ annealing buffer (5 mM Tris, pH 7.5, and 15 
mM NaCl) using a Micro Bio-Spin P-6 column (Bio-Rad) and sample concentration was quantified 
by UV absorbance (A260). The overall yield is 10–20%, providing 0.5–1 nmol of the DNA-protein 
conjugates. 
Immobilization of His6-tagged substrates on Ni-NTA agarose. Low-retention 
microcentrifuge tubes were treated by allowing to stand overnight with 2 mL of 5% (w/v) PEG3350 
(Sigma-Aldrich, cat. no. P3640) and rinsing with 3× 1 mL of water. A 100 µL sample containing 
30 nmol of His6-tagged peptide or protein substrate and 50 µL of Ni-NTA agarose was incubated 
in 20 mM sodium phosphate, pH 8.5, and 100 mM KCl by shaking on a vortexer at the lowest 
setting overnight at 4 °C. The Ni-NTA agarose was washed with 3× 50 µL of aptamer binding 
buffer (70 mM HEPES, pH 7.5, 150 mM NaCl, and 1 mM 2-mercaptoethanol), and stored in 50 
µL of aptamer binding buffer. Immobilization efficiency was quantified by Bradford protein assay 
as ~60%. 
Synthesis of His6-lysozyme. A sample containing 10 nmol of chicken egg white lysozyme 
was brought to 50 µL total volume containing 100 mM MES, pH 6.0, 1 mM His6Ala2 peptide, 
1 mM N-hydroxysuccinimide (NHS), 100 mM N-(3-dimethylaminopropyl)-N¢-ethylcarbodiimide 
(EDC), and 10% (v/v) DMF. The sample was incubated at room temperature for 12 h and buffer-
exchanged into 10 mM NaCl using a Micro Bio-Spin P-6 column. 
Synthesis of 2-(azidomethyl)naphthalene. The synthesis of 2-(azidomethyl)naphthalene 
was performed by the previously reported procedures with minor modifications.16 To a 0.5 M 
solution of NaN3 (1.1 equiv) in 1 mL of DMSO was added 111 mg of 2-(bromomethyl)naphthalene 
(0.5 mmol, 1.0 equiv), and the clear colorless solution was stirred at room temperature for 3 h. The 
mixture was quenched with 4 mL of water and extracted with 3× 5 mL of ethyl acetate. The organic 
layer was separated, washed with 3× 10 mL of brine, and dried over Na2SO4. After filtration and 
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concentration in vacuo, the product was obtained as a white solid (83 mg, 91%). 1H NMR (CDCl3, 
500 MHz, d; ppm): 7.88–7.80 (3H, m), 7.76 (1H, s), 7.52–7.48 (2H, m), 7.42 (1H, dd), 4.49 (2H, 
s). EI-MS: m/z calcd. for C11H9N3 [M]+ 183.1; found 183.0. 
Synthesis of 3-(2-azidoethyl)indole. The synthesis of 3-(2-azidoethyl)indole was 
performed by the previously reported procedures with minor modifications.16 To a 0.5 M solution 
of NaN3 (1.1 equiv) in 1 mL of DMSO was added 112 mg of 3-(2-bromoethyl)indole (0.5 mmol, 
1.0 equiv), and the clear yellow solution was stirred at room temperature for 15 h. The mixture 
was then quenched with 4 mL of water and extracted with 3× 5 mL of ethyl acetate. The organic 
layer was separated, washed with 3× 10 mL of brine, and dried over Na2SO4. After filtration and 
concentration in vacuo, the product was obtained as yellow oil (87 mg, 93%). 1H NMR (CDCl3, 
500 MHz, d; ppm): 7.95 (1H, s), 7.53 (1H, d), 7.31 (1H, d), 7.22 (1H, m), 7.08 (1H, m), 7.01 (1H, 
s), 3.51 (2H, t), 3.01 (2H, d). EI-MS: m/z calcd. for C10H10N4 [M]+ 186.1; found 186.1. 
Immobilization of His6-tagged substrates on the magnetic beads. The immobilization of 
His6-tagged substrates with the magnetic beads was performed by the previously reported 
procedures.4 Unless indicated, all washes were performed by resuspending the magnetic beads in 
the appropriate solution, mixing for 30 s, separating the beads with a magnet, and removing the 
supernatant. In a microcentrifuge tube, 125 µL of the magnetic beads was washed with 3× 500 µL 
of BW buffer (50 mM sodium phosphate, pH 8.0, 300 mM NaCl, and 0.01% Tween-20) and mixed 
with 0.1 mg of His6-tagged substrate in 1 mL of BW buffer. The mixture was nutated at room 
temperature for 30 min and stored at 4 °C until use. 
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Table 4.5: Oligonucleotide sequences used in the selection experiments. All sequences are written 
5¢ to 3¢. Lowercase letters represent ribonucleotides. p represents a phosphoryl group. For all 
selections, the reverse PCR primer was (AAC)4XCCATCAGGATCAGCT, where X denotes the 
hexa(ethylene glycol) [HEG] spacer to stop Taq polymerase. 
oligonucleotide purpose oligonucleotide sequence 
  
AK2 and CP2 selection experiments 
(annexin V)-HEG-DNA substrate (annexin V)-HEG-GAAGAGATGGCGACgga 
forward primer for selection p-CGAAGTCGCCATCTCTTC 
random pool for selection p-CGAAGTCGCCATCTCTTC-N40-ATAGTGAGTCGTATTAAGCTGATCCTGATGG 
  
AL2 and CQ2 selection experiments 
(annexin V)-HEG-DNA substrate (annexin V)-HEG-GAAATAGCCATCATgga 
forward primer for selection p-CGAAATGATGGCTATTTC 
random pool for selection p-CGAAATGATGGCTATTTC-N80-ATATGTCTTTCAATAGAGCTGATCCTGATGG 
  
AM2 and CR2 selection experiments 
TRAIL-HEG-DNA substrate TRAIL-HEG-GAAATAGCCATCATgga 
forward primer for selection p-CGAAATGATGGCTATTTC 
random pool for selection p-CGAAATGATGGCTATTTC-N40-ATATGTCTTTCAATAGAGCTGATCCTGATGG 
  
AN2 and CS2 selection experiments 
TRAIL-HEG-DNA substrate TRAIL-HEG-GAAGAGATGGCGACgga 
forward primer for selection p-CGAAGTCGCCATCTCTTC 
random pool for selection p-CGAAGTCGCCATCTCTTC-N80-ATAGTGAGTCGTATTAAGCTGATCCTGATGG 
  
AP2 and CT2 selection experiments 
PP-HEG-DNA substrate APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRYC- 
HEG-GAATTCAGTCTTAAgga 
forward primer for selection p-CGAATTAAGACTGAATTC 
random pool for selection p-CGAAGTATAAACCTGTTC-N40-ATAAGAAACGAGATATAGCTGATCCTGATGG 
  
AQ2 and AV2 selection experiments 
forward primer for selection CGAAGTCGCCATCTCTTC 
random pool for selection CGAAGTCGCCATCTCTTC-N30-ATAGTGAGTCGTATTAAGCTGATCCTGATGG 
  
AR2 and AW2 selection experiments 
forward primer for selection CGAACGAAAGCCTCCTTC 
random pool for selection CGAACGAAAGCCTCCTTC-N30-ATACGCATAAAGGTAGAGCTGATCCTGATGG 
  
AS2 and AX2 selection experiments 
forward primer for selection CGAAATGATGGCTATTTC 
random pool for selection CGAAATGATGGCTATTTC-N30-ATATGTCTTTCAATAGAGCTGATCCTGATGG 
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Table 4.5 (cont.) 
oligonucleotide purpose oligonucleotide sequence 
  
AT2 and AY2 selection experiments 
forward primer for selection CGAAATAGATTATCATTC 
random pool for selection CGAAATAGATTATCATTC-N30-ATAATTAGTAACCTGAAGCTGATCCTGATGG 
  
DE2–DM2 selection experiments 
forward primer for selection CGAACAACGCTAAAATTC 
random pool for selection CGAACAACGCTAAAATTC-N30-ATAGGAGACGGGCAACAGCTGATCCTGATGG 
lysozyme aptamer Apta1 CGAACAACGCTAAAATTCGCAGCTAAGCAGGCGGCTCACAAAACCATTCGCATGCGGC- 
ATAGGAGACGGGCAACAGCTGATCCTGATGG 
lysozyme aptamer Apta8 CGAACAACGCTAAAATTCGCACCTTGATGACATGATAGTCGTTGTGTATGCAGTTGGC- 
ATAGGAGACGGGCAACAGCTGATCCTGATGG 
  
EA2–EJ2 and FA2–FJ2 selection experiments 
forward primer for selection CGAATTAAGACTGAATTC 
random pool for selection CGAAGTATAAACCTGTTC-N40-ATAAGAAACGAGATATAGCTGATCCTGATGG 
  
 
4.4.2 DNA Enzyme In Vitro Selection Procedures 
4.4.2.1 In Vitro Selection Procedures for the AK2–AP2 Selection Experiments 
Procedure for PCR was performed as described in Chapter 2. 
Procedure for ligation step in round 1. A 21 µL sample containing 200 pmol of 5¢-
phosphorylated DNA pool and 220 pmol of DNA-anchored protein or peptide substrate was cooled 
on ice for 5 min in 5 mM Tris, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA. To this solution was 
added 6 µL of 5´ T4 RNA ligase buffer that lacks DTT (250 mM Tris, pH 7.5, 25 mM MgCl2, and 
0.25 mM ATP) and 3 µL of 10 U/µL T4 RNA ligase (Thermo Fisher). The sample was incubated 
at 37 °C for 12 h and buffer-exchanged into 1´ annealing buffer (5 mM Tris, pH 7.5, and 15 mM 
NaCl) using a Micro Bio-Spin P-6 column (Bio-Rad). 
Procedure for ligation step in subsequent rounds. A 15 µL sample containing the PCR-
amplified 5¢-phosphorylated DNA pool (~5–10 pmol) and 50 pmol of DNA-anchored protein or 
peptide substrate was cooled on ice for 5 min in 5 mM Tris, pH 7.5, 15 mM NaCl, and 0.1 mM 
EDTA. To this solution was added 4 µL of 5´ T4 RNA ligase buffer that lacks DTT (250 mM 
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Tris, pH 7.5, 25 mM MgCl2, and 0.25 mM ATP) and 1 µL of 10 U/µL T4 RNA ligase (Thermo 
Fisher). The sample was incubated at 37 °C for 2 h and buffer-exchanged into 1´ annealing buffer 
(5 mM Tris, pH 7.5, and 15 mM NaCl) using a Micro Bio-Spin P-6 column (Bio-Rad). 
Procedure for selection step in round 1. A 16 µL sample containing ligated pool was cooled 
on ice for 5 min in 5 mM Tris, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA. The selection reaction 
was initiated by bringing the sample to 40 µL total volume containing 70 mM HEPES, pH 7.5, 40 
mM MgCl2, 20 mM MnCl2, 1 mM ZnCl2, 150 mM NaCl, and 100 µM 2′-Az-dATP. The Mn2+ was 
added from a 10´ stock solution containing 200 mM MnCl2. The Zn2+ was added from a 10´ stock 
solution containing 10 mM ZnCl2, 20 mM HNO3, and 200 mM HEPES at pH 7.5; this stock 
solution was freshly prepared from a 100´ stock of 100 mM ZnCl2 in 200 mM HNO3. The metal 
ion stocks were added last to the final sample. The sample was incubated at 37 °C for 14 h and 
precipitated with ethanol. 
Procedure for selection step in subsequent round. An 8 µL sample containing the ligated 
pool was cooled on ice for 5 min in 5 mM HEPES, pH 7.5, 15 mM NaCl, and 0.1 mM EDTA. The 
selection reaction was initiated by bringing the sample to 20 µL total volume containing 70 mM 
HEPES, pH 7.5, 40 mM MgCl2, 20 mM MnCl2, 1 mM ZnCl2, 150 mM NaCl, and 100 µM 2′-Az-
dATP. The sample was incubated at 37 °C for 14 h and precipitated with ethanol. 
Procedure for capture step in each round. Low-retention microcentrifuge tubes were treated 
by allowing to stand overnight with 2 mL of 5% (w/v) PEG3350 (Sigma-Aldrich, cat. no. P3640) 
and rinsing with 3 × 1 mL of water. All centrifugation steps were performed at 1000×g for 1 min. 
The sample from the selection step was dissolved in a PEG-treated tube to 10 µL total volume 
containing 100 mM HEPES, pH 7.5, 2 mg 3′-alkyne-modifier serinol CPG (Glen Research, 42 
µmol/g), 40 mM tris(3-hydroxypropyltriazolylmethyl)amine (THPTA), 10 mM sodium ascorbate, 
5 mM CuSO4, and 0.5 µg herring sperm DNA (Sigma-Aldrich). The concentrations of THPTA, 
sodium ascorbate, and CuSO4 were optimized (not shown). The three reagents were added from 1 
M (25´), freshly prepared 100 mM (10´), and 100 mM (20´) stock solutions, respectively; the 
three reagents were mixed together and then added at once to the other components. The sample 
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was shaken on a vortexer at the lowest setting for 1 h at 4 °C, transferred to a spin column, 
centrifuged, washed with 3× 100 µL of 50 mM Na3EDTA, pH 8.0 and 8 M urea, and further 
washed with 3× 100 µL of water. The washes were combined into a single wash fraction. The 
bound sequences were eluted with 20 µL of 100 mM HEPES, pH 7.5, and 50 mM DTT at 37 °C 
for 1 h. The supernatant in the sample was transferred to a scintillation vial (elution fraction). 
Scintillation counting of the wash and elution fractions was used to quantify selection activity. The 
elution fraction was precipitated with ethanol and taken onward to the PCR step of the in vitro 
selection procedure. 
4.4.2.2 In Vitro Selection Procedures for the CP2–CT2 Selection Experiments 
Procedure for PCR was performed as described in Chapter 2. 
Procedures for ligation and selection were identical to those in the selections with protein 
substrates using the resin-based capture method. 
Procedure for capture step in each round. The sample from the selection step was brought 
to 10 µL total volume containing 100 mM HEPES, pH 7.5, 10 mM PEG10k-alkyne, 40 mM tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA), 10 mM sodium ascorbate, and 5 mM CuSO4. The 
concentrations of PEG10k-alkyne, THPTA, sodium ascorbate, and CuSO4 were optimized (not 
shown). The four reagents were added from 100 mM (10´), 1 M (25´), freshly prepared 100 mM 
(10´), and 100 mM (20´) stock solutions, respectively; the three reagents were mixed together and 
then added at once to the other components. The sample was incubated at 4 °C for 1 h and separated 
by 8% SDS-urea PAGE, in which the PAGE gel included each of 0.1% (w/v) SDS and 7 M urea. 
The product was extracted from the gel in 10 mM Tris, pH 8.0, 300 mM NaCl, 1 mM EDTA, and 
50 mM DTT. The extracted product was precipitated with ethanol and purified again by 8% PAGE. 
4.4.3 DNA Aptamer In Vitro Selection Procedures 
4.4.3.1 In Vitro Selection Procedures for the AQ2–AY2 Selection Experiments 
Procedure for PCR was performed as described in Chapter 2. 
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Procedure for selection step in round 1. Each selection experiment was initiated with 200 
pmol of the DNA pool. Low-retention microcentrifuge tubes were treated by allowing to stand 
overnight with 2 mL of 5% (w/v) PEG3350 (Sigma-Aldrich, cat. no. P3640) and rinsing with 3× 1 
mL of water. All centrifugation steps were performed at 1000×g for 1 min. A 10 µL sample 
containing 200 pmol of pool in a PEG-treated tube was annealed in 5 mM HEPES, pH 7.5, 15 mM 
NaCl, and 0.1 mM EDTA by heating at 95 °C for 3 min and cooling on ice for 5 min. A pre-
selection step was performed by bringing the sample to 50 µL total volume containing 70 mM 
HEPES, pH 7.5, 5 or 40 mM MgCl2, 150 mM NaCl, 1 mM 2-mercaptoethanol, 1 µg herring sperm 
DNA, and 10 µL of unmodified Ni-NTA agarose. The sample was shaken on a vortexer at the 
lowest setting for 1 h at 37 °C or room temperature, transferred to a spin column, and centrifuged. 
The spin column used in the pre-selection step was transferred to a scintillation vial (sample A). 
The retained flow-through from the pre-selection step was brought to 100 µL total volume 
containing 70 mM HEPES, pH 7.5, 5 or 40 mM MgCl2, 150 mM NaCl, 1 mM 2-mercaptoethanol, 
2 µg herring sperm DNA, and 20 or 200 pmol of target protein immobilized on Ni-NTA agarose. 
The selection incubation was performed under identical conditions as those of the pre-selection 
step. After incubation, the sample was transferred to a spin column, centrifuged, washed with 
3× 100 µL of aptamer binding buffer (70 mM HEPES, pH 7.5, 150 mM NaCl, and 1 mM 2-
mercaptoethanol). The washes were combined into a single wash fraction (sample B). The spin 
column used in the selection step was transferred to a scintillation vial (sample C). Scintillation 
counting of the three samples A–C was used to quantify background binding and selection activity. 
After counting, the filter of the spin column in sample C was transferred to a low-retention 
microcentrifuge tube that contained 100 µL of water. DNA sequences that bound to target peptide 
or protein were recovered from the filter by phenol/chloroform extraction followed by ethanol 
precipitation. 
Procedure for selection step in rounds 2–5. The procedure was identical to the selection 
step in round 1, except that 0.5 µL of unmodified Ni-NTA agarose was used in the pre-selection 
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step and 1 or 10 pmol of target protein immobilized on Ni-NTA agarose was used in the selection 
step. 
Procedure for selection step in rounds 6–16. The procedure was identical to the selection 
step in round 1, except that 2 µL of unmodified Ni-NTA agarose was used in the pre-selection step 
and 10 or 40 pmol of target protein immobilized on Ni-NTA agarose was used in the selection 
step. 
4.4.3.2 In Vitro Selection Procedures for the DE2–DM2 Selection Experiments 
Procedure for PCR was performed as described in Chapter 2. 
Procedure for selection step in round 1. Each selection experiment was initiated with 200 
pmol of DNA sequence population that is composed of random pool and reported lysozyme 
aptamer at the intended ratio (Table 4.2). Low-retention microcentrifuge tubes were treated by 
allowing to stand overnight with 2 mL of 5% (w/v) PEG3350 (Sigma-Aldrich, cat. no. P3640) and 
rinsing with 3× 1 mL of water. All centrifugation steps were performed at 1000×g for 1 min. A 10 
µL sample containing the mixture of random DNA pool and Apta1 or Apta8 aptamer sequence in 
a PEG-treated tube was annealed in 25 mM Tris, pH 8.3, 5 mM K2HPO4, and 192 mM glycine by 
heating at 95 °C for 3 min and cooling on ice for 5 min. A pre-selection step was performed by 
bringing the sample to 50 µL total volume containing 25 mM Tris, pH 8.3, 5 mM K2HPO4, 192 
mM glycine, 1 µg herring sperm DNA, and 10 µL of unmodified Ni-NTA agarose. The sample 
was shaken on a vortexer at the lowest setting for 30 min at room temperature, transferred to a spin 
column, and centrifuged. The spin column used in the pre-selection step was transferred to a 
scintillation vial (sample A). The retained flow-through from pre-selection step was brought to 
100 µL total volume containing 25 mM Tris, pH 8.3, 5 mM K2HPO4, 192 mM glycine, 2 µg herring 
sperm DNA, and with 200 pmol of His6-lysozyme immobilized on Ni-NTA agarose. The selection 
incubation was performed under identical conditions as those of the pre-selection step. After 
incubation, the sample was transferred to a spin column, centrifuged, washed with 3× 100 µL of 
washing solution that contained 25 mM Tris, pH 8.3, 5 mM K2HPO4, 192 mM glycine. The washes 
134 
were combined into a single wash fraction (sample B). The spin column used in the selection step 
was transferred to a scintillation vial (sample C). Scintillation counting of the three samples A–C 
was used to quantify background binding and selection activity. After counting, the filter of the 
spin column in sample C was transferred to a low-retention microcentrifuge tube that contained 
100 µL of water. DNA sequences that bound to lysozyme were recovered by phenol/chloroform 
extraction followed by ethanol precipitation. 
Procedure for selection step in subsequent rounds. The procedure was identical to selection 
step in round 1, except that 0.5 µL of unmodified Ni-NTA agarose was used in the pre-selection 
step and 10 pmol of His6-lysozyme immobilized on Ni-NTA agarose was used in the selection 
step. 
4.4.3.3 In Vitro Selection Procedures for the EA2–EJ2 Selection Experiments 
Procedure for selection was performed as described above for the AQ2–AY2 selection 
experiments, except that the ratio of immobilized target protein or peptide to DNA pool was kept 
as 1:1 throughout the selection rounds. 
Primer extension to generate EdU-modified pools for round 1. To generate the initial 25% 
EdU-modified pools by primer extension, a reverse complement of the pool containing 25% A was 
synthesized with a 3′-tail to enable separation from the product after primer extension. A 25 µL 
sample was prepared containing 250 pmol of reverse-complement template, 300 pmol of forward 
primer, 7.5 nmol each of dATP, dGTP, dCTP, and EdUTP, 2.5 µL of 10× KOD XL polymerase 
buffer [1.2 M Tris-HCl, pH 8.0, 60 mM (NH4)2SO4, 100 mM KCl, 1% Triton X-100, 0.01% BSA], 
and 2 µL of KOD XL polymerase. To generate the initial pool, 8 × 25 µL reactions were 
performed. Primer extension was performed in a PCR thermocycler according to the following 
program: 94 °C for 2 min, 47 °C for 2 min, 72 °C for 1 h. The 8 × 25 µL samples were combined, 
precipitated with ethanol, and separated by 8% PAGE. 
Primer extension to generate EdU-modified pools for subsequent rounds. A 25 µL sample 
was prepared containing the reverse-complement single strand, 50 pmol of forward primer, 7.5 
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nmol each of dATP, dGTP, dCTP, and EdUTP, 10 µCi of a-32P-dCTP (3000 Ci/mmol), 2.5 µL of 
10× KOD XL polymerase buffer [1.2 M Tris-HCl, pH 8.0, 60 mM (NH4)2SO4, 100 mM KCl, 1% 
Triton X-100, 0.01% BSA], and 0.5 µL of KOD XL polymerase. Primer extension was performed 
in a PCR thermocycler according to the following program: 94 °C for 2 min, 47 °C for 2 min, 72 
°C for 1 h. The sample was separated by 8% PAGE. 
Procedure for click reaction of EdU-modified pools. The sample from the primer extension 
step was brought to 20 µL total volume containing 100 mM HEPES, pH 7.5, 10 mM azide 
compound, 40 mM tris(3-hydroxypropyltriazolylmethyl)amine (THPTA), 10 mM sodium 
ascorbate, 5 mM CuSO4, and 60% (v/v) DMSO. The concentrations of azide compound, THPTA, 
sodium ascorbate, and CuSO4 were optimized (not shown). The four reagents were added from 
100 mM (10´), 1 M (25´), freshly prepared 100 mM (10´), and 100 mM (20´) stock solutions, 
respectively; the four reagents were mixed together and then added at once to the other components. 
The sample was incubated at 37 °C for 1 h and precipitated with ethanol. A second click reaction 
was performed with the precipitated sample. The product was purified by 8% PAGE. 
Procedure for PCR of modified pools. In each selection round, two PCR reactions were 
performed, a 10-cycle PCR followed by a 30-cycle PCR. First, a 100 µL sample was prepared 
containing the capture product, 50 pmol of forward primer, 200 pmol of reverse primer, 20 nmol 
of each dNTP, and 10 µL of 10× KOD XL polymerase buffer [1.2 M Tris-HCl, pH 8.0, 60 mM 
(NH4)2SO4, 100 mM KCl, 1% Triton X-100, 0.01% BSA], and 1 µL of KOD XL polymerase. This 
sample was primer-extended and then cycled according to the following PCR program: 94 °C for 
2 min, 47 °C for 2 min, 72 °C for 30 min; then 94 °C for 2 min, 10× (94 °C for 1 min, 47 °C for 1 
min, 72 °C for 1 min), 72 °C for 5 min. KOD XL polymerase was removed by phenol/chloroform 
extraction. Second, a 50 µL sample was prepared containing 1 µL of the 100 µL 10-cycle PCR 
product, 25 pmol of forward primer, 100 pmol of reverse primer, 10 nmol of each dNTP, 5 µCi of 
a-32P-dCTP (3000 Ci/mmol), 5 µL of 10× Taq polymerase buffer, and 0.5 µL of Taq polymerase. 
This sample was cycled according to the following PCR program: 94 °C for 2 min, 30× (94 °C for 
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30 s, 47 °C for 30 s, 72 °C for 30 s), 72 °C for 5 min. The reverse-complement single strand was 
separated by 8% PAGE for the subsequent primer extension. 
4.4.3.4 In Vitro Selection Procedures for the FA2–FJ2 Selection Experiments 
Procedures for primer extension, click reaction, and PCR were performed identically as 
those in EA2–EJ2 selection experiments. 
Procedure for buffer-exchange and resuspension of the target protein or peptide 
immobilized on the magnetic beads. In a microcentrifuge tube, 50 µL of the target protein or 
peptide immobilized on the magnetic beads was washed with 3× 50 µL of BW buffer then 1× 100 
µL of SB buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 1 mM 2-mercaptoethanol, 
and 0.05% Tween-20). The washed beads were resuspended in 50 µL of SB buffer. 
Procedure for buffer-exchange and resuspension of the His6Ala2 peptide immobilized on 
the magnetic beads. In a microcentrifuge tube, 50 µL of the His6Ala2 peptide immobilized on the 
magnetic beads was washed with 3× 50 µL of BW buffer then 1× 100 µL of SB buffer. The washed 
beads were resuspended in 25 µL of SB buffer. 
Procedure for selection step. Each selection experiment was initiated with 200 pmol of 
DNA pool. A pre-selection step was performed by incubating DNA pool with 25 µL of the 
His6Ala2 peptide immobilized on the magnetic beads and 5 µL of SB buffer at 37 °C for 15 min. 
The magnetic beads used in the pre-selection step were separated with a magnet and transferred to 
a scintillation vial (sample A). The supernatant from the pre-selection step was incubated with 50 
µL of the target protein or peptide immobilized on the magnetic beads, 20 µL of SB buffer, 10 µg 
of herring sperm DNA, 0.1 mg of BSA (Sigma-Aldrich, cat. no. A9418), and 100 nmol of casein 
(USB, cat. no. 12840) at 37 °C for 15 min. After incubation, the supernatant was separated with a 
magnet, and the magnetic beads used in the selection step were washed with 3× 100 µL of 37 °C 
SB buffer that contained 10 µg of herring sperm DNA. The washes were combined with the 
supernatant from the selection step into a single fraction (sample B). DNA sequences bound to the 
target protein or peptide immobilized on the magnetic beads were eluted with 100 µL of SB buffer 
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that contained 2 M of guanidine-HCl via incubation at 37 °C for 5 min. The elution fraction was 
separated with a magnet and transferred to a scintillation vial (sample C). The magnetic beads after 
the elution step were transferred to another scintillation vial (sample D). Scintillation counting of 
the samples A–D was used to quantify background binding and selection activity. After 
scintillation counting, DNA sequences in sample C were precipitated with ethanol and taken 
onward to the PCR step. 
4.5 References 
(1) Chandrasekar, J.; Silverman, S. K. Catalytic DNA with phosphatase activity. Proc. Natl. 
Acad. Sci. U. S. A. 2013, 110, 5315-5320. 
(2) Chu, C.; Silverman, S. K. Assessing histidine tags for recruiting deoxyribozymes to catalyze 
peptide and protein modification reactions. Org. Biomol. Chem. 2016, 14, 4697-4703. 
(3) Chu, C. DNA Enzymes for Peptide-Nucleic Acid Conjugation and for Lysine Methylation. 
Ph.D. Thesis, University of Illinois at Urbana-Champaign, 2017. 
(4) Gold, L.; Ayers, D.; Bertino, J.; Bock, C.; Bock, A.; Brody, E. N. et al. Aptamer-based 
multiplexed proteomic technology for biomarker discovery. PLoS One 2010, 5, e15004. 
(5) Rohloff, J. C.; Gelinas, A. D.; Jarvis, T. C.; Ochsner, U. A.; Schneider, D. J.; Gold, L.; Janjic, 
N. Nucleic acid ligands with protein-like side chains: modified aptamers and their use as 
diagnostic and therapeutic agents. Mol. Ther. Nucleic Acids 2014, 3, 201. 
(6) Ren, X.; Gelinas, A. D.; von Carlowitz, I.; Janjic, N.; Pyle, A. M. Structural basis for IL-1a 
recognition by a modified DNA aptamer that specifically inhibits IL-1a signaling. Nat. 
Commun. 2017, 8, 810. 
(7) Tolle, F.; Brändle, G. M.; Matzner, D.; Mayer, G. A versatile approach towards nucleobase-
modified aptamers. Angew. Chem. Int. Ed. 2015, 54, 10971-10974. 
(8) Hjertén, S.; Liu, Z. Q.; Zhao, S. L. Polyacrylamide gel electrophoresis: recovery of non-
stained and stained proteins from gel slices. J. Biochem. Biophys. Methods 1983, 7, 101-113. 
138 
(9) Meers, P.; Mealy, T. Phospholipid determinants for annexin V binding sites and the role of 
tryptophan 187. Biochemistry 1994, 33, 5829-5837. 
(10) Koopman, G.; Reutelingsperger, C. P.; Kuijten, G. A.; Keehnen, R. M.; Pals, S. T.; van Oers, 
M. H. J. Annexin V for flow cytometric detection of phosphatidylserine expression on B 
cells undergoing apoptosis. Blood 1994, 84, 1415-1420. 
(11) Vermes, I.; Haanen, C.; Steffens-Nakken, H.; Reutelingsperger, C. A novel assay for 
apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic 
cells using fluorescein labelled Annexin V. J. Immunol. Methods 1995, 184, 39-51. 
(12) Song, J. J.; Lee, Y. J. Differential cleavage of Mst1 by caspase-7/-3 is responsible for 
TRAIL-induced activation of the MAPK superfamily. Cell. Signalling 2008, 20, 892-906. 
(13) Lonovics, J.; Devitt, P.; Watson, L. C.; Rayford, P. L.; Thompson, J. C. Pancreatic 
polypeptide. Arch. Surg. 1981, 116, 1256-1264. 
(14) Velez, T. E.; Singh, J.; Xiao, Y.; Allen, E. C.; Wong, O.; Chandra, M.; Kwon, S. C.; 
Silverman, S. K. Systematic evaluation of the dependence of deoxyribozyme catalysis on 
random region length. ACS Comb. Sci. 2012, 14, 680-687. 
(15) Tran, D. T.; Janssen, K. P. F.; Pollet, J.; Lammertyn, E.; Anné, J.; Van Schepdael, A.; 
Lammertyn, J. Selection and characterization of DNA aptamers for egg white lysozyme. 
Molecules 2010, 15, 1127-1140. 
(16) Suzuki, T.; Ota, Y.; Ri, M.; Bando, M.; Gotoh, A.; Itoh, Y.; Tsumoto, H.; Tatum, P. R.; 
Mizukami, T.; Nakagawa, H.; Iida, S.; Ueda, R.; Shirahige, K.; Miyata, N. Rapid discovery 
of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to 
generate candidate libraries. J. Med. Chem. 2012, 55, 9562-9575. 
(17) Logue, S. E.; Elgendy, M.; Martin, S. J. Expression, purification and use of recombinant 
annexin V for the detection of apoptotic cells. Nat. Protoc. 2009, 4, 1383-1395. 
(18) Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities 
of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254. 
139 
(19) Lee, H. W.; Lee, S. H.; Lee, H. W.; Ryu, Y. W.; Kwon, M. H.; Kim, Y. S. Homomeric and 
heteromeric interactions of the extracellular domains of death receptors and death decoy 
receptors. Biochem. Biophys. Res. Commun. 2005, 330, 1205-1212. 
 
